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“There’s a few things, about three things to my account, that I need each day. One of
them is something to look up to, another is something to look forward to, and another is
someone to chase. First off, I want to thank God because that’s who I look up to. He has
graced my life with opportunities that I know are not of my hand or any other human
hand. He has shown me that it is a scientific fact that gratitude reciprocates. To my
family, that’s who and what I look forward to. To my father […] to you Dad, you taught
what it means to be a man. To my mother […] who taught me and [my sisters] to respect
ourselves and what we in turn learned was that we were better able to respect others.
Thank you for that momma. To my [sisters Claritza, Ariana, and Ana along with Mom,
Dad and Milan] the courage and significance you have given me [through this journey]
is unparalleled you are the [six] people who I want to make most proud of me. Thank
you. To my hero, that’s who I chase. [My hero is me in ten years]. You see every day,
every week, every month, and every year of my life, my hero is always ten years away.
I’m never going to be my hero. I’m not going to attain that. I know I’m not. And that’s
just fine with me because that keeps me with someone to keep on chasing.”

Rephrased Matthew McConaughey speech - Best Actor for Dallas Buyers Club
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ABSTRACT

Author: Peña, Ramon. PhD
Institution: Purdue University
Degree Received: December 2017
Title: Process Intensification through Spherical Crystallization: Novel Experimental and
Modeling Approaches
Major Professor: Zoltan K. Nagy
Process intensification is defined as the use of innovative techniques and technologies to
create sustainable solutions to industrial production difficulties. Continuous spherical
crystallization is a process intensification technique that could resolve production issues
for pharmaceutical and solids processing industries, consequently, allowing for the
integration of upstream and downstream manufacturing units. Spherical crystallization is
carried out through emulsion based crystallization and/or agglomeration in suspension of
fine crystals to produce aggregates of improved bulk and micromeritic properties. The
advantages of spherical crystallization include: (i) replacing downstream particle
correction units (i.e., milling, granulation), (ii) providing control of crystalline properties
by decoupling crystallization and agglomeration mechanisms, and (iii) reducing plant foot
print and allowing for reconfigurable units. The overall aim of the thesis is to further
develop the scientific understanding of spherical crystallization mechanisms and introduce
a systematic approach for implementing continuous spherical crystallization as a smart
manufacturing platform enabled by a quality-by-design framework.
Experimentally, the thesis achieves: (i) better mechanistic understanding of spherical
crystallization in semi-batch systems using process analytical technologies (PAT); and (ii)
the assessment of the feasibility of continuous spherical crystallization in mixed suspension
mixed product removal (MSMPR) and oscillatory flow baffled crystallizer (OFBC)
systems. Computationally, a coupled population balance model is developed that leads to
an optimization framework for bioavailability and manufacturability through spherical
crystallization. Together the experimental and modeling approaches deliver a model-based
framework for process intensification that can lead to adaptive manufacturing systems for
high value-added particulate products.

1

1. INTRODUCTION

Motivation
Crystallization, originally conceived as a purification and separation process, has become
a predominant technique in particle design technology. Crystallization is a unit operation
in process systems in a broad range of industries including pharmaceuticals, bulk and fine
chemicals, food, and electronics. Crystallization is the characteristic-and propertydetermining step in most solid processes. Given that it is also one of the initial steps, it has
a major impact on downstream processes (e.g., filtering, drying, milling, handling, and
storage).1 The pharmaceutical industry, with an estimated worth of USD $300 billion/year2,
is a major dependent of crystallization as 90% of its active pharmaceutical ingredients (API)
are derived from a crystallization step.3
Due its industrial importance and economic significance, crystallization has been
studied extensively within academia and industry research. Advancements have been made
in the area of crystal size4,5 and shape1,6,7 distribution design, in-situ measurement/online
monitoring8-11, modeling12-15, optimization7,8,14,16 and control.16-19 The introduction of
process analytical technology (PAT) allowed for major advancement in the monitoring of
both batch and continuous processes. The pharmaceutical industry, through initiatives
supported by the U.S. Food and Drug Administration (FDA), has been one of the main
beneficiaries of the technology avoiding major product loss from its traditional recipebased batch operation approach.20 Application of predictive models in combination with
real-time in-situ sensors has allowed the ability to not only monitor and control but also
optimize the crystal product properties.17,21 The ability to monitor processes online along
with continued advances in computation speed can lead to the development of improved
models and improved real-time control, which in turn will improve crystal product quality.
Crystal properties are directly related to the efficiency of downstream processes that
are used to achieve the final dosage form. For example, fine crystals are preferred for
pharmaceutical application due their bioavailability properties, but their subpar flow
properties make them undesirable for processing.22 There are many techniques available
(e.g., wet/dry granulation, roller compaction, milling) to help improve crystal properties to
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improve manufacturability; however, these processes often require extra unit operations
which comes with more capital, labor, and operational costs. Moreover, given the
historically batch nature of pharmaceutical processes, increasing the number of unit
operations can cause increases in variability at each stage of production.
To achieve consistent product quality, the pharmaceutical industry has begun to
investigate innovative continuous manufacturing platforms. With the goal for the industry
being continuous end to end manufacturing, from drug substance to final drug product. The
motivation for the aim is not only product quality, but due to expiring patents and the
fluctuating cost of energy, the economic burden of inefficient manufacturing can no longer
be ignored.23 Thus the need to reduce operating costs, limit energy consumption and
improve process efficiency has also become very significant. The adoption of continuous
manufacturing technologies can be a key stride in achieving their objective.
It is estimated that the shift from batch to continuous manufacturing will have
significant impact on high value-added solids manufacturing, through improved flexibility,
agility, and sustainability in the process design (see Figure 1.1). This can result in plant
footprint reduction (40-90% space, 25-60% reduced capital expenditure), lower operating
costs (25-60%), and reduced energy requirements (40-70%).25 Crystallization becomes a
key focus in efforts to go continuous given it is one of the first steps in drug substance
separations, accounts for 90% of API purification processes3 and more than 70% of all
pharmaceutical formulations are in the solid dosage form.26 However, little implementation
of continuous crystallization or other process alterations/intensifications has occurred.
Intensifying the processes involved in pharmaceutical formulations within a continuous
system can greatly improve efficiency, integrate processes for drug substance with drug
product, decrease development time, and afford line-of-sight from the laboratory to full
commercial scale operations. When applied to pharmaceutical manufacturing, process
intensification (PI) techniques present integrative and adaptive attributes that make them
the key framework for smart manufacturing techniques.
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Figure 1.1 Schematic of increase process performance due to innovation and shift in focus from
batch to continuous. Adapted from [24].

Spherical crystallization is a PI technique that produces large (micron to millimeter)
particles of spherical shape with improved micromeritic properties using a minimum
number of unit operations. Spherical crystallization is the agglomeration of fine crystals
during the crystallization process. This eliminates the need for further unit operations (e.g.,
milling or granulation) to overcome negative physical properties typical to micronized drug
substance or poor powder flow common to most APIs. Spherical crystallization produces
ready to formulate material with specific dissolution properties, improved drug
homogeneity, and decreased energy usage27-30; incorporating both the beneficial
biopharmaceutical and manufacturability properties of the fine crystals and agglomerates,
respectively. Spherical crystallization via spherical agglomeration (SA) is a technique that
was first introduced in the 1960s. Sirianni et al.31 (1969) described SA as a separation
technique that allows particles to be removed from liquid suspension through selective
wetting and agglomeration by the addition of an immiscible solvent, termed the bridging
liquid.
Industrial processes that have benefited from spherical crystallization (SC) technique
include coking of coals, pelletization of fine crystals, and beneficiation of ores. Current
API manufacturing processes are poised to also benefit from SC. The most significant
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challenges in manufacturing APIs is their common needle or plate-like morphologies that
are difficult to isolate and process. Micronization is also often required for increased
surface area to tailor bioavailability, which hinders downstream manufacturing. Properly
understood and designed SC processes may provide a manufacturing platform that can
solve many of the current processing and handling issues related to API size and
morphology. Moreover, successfully designed continuous spherical crystallization (CSC)
processes can provide the medium by which to integrate drug substance and drug product;
allowing for end to end production that pharmaceutical industry desperately seeks.

Research Aims
The overall aim of this thesis is to investigate the viability of SC as a PI technique as well
as assess continuous crystallization technologies to perform CSC. The aims are examined
through a combined experimental and computational analysis.
The aims of this thesis work can be summarized as follows:
•

To recognize the advancements in SC, gain a broad understanding of its potential
impact on pharmaceutical processes, and identify areas of research interest within
the field via a thorough review of the literature.

•

To develop of deeper scientific understanding of the mechanisms that govern the
agglomeration of fine crystals during SC using PAT tools with a detailed
investigation of the effects of process parameters on particle properties and process
efficiency.

•

To develop a first principles modeling framework that describes the primary
particle formation (via crystallization) and agglomerate formation (via SA) using a
coupled population balance.

•

Use the coupled population balance model (PBM) to develop a multi-objective
optimization framework to design and achieve processes of both desired
bioavailability (primary crystal size) and improved manufacturability (agglomerate
size).

•

Investigate, validate and assess the use of different continuous crystallization
technologies for the purposes of the CSC with decoupled crystallization and
agglomeration mechanisms.
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•

To develop a set of dimensionless quantities that describe the critical process
parameters of SC to allow regime map development and dimensional analysis that
will enable rapid design of SC processes.

•

Consolidate the literature data of compound and solvent system combinations used
for different SC processes and use principal component analysis for bridging liquid
selection.

•

Evaluate the coupling of continuous downstream unit operations with continuous
crystallization to assess the feasibility of PI via multiple unit operations.

Research Contributions
The main contributions of this thesis can be summarized as follows:
•

Identification of key agglomeration mechanisms during SC processes using modern
PAT providing greater insight for the design of such processes. Agglomerates
produced via different mechanisms were characterized for different flow and bulk
properties, and the mechanism leading to favorable downstream process
performance was identified.

•

A coupled PBM was developed to simulate the evolution of crystals and
agglomerates in a SC. The model allowed for decoupled kinetic parameters as the
populations are tracked independently as opposed to traditional lumped kinetic
parameters. The model provides first principles based process properties; for
example, agglomeration efficiency and porosity.

•

Implementation of a multi-objective framework for targeted bioavailability and
manufacturability. The framework identifies different phases of a semi-batch SC
process required to achieve different biopharmaceutical and manufacturing targets.

•

The design of CSC in a mixed suspension mixed product removal (MSMPR)
crystallizer with decoupled nucleation/growth and agglomeration mechanisms.
Validating the concept of PI through CSC.

•

The design of CSC in an oscillatory flow baffled crystallizer (OFBC) with spatially
distributed solvent injection along the length of the crystallizer. The optimal
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operating parameters for achieving efficient agglomeration and difference between
an oscillatory flow system and traditional crystallizers were identified.
•

A continuous filtration carousel (CFC) coupling with a mixed suspension mixed
product removal crystallizer was evaluated for performance and validation of PI via
coupled unit operations.

•

Enabling the rapid design of SC process via mechanistic and process regime maps,
and the selection of an appropriate bridging liquid via principal component analysis.

Thesis Structure
Chapter 2 is a literature review of crystallization which includes the fundamentals of
crystallization, various crystallization techniques and their mode of operation. The
description of the various process analytical technologies and characterization tools used
in the experimental work is also given. An overview of modeling of crystallization via
population balance equations (PBEs) using method of moments and quadrature method of
moments (QMOM) is provided. The basics of using principal component analysis for
multivariate data analysis is also discussed. The definition PI and its role in pharmaceutical
manufacturing is presented. Lastly, most of the literature review focuses on critically
reviewing all the relevant SC literature to provide the proper context for assessing the
contributions of this thesis work.
Chapter 3 is a literature review specific to SC which includes an understanding of the
parameters affecting SC and the fundamental mechanisms of the process. The review also
details the work accomplished in the modeling and simulation of SC processes. The chapter
also briefly discusses some CSC applications.
Chapter 4 describes the use of process analytical technologies to identify the
agglomeration mechanism for various bridging liquid addition methods for a semi-batch
process. For bridging liquid additions methods that are decoupled from solution addition,
i.e., post crystallization, the effect of primary particle size on the final agglomerate size is
evaluated. A critical bridging liquid to primary particle size ratio is established as the
inflection point where the agglomeration mechanism changes from immersion to
distributed. For successful bridging liquid addition methods, i.e., methods that create
agglomerates, bulk and flow properties for the different methods are compared. The
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combination of results lead to the development of guidelines for designing processes based
on mechanism and flow properties.
Chapter 5 describes the development of the coupled PBM, the efficient solution method
employed, and the implementation of a multi-objective optimization framework. The
chapter describes how using the mass balance equations it is assured that mass is conserved
and that the set of PBEs are coupled. It also describes the transformation of the PBEs using
a QMOM approach that allows for efficient solution of the model while still handling
otherwise difficult integral terms. Lastly, the targeted primary particle size and
agglomeration size multi-objective framework is demonstrated for various scenarios.
Chapter 6 initiates the use of CSC as a PI technique. In this chapter, a two-stage
MSMPR crystallizer is employed. The first stage serves as a nucleation and growth stage
controlled by solution and anti-solvent addition. The second stage serves as the
agglomeration stage controlled by bridging liquid addition and increased agitation rate.
The chapter experimentally demonstrates that decoupling of nucleation/growth from
agglomeration allows for tailored product design.
Chapter 7 extends the work of Chapter 6 to flow based system. In this chapter, an OFBC
is employed. The OFBC is divided into different zones: nucleation, growth, and
agglomeration. While the oscillatory flow baffled crystallizer superimposes an oscillatory
motion on the net flow causing significant back-mixing, the zones are dominant by the
specific crystallization mechanisms. The chapter presents the optimal conditions for design
a CSC process in an OFBC and how the product quality and process efficiency are affected
by changes in operating parameters.
Chapter 8 extends the PI concept to the coupling of two continuous unit operations:
MSMPR crystallizer and CFC. The CFC is evaluated for its use in combination with a
cooling and anti-solvent crystallization in a mixed suspension mixed product removal
system. The process was evaluated in regards to its ability to reach a controlled state of
operation (CSO) and for final moisture content of crystals.
Chapter 9 summarizes the finding of the thesis into main conclusions and future work.
It provides suggestions on which areas of research should be expanded upon and what new
directions can be explored. The emphasis of this chapter is to provide suggestions for
achieving end to end integration of drug substance and drug product.

8

2. LITERATURE REVIEW

Crystallization is the leading solid-liquid separation technique in industrial processes.
During crystallization, randomly organized molecules in solution undergo a phase change,
coming together to create crystalline structures (solids) with three dimensional
arrangements of periodic repeating patterns.32 The conditions (i.e., supersaturation) under
which the crystalline structures are created determines morphology and properties. Proper
design of the crystallization process by controlling the conditions of the solution
environment is required to achieve the desired level of yield, purity, micromeritic
properties.

Solubility and Phase Equilibrium
Crystallization is a rate driven, kinetic process, with supersaturation as the driving force.
Most practical crystallization processes use some type of solution crystallization technique.
A solution is a homogeneous, single phase, mixture of two or more components. In
crystallization, a solution is usually composed of a solvent (liquid phase) and a solute (solid
phase).32,33 Dissolving the solute in the solvent at a given temperature forms a
homogeneous solution. At a specific temperature, there is a maximum amount of solute
that can dissolve in a specific amount of solvent. This is known as solubility of the solute
in the solvent.
Solubility depends on temperature and composition of the system. At solubility, the
solution is said to be saturated. A saturated solution is in equilibrium with the dissolved
solute. An undersaturated solution represents a solute concentration that is below the
equilibrium concentration and the solute present will readily dissolve. Undersaturated
solutions lie below the solubility curve. A supersaturated solution represents a solute
concentration that exceeds the equilibrium concentration and lies above the solubility
curve.32,34 Due to the excess amount of solute in supersaturated solutions, the solute
molecules crystallize to reach the equilibrium concentration in solution. The solubility
curve describes the change in solute solubility with respect to temperature and
concentration. A phase diagram can be used to understand the solubility of a compound
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and identify its phase equilibrium point (Figure 2.1). Solubility and phase diagrams can be
altered by using solvent mixtures instead of pure solvent solutions. Solvent mixtures are
important when temperature changes do not significantly affect solubility and phase
changes.32

Figure 2.1 Phase diagram.

The most common way of expressing supersaturation (𝑆) is shown in equation 2.1 as
the difference in concentration. This expression is formulated under the assumption of ideal
solution. The assumption of ideal solution allows for simpler, kinetic based, expressions of
supersaturation. Otherwise the expression would depend on values of the activity
coefficient and other thermodynamic parameters.32
𝑆 = Δ𝑐 = 𝑐 − 𝑐 ∗

2.2

In equation 2.1, 𝑐 ∗ represents the solubility point or saturation concentration and 𝑐 is the
concentration in solution. Equation 2.3 shows the supersaturation expressed as a ratio
where 𝜎 represents the relative supersaturation; as opposed to 𝑆 the absolute
supersaturation.
𝑐

𝜎 + 1 = 𝑐∗

2.4

Supersaturation, although the driving force in crystallization, does not guarantee
crystallization. Supersaturated solutions exhibit a metastable zone. The metastable zone is
a region between the solubility curve (saturation level) and supersaturation region where
crystallization is not spontaneous (Figure 2.1). The width of this region depends on the
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process conditions and the metastable zone limit which indicates the supersaturation level
at which crystallization is spontaneous due to instability. In the metastable region,
crystallization is governed by nucleation and growth mechanisms. Nucleation refers to the
birth of new crystals. However, there is a free energy barrier that needs to be overcome for
nuclei to be created. The energy barrier is overcome when nuclei reach a critical size. A
size above which growth is favored over dissolving back into solution. As the
supersaturation increases the energy barrier and cluster critical size decrease.32 For this
reason, supersaturation does not guarantee spontaneous crystallization, unless the
supersaturation level is near the metastable zone limit. Near the metastable limit small
crystals will begin to nucleate because of the reduced free energy barrier. In practice,
however, the metastable limit is never closely approached as process conditions dictate the
width of the metastable zone, and operating within the metastable zone (away from the
metastable limit) makes it is easier to control crystalline properties.

Kinetic Process in Crystallization
Solution crystallization occurs in a two-step process that includes the initial phase
separation, termed nucleation, and the growth of these nuclei, termed crystal growth. For
either of these processes to occur the solution must be supersaturated. Once crystallization
begins, both nucleation and crystal growth will commence, reducing supersaturation with
the more significant of the two-determining size and shape characteristics.32 In the
metastable zone, the supersaturated solution can exist as a complete solution or as a crystalliquid mixture (slurry). In this region, nucleation will not occur spontaneously; it must be
induced by agitation or some other mechanical force.33 At the metastable limit (i.e., very
high supersaturation) nucleation will occur spontaneously. The region between the
solubility curve and the metastable limit (metastable zone width) is governed by both
nucleation and growth.32 The metastable zone width becomes an important parameter and
measurement in the design of particles of a desired shape and size.
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2.2.1

Nucleation

Nucleation is often the more dominant of the rate process during crystallization. Nucleation
may or may not be a spontaneous process. Because of the ambiguity of a nucleation event,
nucleation has been studied in two separate mechanisms: primary and secondary nucleation
(Table 2.1). Primary nucleation is categorized as either homogeneous or heterogeneous,
and refers to nucleation in the absence of another crystalline surface. Secondary nucleation
refers to nucleation induced by the presence of an already existing crystal.32,33
Table 2.1 Nucleation mechanisms
Primary Nucleation
Homogeneous – spontaneous
Heterogeneous – induced by foreign entity

Secondary Nucleation
Induced by crystals

Homogeneous nucleation, although unpractical in industrial and research settings, has
been the basis for many nucleation theories. One of these theories is classical nucleation
theory (CNT). Classical nucleation assumes that the formation of a nucleus occurs by the
molecular additions of two molecules until a critical cluster size is reached. Equation 2.5
depicts the addition of molecules (𝐴) onto each other until the critical cluster size is reach
(𝐴𝑛 ). Following this theory, nucleation rates that consider a viscous energy term have been
developed.35
𝐴 + 𝐴 = 𝐴2
𝐴2 + 𝐴 = 𝐴3
…
𝐴𝑛−1 + 𝐴 = 𝐴𝑛 (𝑐𝑟𝑖𝑡𝑖𝑐𝑎𝑙 𝑐𝑙𝑢𝑠𝑡𝑒𝑟 𝑠𝑖𝑧𝑒)

2.6

Once this critical cluster size is reached, the addition of more molecules would cause phase
separation, nucleation and later growth. This can be explained thermodynamically in terms
of Gibbs free energy. Assuming the critical cluster is a sphere of radius 𝑟, the total change
in free energy is equal to the sum of the change in free energy from the formation a nucleus
(surface free energy) plus the change in free energy from the phase separation and
transformation (volume free energy).
4

∆𝐺 = ∆𝐺𝑆 + ∆𝐺𝑉 = 4𝜋𝑟 2 𝛾 − 3 𝜋𝑟 3 Δ𝐺𝜐

2.7
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In the above equation, γ is surface tension at the interface between the surface of the
nucleus and the supersaturated solution and Δ𝐺𝜐 is the phase transformation change in free
energy on a per unit volume basis.32,33 The surface free energy term is positive due the
increase in surface tension as the nucleus grows larger. The phase transformation term is
negative because transformation decreases as the nucleus grows larger. Due to this
relationship between surface and volume free energy, and the fact that the phase
transformation term has a higher dependence on 𝑟, the total change in free energy has a
maximum value. This maximum value corresponds to the critical cluster size (𝑟𝑐 ) which is
calculated by maximizing equation 2.5.
dΔ𝐺
𝑑𝑟

= 8𝜋𝑟𝛾 − 4𝜋𝑟 2 Δ𝐺𝜈 = 0
16𝜋𝛾3
2
𝜈)

Δ𝐺𝑐𝑟𝑖𝑡 = 2(Δ𝐺

=

4𝜋𝛾𝑟𝑐2
3

2.8
2.9

The rate of nucleation (𝐵𝑛𝑢𝑐 ) derived from classical nucleation theory can now be describe
by an Arrhenius equation of the form:
𝐵𝑛𝑢𝑐 = 𝐴𝑒𝑥𝑝(−

Δ𝐺𝑐𝑟𝑖𝑡
𝑘𝑇

)

2.10

where 𝑘 is the Boltzmann constant and 𝐴 is a pre-exponential factor. Using the GibbsThompson equation describing growth of clusters, 𝐵𝑛𝑢𝑐 can be expressed in terms of
temperature, 𝑇; supersaturation, 𝑆; and surface tensions, 𝛾.32,33
𝑐

2𝛾𝜈

ln (𝑐 ∗) = ln(𝑆) = 𝑘𝑇𝑟
𝐺𝑐𝑟𝑖𝑡 =

16𝜋𝛾3 𝜈 2
3(𝑘𝑇𝑙𝑛(𝑆))

2.11
2.12

2

16𝜋𝛾3 𝜈 2

𝐵𝑛𝑢𝑐 = 𝐴𝑒𝑥𝑝 (− 3𝑘 3 𝑇 3 (ln(𝑆))2 )

2.13

This nucleation rate developed by CNT increases indefinitely with increasing
supersaturation. This is not observed in practice, and because of the difficulty to observe
this in practice the equations derived from CNT will never completely describe real
systems. Heterogeneous nucleation is more widely accepted as the principal form of
primary nucleation. During crystallization, there almost always exist some form of
impurity, foreign substance or surface where heterogeneous nucleation can take place.
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Impurities lower the free energy barrier and allow nucleation to take place at lower
supersaturation levels. Hence, why the metastable limit is rarely ever reached in
practice.32,33 One way of deriving nucleation rates experimentally is through induction time
experiments. Induction time is defined as the time elapsed between the onset of
supersaturation and the creation of an observable new phase.32 Nucleation rate is
proportional to the inverse of induction time.34
It is common practice in pharmaceutical crystallization to use secondary nucleation
whenever possible. Secondary nucleation is nucleation caused by the presence of crystal
surfaces in solution. When crystals are already present solution, whether by previous
nucleation or crystal seeding, it lowers the supersaturation level while also lowering the
free energy barrier for nucleation. In turn, nucleation occurs at a much lower
supersaturation level than for homogeneous nucleation. Initial breeding or seeding is a
commonly used technique because it allows for growth dominant crystallization processes.
Contact nucleation theory (Table 2.2) is believed to be the most common form of
secondary nucleation in a crystallizer because of the various contact surfaces available in
a crystallizer. Some forms of contact include: crystal-wall, crystal-stirrer, and crystalcrystal.32,33 Supersaturation levels have the most significant impact on secondary
nucleation as supersaturation allows nuclei to form around a parent crystal or another
secondary nucleation mechanism. Secondary nucleation is also influenced by process
conditions such as cooling rate, agitation rate, and impurities. Even factors such as crystal
hardness and impeller material have an impact on secondary nucleation as they present
different surface contacts that induce or reduce secondary nucleation.32
Table 2.2 Secondary nucleation theories
Originates from Parent Crystal
Initial (dust) breeding
Needle/polycrystalline breeding
Collision breeding
Contact nucleation

Originates from Solute in Liquid Phase
Impurity concentration gradient
Fluid shear
Local supersaturation

Due to the lack of practicality from nucleation rates developed from CNT, and the fact
that secondary nucleation is also influenced by hydrodynamic properties within the
crystallizer and solution, more empirical nucleation rates were developed.
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𝐵𝑛𝑢𝑐 = 𝑘𝑁 Δ𝐶 𝑛

2.14
𝑗

𝐵𝑛𝑢𝑐 = 𝑘𝑁′ 𝑊 𝑖 𝑀𝑇 Δ𝐶 𝑛

2.15

Equations 2.11 and 2.12 are nucleation rates derived from the general power law function
where 𝑘𝑁 is the rate constant and Δ𝐶 the absolute supersaturation. Equation 2.12 includes
the agitation rate (𝑊) and suspension density (𝑀𝑇 ) in take into account the hydrodynamics
in the solution.32,34 Both the constants and the exponents are determined by fitting the
equations to experimental data. Experimental methods for determining these values include
metastable zone width measurement, induction time experiments, and measuring the
counts of nuclei.
2.2.2

Growth

When nuclei have surpassed the critical cluster size the growth process begins. Crystal
growth is as important as nucleation rate in determining final product properties. Crystal
growth rates can describe different phenomena; crystal face or characteristic length growth.
A growth rate could be referring to a crystal face, which most likely has a different growth
rate than other crystal faces. In general, of the growth of a crystal face can be explained by
three processes: diffusion of solute molecules from the bulk solution to the crystal face,
bulk transportation; solute molecules desolvate allowing other solute molecules to
incorporate themselves at kink sites, surface integration; and latent heat of crystallization
is exchanged in the system, heat transport. A kink site is a position on the crystal surface
where solute molecules can easily detach and incorporate themselves onto the crystal
lattice.1 A growth rate could also describe the growth of a characteristic length of the crystal;
e.g., a diameter for spherical crystals. Growth rates describing a crystal face are more
appropriate for fundamental understanding as the processes describing crystal face growth
have led to the development of many crystal growth theories. While growth rates
describing a characteristic length and overall growth have more industrial relevance and
practical application.32 There have been numerous growth models developed to describe
the crystal growth process (Table 2.3).
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Table 2.3 Crystal growth theories
Surface energy theories

Shape of crystal is that of minimum free surface energy

Adsorption layer theories

2-D nucleus on crystal surface promotes growth layer by layer

Kinematic theories

Generation of growth steps and their movement across a
crystal face in the presence of other growth steps

Diffusion reaction theories

Disposition of solute molecules on the surface of a crystal face
governed by diffusion and the concentration gradient between
the solid surface and bulk solution

The Burton-Cabrera-Frank (BCF) model is a combination of adsorption layer theories
and kinematic theories. It has received attention due to its ability to better explain the
relation between crystal growth and supersaturation. The idea behind the BCF model is
that dislocations in the crystal structure could provide a step (a kink site) where growth
could occur continuously. The BCF model was specifically based on screw dislocations
that promote spiral growth (Figure 2.2). At these screw dislocations, the internal crystal
structure is exposed to supersaturated solution. This exposure will promote the
incorporation of solute molecules along the length of that step. The incorporation of solute
molecules then causes the step to move in the direction of its outward normal. This process
repeats itself forming a spiral. The spiral will continue to grow so long the solution remains
supersaturated or the crystal meets a boundary.1

Figure 2.2 Spiral growth schematic. Adapted with permission from [1]. Copyright 2008 American
Chemical Society.

The BCF model describes the dependence of crystal growth on supersaturation to be
parabolic at low levels of supersaturation and linear as supersaturation increases. This
relationship is observed experimentally. However, the limitation of the BCF model is that
it was developed for crystal growth from evaporation where diffusion onto the crystal
surface is dominant. While in crystal growth from solution, diffusion from bulk solution to
the crystal surface-solution interface is believed to be more dominant. These diffusion
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differences along with the differences in transport phenomena within a vapor and solution
make the application of the BCF model for solution crystallization questionable.32,33
A second model derived from the BCF model, called the bulk diffusion model, attempts
make up for the difference in diffusion between the vapor and solution crystallization. This
model considers the boundary layer between solute molecules in solution and the crystal
surface. Accounting for this boundary layer brings the model closer to actual practice
where the boundary layer thickness can be affected by process conditions such as
temperature and agitation rates. This boundary layer concept led to a more applicable
model called the diffusion layer model.32 The diffusion layer model considers the diffusion
of solute molecules from the bulk solution, where the concentration of solute molecules is
high; through crystal-solution interface, where the concentration of solute molecules is
depleted due to crystal growth; and onto the crystal surface, where solute molecules are
incorporated into the crystal structure.32 The concentration gradient at the limit between
the bulk solution and crystal-solution interface will always be present under supersaturation;
providing a constant boundary layer. The rate of change of crystal mass can be expressed
by a diffusion rate across the boundary layer:
𝑑𝑚𝑐
𝑑𝑡

= 𝑘𝑑 𝐴(𝐶∞ − 𝐶𝑖 )

𝑘𝑑 = 𝐷/𝛿

2.16
2.17

In Equations 2.13 and 2.14, 𝐶∞ is the bulk concentration, 𝐶𝑖 is the concentration at the
interface, 𝐴 is the surface area of the crystal, 𝐷 is the diffusion coefficient, and 𝛿 is the
boundary layer thickness. The rate of solute integration into the crystal surface can then be
expressed by:
𝑑𝑚𝑐
𝑑𝑡

= 𝑘𝑖 𝐴(𝐶𝑖 − 𝐶)𝑖

2.18

Equations 2.13 and 2.15 are combined and expressed as:
𝑑𝑚𝑐
𝑑𝑡
1
𝐾𝐺

= 𝐾𝐺 𝐴Δ𝐶 𝑔
1

1

=𝑘 +𝑘
𝑑

𝑖

2.19
2.20
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The combination of equations 2.13 and 2.15 eliminates the concentration at the interface
from the growth rate expression. Equation 2.16 is the most commonly used growth rate
expressions in industrial practice. 𝐾𝐺 is the overall mass transfer coefficient and ΔC is the
supersaturation. The growth order 𝑔 is usually between 1 and 2 and is determined from
experimental data.32
Overall, crystal growth is a complex phenomenon and each of the above theories has
limitations. Surface energy theories, although logical thermodynamically, fail to account
for the effects supersaturation.33 Adsorption layer theories fail at low levels of
supersaturation due inaccurate surface energy relationships.32 The one-dimensional growth
rate expression, derived from the diffusion layer model, most commonly used is:
𝐺 = 𝑘𝑔 Δ𝐶 𝑔

2.21

Here 𝑘𝑔 is temperature dependent and can be expressed as an Arrhenius equation. Many
experimental methods exist to obtain data that can be fitted to the above equations. Some
experiments include single crystal experiments grown at a constant supersaturation,
fluidized bed and agitated vessel experiments where a known mass of crystal seeds is added
to the solution, rotating disc method where boundary layer dynamics can be analyzed more
closely, etc.33
2.2.3

Agglomeration and breakage

Nucleation and growth have a significant effect on crystal size and shape; however, in
industrial crystallization, other mechanisms are also taking place. Agglomeration and
breakage are two mechanisms that also greatly affect final product properties. Sometimes
these additional mechanisms are beneficial while other times they ought to be avoided.
Agglomeration can also occur at any point in the process (e.g., crystallization, drying,
storage).36
Agglomeration occurs when two (or more) particles collide to form an aggregate.
Interparticle growth and attractive forces between the particles then determine whether the
aggregate disintegrates or agglomerates. Aggregates are loosely bonded particles resulting
from the initial particle collision. While agglomerates refer to the more tightly packed
particles that result from solid bridges or agglomerative bonds; agglomerates are not easily
disintegrated.36,37 Agglomeration mechanisms depend on process conditions, mainly
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supersaturation and agitation rate, but also on the size of the particles in suspension.
Smaller particles necessitate lesser forces to become agglomerates while larger particles
require phenomena such as solid or liquid bridges to become agglomerates.36 During the
formation of an aggregate there is solution between the crystals that have collided, this is
often referred to as a liquid bridge. The strength of the liquid bridge determines whether
the crystals will adhere long enough for an agglomerative bond to form through intergrowth
and cementation.37
Breakage can occur from continued collisions between particles. At high agitation rates,
it becomes more difficult to form aggregates as the initial forces holding the particles
together may not be able to withstand the shear forces in the fluid. Breakage is mainly
influenced by agitation but can depend on suspension density as well. As the concentration
of crystals in a suspension increases the aggregation process is more greatly influenced by
breakage rather than agglomeration. For that reason, higher suspension concentrations and
higher mixing intensities, tend to produce smaller particle sizes and less agglomeration.36
At high suspension concentrations are particles usually smaller, aggregation forces are
weaker, and supersaturation levels are lower. These factors all inhibit agglomeration
especially under agitation. Agglomeration is predominant at high levels of supersaturation
because colliding particles can bind more firmly as intergrowth and cementation are faster
and stronger.36,37
Rates for agglomeration have been derived empirically throughout the literature. These
empirical rate expressions encompass the both physical (e.g., particle size) and
environmental (e.g., supersaturation and agitation rate) conditions affecting agglomeration
and breakage. Initial aggregation and breakage rates where simply size dependent
expressions that were proportional to the volume of particle:
𝐾𝑎𝑔𝑟 = 𝛽𝑎𝑔𝑟 [𝐿𝑖 + 𝐿𝑗 ]3
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𝐾𝑏𝑟𝑒 = 𝛽𝑏𝑟𝑒 [𝐿𝑖 + 𝐿𝑗 ]3
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In equations 2.19 and 2.20, 𝐾𝑎𝑔𝑟 and 𝐾𝑏𝑟𝑒 represent aggregation and breakage kernels.
This kernels are used in population balance equations (PBEs) that describe various
crystallization processes. 𝛽𝑎𝑔𝑟 and 𝛽𝑏𝑟𝑒 represent the aggregation and breakage rates,
respectively. 𝐿𝑖 and 𝐿𝑗 are the sizes of the particles aggregating or breaking.37 The breakage
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term is also a function of the crystallizer conditions such as supersaturation and agitation.
It can be expressed as:
𝐾𝑏𝑟𝑒 = 𝛽𝑏𝑟𝑒 𝜖 𝑟 𝑆 𝑠 𝑓(𝐿𝑖 , 𝐿𝑗 )
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In this equation, 𝑆 represents the supersaturation and 𝜖 is the energy dissipation in the tank
which is indicative of the shear field produced from agitation. Considering the aggregation
and breakage rates there will be a net agglomeration rate that can be expressed as:
𝐾𝑎𝑔𝑔 = 𝛽𝑎𝑔𝑔 𝜖 𝑝 𝑆 𝑞 𝑓(𝐿𝑖 , 𝐿𝑗 )
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Equation 2.22 considers the effects of supersaturation and energy dissipation. In the
equation, 𝛽𝑎𝑔𝑔 accounts for both aggregation and breakage. The powers in equations 2.21
and 2.22 (𝑟 , 𝑠 , 𝑝 , and 𝑞 ) can be fitted to experimental data.37 The section refers to
agglomeration and breakage on from a broadly scope. Agglomeration as it pertains to SC
will be discussed in proceeding chapters.
2.2.4

Crystal morphology and polymorphism

The morphology, or shape, of a crystal is an important property of a crystal structure. It
affects flow properties, filtration, bulk density, and other rheological properties.32 The
morphology of a crystal is a function of both internal structure (e.g., the internal symmetry
of the crystal) and external conditions (e.g., growth rates, choice of solvent, impurities).34
Shape factors for both volume and area are a mathematical way of describing the shape of
crystal as a function of its characteristic length.32
Polymorphism is a molecule’s ability to exhibit more than one crystal structure. Each
polymorph has different physical properties; which could include different morphologies.
The crystallization conditions will affect which polymorph(s) crystallize. Molecules that
have different polymorphs present crystallization challenges. In many pharmaceutical
crystallization cases, one polymorph is preferred over another. However, it can be difficult
to control which polymorph crystallizes outs of solution or to identify which polymorph is
present because one polymorph can also transform to another.32 Transformation of one
polymorph to another usually occurs at a specific transition temperature and can be
characterized by changes in thermodynamic properties.34 Control and understanding of
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nucleation and growth mechanisms help produce the desired polymorph and subsequent
morphology.

Crystallization techniques
Supersaturation is the key parameter in crystallization. For this reason, generation and
control of supersaturation is the focus of most crystallization techniques. There are many
different methods to generate and maintain supersaturation, but they all rely on the two
properties that most significantly influence the level of supersaturation; concentration and
temperature.
Cooling crystallization is a very common type of crystallization technique. For most
compounds, solubility decreases with decreasing temperature. If solubility changes
significantly with temperature, and the temperature range required to create a significant
change is attainable, then cooling crystallization is a viable option. In such cases, cooling
crystallization results in high product yield.32,34 Cooling crystallization is carried out by
preparing a saturated solution at given temperature and then cooling the solution until the
system becomes supersaturated. Supersaturation then results in nucleation and growth of
crystals. Controlling the cooling rate will control the rate at which supersaturation is
generated. Cooling rate, or the rate of supersaturation generation, will also have a
significant influence on the nucleation and growth processes.
Anti-solvent crystallization, also referred to as drowning-out, is a viable crystallization
option when the solubility changes are negligible with significant changes in temperature,
or when the necessary operating temperature range is unachievable. The anti-solvent
method changes the saturation level of solution by adding a solvent mixture to the system.
The solvent mixture should be miscible and significantly decrease the solubility of the
solute in the system.32 The solvent used for the mixture is often referred to as the antisolvent or poor solvent. Controlling the rate of anti-solvent addition will control the rate at
which supersaturation is generated. Anti-solvent addition rate will be the main parameter
governing the nucleation and growth processes for this technique. Reverse anti-solvent
crystallization also works by introducing a solvent mixture the system, but instead the
solution is added to the anti-solvent. The reverse addition technique causes the system to
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approach the metastable zone limit rapidly which in turn produces small crystals or
amorphous solids.
Evaporation crystallization is also viable option when changes in solubility with respect
to temperature are insignificant and/or a third miscible solvent is not available. This
technique is especially useful for non-aqueous, high vapor pressure solvents. The saturation
level increases by evaporating the solvent until the system finally becomes supersaturated.
The process is typically run under vacuum and constant temperature to better control the
evaporation rate.32 The rate of evaporation will control the crystallization kinetics in this
technique.
Crystallization can also be carried out through a chemical reaction. This is often
referred to as reaction precipitation. In reaction precipitation, two soluble compounds are
mixed in solution and react with each other. The resulting product from the reaction then
has low solubility in the solution causing the solution to become supersaturated and
crystallize or precipitate.32 The key parameter controlling supersaturation in this case is the
reaction rate. Reaction crystallization can be more difficult to control when compared to
key parameters of other techniques because the reaction rate itself depends on many other
parameters and reaction conditions.
In all crystallization techniques, the key is to maintain uniform supersaturation levels.
This is done by ensuring proper mixing throughout the system. Local supersaturation can
cause many problems including fines and wide particle size distributions (PSDs).

Operating modes
A crystallization process can be operated in either batch or continuous mode. Batch
crystallization is a versatile, recipe based, mode of operation that can be adapted for
specific product properties and can be used for different products. Batch crystallizers are
also relatively inexpensive when compared to other methods of operation and are simple
to use. Continuous operation allows for lower overall capital investment, more efficient
production, easier scalability, and better waste or off-specification product management.
Batch operation is difficult to scale up because the inherent science is unknown and
operation occurs dynamically (unsteady state). Continuous operation, although easier to
scale, makes the process design more difficult because of all the interplaying parameters.
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However, continuous operation is primarily viable when production rates are very large (>
50 tons/day).32
2.4.1

Batch

Batch crystallization can be carried using out any of the techniques described previously
or in combination with one or more techniques. Cooling crystallization carried out in batch
is most common because of the ease with which the temperature of the crystallizer can be
controlled. Anti-solvent crystallization in batch can be carried out alone or combined with
cooling crystallization to create supersaturation and/or change the solubility of the solute.
One downside to this method is the potential for local high supersaturation at the addition
point of the anti-solvent. This can cause spontaneous nucleation which can have a major
effect on the final CSD.36 One common technique used in batch crystallization is seeded
crystallization. Here crystal seeds are used to initiate the crystallization process. The seeds
are usually crystalline material of the solute and help reduce spontaneous nucleation and
control polymorphism and CSD.36
2.4.2

Continuous

For continuous crystallization, the two most common operation configurations are mixed
suspension mixed product removal (MSMPR) crystallizer and plug flow crystallizer (PFC).
The MSMPR is like the ideal continuous stirred tank reactor in that it assumes perfect
mixing without spatial variations. Figure 2.3 shows the two-stage MSMPR used in this
thesis work. The system employs a vacuum and nitrogen based transfer line to remove
slurry from one vessel to the another. By using nitrogen, an inert gas, impurities are kept
away from the slurry so to not affect the crystallization process. A control box is used to
set the cycle time, vacuum buildup time, sampling time, pressure buildup time and purging
times that control the rate of removal from each stage. The MSMPR system is versatile in
that it can be constructed from vessels used in previous batch systems and employs the
same mixing mechanism as a batch system. Several literature examples exists displaying
the design and evaluation of the MSMPR for crystallization processes.18,19,38-40
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Figure 2.3 Two-stage mixed suspension mixed product removal (MSMPR).

The PFC is assumed to have plug flow behavior meaning that it has complete radial
mixing and negligible axial mixing.41 However, it is difficult to attained sufficient mixing
to model a system as plug flow because that usually requires very high flow rates or very
long reactors. Both of which are not common in industrial crystallization. Because of this,
crystallizers have been design to induce this mixing through turbulent flows generated by
process enhancements. One such crystallizer is the continuous oscillatory baffled
crystallizer (COBC). The COBC has periodically spaced baffles along the length of the
reactor and superimposed oscillatory motion on the fluid, at a set frequency and amplitude,
which promotes the necessary radial and axial mixing for plug flow behavior to be
achieved.42,43

Process analytical technologies (PAT)
Prior to 2004, process analytical technologies were not common in pharmaceutical
development and manufacturing processes. The industry had become accustomed to
predominantly batch processes and end-point laboratory testing to assess product quality.
Given their familiarity with regulatory standards and fearing an increase in regulatory
hurdles, the industry was hesitant to introduce any innovation into their development and
manufacturing systems.44 This widespread sentiment prompted the U.S. Food and Drug
Administration (FDA) to issue its “Guidance for Industry: PAT – A Framework for
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Innovative Pharmaceutical Development, Manufacturing, and Quality Assurance.” The
goal of the guidance was to encourage innovation and process understanding that would
lead to more accurate and efficient processes with improved product quality by taking
advantage of the significant advances in PAT tools. The guidance defined PAT as “a
system for designing, analyzing, and controlling manufacturing through timely
measurements (i.e., during processing) of critical quality and performance attributes of raw
and in-process materials and processes, with the goal of ensuring final product quality.”
The tools can be categorized as: multivariate tools for design, data acquisition and analysis;
process analyzers; process control tools; and continuous improvement and knowledge
management tools.20 Process analyzers have quickly become of interest in the
pharmaceutical industry, especially for crystallization processes, due to the various
measurement types and large volume of process information and insight produced by these
tools.
Process analyzers are typically senor-based and can be categorized to have at-, on-, or
in-line measurement. A measurement is considered: at-line when produced from a sample
that is removed and isolated from the process, and analyzed in close proximity to the
process stream; on-line when produced from a sample that is diverted from, and possibly
returned to, the process stream; and in-line when produced from a sample that is not
removed from the process stream through either invasive or noninvasive means.20 By
providing various measurement types, process analyzers allow for flexible implementation.
The most insightful type of measurement is often a real-time in-line measurement because
it requires no sample preparation and provides in process attributes. These features provide
a method by which processes can be understood mechanistically and frequently assessed
for rapid troubleshooting. Crystallization processes are a great beneficiary of real-time inline process analyzers because its process parameters ultimately determine purity,
morphology, polymorphic form, crystallinity, crystal size and size distribution, dissolution,
bioavailability, and pharmacokinetics/pharmacodynamics (PK/PD).0,46
Examples of PAT implementation in crystallization processes are abundant throughout
the literature.17,21,47-49 However, there is a general lack of use of PAT tools in SC systems.
Some of the most common PAT tools are used in this thesis and include the focused beam
reflectance measurement (FBRM), particles vision microscopy (PVM), and attenuated
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total reflectance (ATR)-UV/Vis. Other common tools include the ATR-FTIR, Raman
spectroscopy, and NIR. These tools are used to monitor solute concentration. The
proceeding sections will a detailed explanation of the PAT tools used in this thesis and
their implementation.
2.5.1

Focused beam reflectance measurement (FBRM)

Particle size, morphology, and size distribution information are critical quality attributes
of a crystallization process that effect other downstream processes and final product
application. The ability to characterize these properties, particularly in-situ, can
significantly aid in the design and optimization of a pharmaceutical manufacturing line.
The FBRM is an in-situ laser reflectance technique that can be used in many crystallization
applications including: solubility and metastable zone width determination50, evaluation of
seed effectiveness51, identification of polymorphic transformations52, effects of different
impurity profiles53, estimation of nucleation kinetics54, particle size optimization55, and
process control.56-58 The FBRM uses a solid state laser light source to produce a continuous
beam of light that is highly focused on a spot near the surface of the probe’s window. An
electric motor then rotates the optics, allowing the focused beam of laser light to
continuously scan over particles passing through the probe window. As the rotating laser
crosses the path of a particle, light is backscattered to the probe where the reflectance is
detected.58 Given the known rotation speed of the optics (2 m/s), the duration of the
reflectance determines the distance the beam has scanned on the particle’s surface. This
measured distance is known as the chord length and the resulting measurement of the
system is a chord length distribution (CLD). An assumption in this measurement is the
particle velocity is much smaller than the rotating laser velocity, relative to the probe
window.58,59 Figure 2.4 depicts the how the ParticleTrack with FBRM technology by
Mettler Toledo works.
Many attempts and methods have been proposed to determine the CSD from the
CLD.61-65 Ultimately, the CLD is correlated but not the same as the CSD because the
random motion and orientation of the particles in suspension does not guarantee
measurement of the true characteristic length of a particle (e.g., diameter). However, the
CLD is a function of particle concentration, size and shape and is highly sensitive to
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changes in these properties. This sensitivity allows the FBRM to be used as a process
analyzer that can provide a process signature20 of the system dynamics for design and
optimization. An advantage of the FBRM, over traditional offline laser diffraction
techniques, is the measurement principle does not require assumptions regarding particle
shape and the FBRM has much higher statistical robustness. A typical FBRM probe can
also be exposed to a wide range of operating temperatures and pressures.58 An important
consideration when using the FBRM is the optical property of the material of interest as
the measurement technique requires light backscattering.66 Other considerations when
using an FBRM include understanding the effects of stirring conditions, particle properties,
particle concentration, laser beam spreading, and particle weighting.58,59,67

Figure 2.4 Schematic representation of the ParticleTrack (FBRM) by Mettler Toledo. Reprinted
with permission from [60] Mettler Toledo.

2.5.2

Particle vision measurement (PVM)

Due to the relative data produced by the FBRM, i.e., chord length distribution as opposed
to size distribution, it is often used in tandem with in-situ microscopy techniques. These
techniques capture images of a process which aid in interpreting data from other process
analyzers like the FBRM. In-situ microscopy has origins in the early 1990s where it was
commonly used to observe bioprocess (e.g., yeast cells in brewery tanks).68 These
techniques can be characterized into two categories: incident light microscopes and
transmitted light microscopes.69 Today there are numerous examples in the literature of
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crystallization monitoring via in-situ microscopy techniques, in particular the use of PVM
in combination with FBRM.17,21,44,46,50,52,54 Applications include process understanding,
polymorph transformation, agglomeration, and breakage.70,71 The PVM is a probe-based
instrument that produces high resolution images of particles and their interactions in
suspension, in real-time. Allowing the in the visualization of process mechanisms without
process sampling. The latest version Mettler Toledo’s ParticleView V19, which is used in
this thesis consists of four front lasers and four back lasers. The lasers serve as light sources
with the front lasers focused on the field of view to provide backscatter from particles and
the back lasers are focused beyond the field of view to provide trans-illumination lighting.
The high resolution (>2 µm) images produced by the PVM provide size and shape
characteristics of the particles (or droplets72) in suspension. Like the FBRM, the PVM can
operate under a board range of operating temperatures and pressures. The high frequency
of high quality images the PVM can capture also provides the statistical robustness
necessary for image analysis techniques.21 Figure 2.5 depicts the how the ParticleView
with PVM by Mettler Toledo works.

Figure 2.5 Schematic of the ParticleView (PVM) by Mettler Toledo. Reprinted with permission
from [73] Mettler Toledo.
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2.5.3

UV-Vis Spectroscopy

UV-Vis spectroscopy is a simple, versatile, quick and accurate technique that measures
photon absorption in the ultra-violet (UV) (200-400 nm) and visible (Vis) (400-800 nm)
ranges of the electromagnetic spectrum. The instrument measures the discrete transition
from one electronic state to another upon light radiation. The measurement (absorbance) is
correlated with the molecular structure and geometry of a compound. 74 Hence, the
technique is often utilized to measure solute concentration in solution. The absorbance is
related to solute concentration in solution via Bouguer-Lambert-Beer law:
𝐴 = 𝜀𝐶𝑙
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where 𝜀 is the molar absorption (extinction) coefficient, 𝐶 is the concentration of the
absorbing species, and 𝑙 is the length of the radiation path through the sample.75
Given its versatility, in-situ UV-Vis spectroscopy has been widely employed to monitor
solution concentration and implement control schemes for crystallization processes.9,76-78
However, for optimal use of such spectroscopy the solvent of choice, material properties
(e.g., refractive index), and process conditions (e.g., solids concentration)

must be

considered. Some solvents can have different wavelength cutoffs than necessary for a
specific compound while other solvents can cause band broadening making identification
and monitoring more difficult and less sensitive.75 In cases where compounds have
overlapping bands (peaks) or weak resolution, the derivative of the absorbance can be used
for more precise identification of the solute molecule of interest.74

Principal component analysis (PCA)
Per the definition of PAT, designing, analyzing and/or controlling a process are key
applications for PAT tools. Some of the common process analyzers aid in gaining process
understanding via real-time, in-situ process measurements. Modeling via PBEs can allow
for better experimental design, process understanding and reduced experiments.
Combining PBMs with an optimization framework can provide optimal process conditions
to achieve desired final product properties. However, none of these techniques provide a
method by which process data can be easily analyzed and interpreted. In fact, in the case
of process analyzers, many times the process data can become even more complex and
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multivariate with less conclusive trends to help identify key process signatures. Principal
component analysis (PCA) forms the basis for multivariate data analysis, and approximates
a data set via a reduction in the data matrix. PCA has many different applications from data
simplification and reduction to variable selection, classification and outlier detection to
modeling and predicting.79 Examples of PCA applications in crystallization include
simplification and calibration of spectroscopy data (e.g., UV/Vis, FTIR, Raman), image
analysis, solvent selection, process monitoring, prediction, and control.10,17,74,80-82
A data matrix 𝑋 is composed of 𝑁 rows representing objects and 𝐾 columns
representing variables. By selecting the appropriate objects and variables, the data matrix
𝑋 of 𝐾-dimensional space can be well modeled or explained by a submatrix on an 𝐴dimensional subspace. The reduction into a lower-dimensional subspace is done by
projecting the 𝑋 into vectors 𝑡 and 𝑝′ which compose the columns of matrix 𝑇 and the
rows of matrix 𝑃′, respectively.79 The number of rows of 𝑃′ and columns of 𝑇 correspond
to the number of principal components used to reduce 𝑋. The PCA model for 𝑋 then
becomes:
𝑋 = 1𝑥̅ + 𝑇𝑃′ + 𝐸
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𝐸 represents the matrix of deviations or residuals between the projections (𝑇𝑃′ ) and the
original data 𝑋. The residuals contain the unexplained variance within the data set. 𝑥̅ is the
mean vector and is used to mean center and scale the original data to ensure that all
variables are weighted equally by the statistical model; avoiding any bias due to differences
in magnitude. Other matrix transformations can be applied to smooth or centralize the data.
Vectors are 𝑡𝑖 known as score vectors and explain the correlation or dominant patterns
between objects while the vectors 𝑝𝑖 are known as loadings and contain the dominant
variable patterns of the data set. Score plots, i.e., plots of score vectors against each other
(e.g., 𝑡1 vs 𝑡2 ), can help identify clusters or classes between the objects.79 Score plots can
be superimposed with loading plots to provide information about the relationship with
classes of objects and classes of variables. Scores and loadings correspond to the
eigenvalues containing the most information. The larger the eigenvalue of a principal
component the more information the component contains about the original data set. The
rule of thumb is principal components with eigenvalues larger than one have significant
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capability in describing the original data set. Principal components with eigenvalues less
than one are mainly comprised of the noise in the data. The evaluation of eigenvalues is a
mathematical technique, where the eigenvectors of large eigenvalues represent the
directions of maximum variance and hence the most amount of information. If the data
exhibits high levels of similarity, a fewer number of principal components is required to
approximate the data set.79

Crystallization modeling
Polymorphism, crystal morphology, and CSD are crystal product properties that are a direct
result of the crystallization process and its operating conditions. The CSD inside a
crystallizer affects the consumption of supersaturation, which in turn influences nucleation
and growth rates, morphology, operation stability, and many other product and process
properties.34 Prediction, monitoring and control of the CSD is essential in understanding
the crystallization process and producing particles of high quality. The most widely applied
method of understanding and modeling the interactions between CSD and process and
product properties is the use of PBEs first introduce by Randolph & Larson (1988).83
The population balance essentially requires a number balance be satisfied in the
crystallization process. The equations for the population balance are therefore expressed in
terms of number distributions. The population balance can then be expressed in a similar
manner as the energy and mass balances:
𝐴𝑐𝑐𝑢𝑚𝑢𝑙𝑎𝑡𝑖𝑜𝑛 = 𝐼𝑛𝑝𝑢𝑡 − 𝑂𝑢𝑡𝑝𝑢𝑡 + 𝑁𝑒𝑡 𝐺𝑒𝑛𝑒𝑟𝑎𝑡𝑖𝑜𝑛
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If the 𝑁𝑒𝑡 𝐺𝑒𝑛𝑒𝑟𝑎𝑡𝑖𝑜𝑛 of particles is taken to be (𝐵 − 𝐷)𝑑𝐿, where 𝐵 and 𝐷 are the birth
and death functions, respectively, and the region of interest is said to move convectively
with the particles so that there is no 𝐼𝑛𝑝𝑢𝑡 or 𝑂𝑢𝑡𝑝𝑢𝑡 . The total population can be
described as:
𝑑
𝑑𝑡

∫ 𝑛 𝑑𝐿 = ∫(𝐵 − 𝐷) 𝑑𝐿
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Using various mathematical techniques, the above can simplified and written as:
𝜕𝑛
𝜕𝑡

+ ∇ ∗ (𝒗𝑛) − 𝐵 + 𝐷 = 0

2.30
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Here 𝒗 refers to the rate of change of the set of external and internal coordinates.34,83 The
internal coordinate can be taken to be crystal size (𝐿) or any other internal property of
interest, and the external coordinate can be taken to be the crystallizer length ( 𝑥 ).
Considering a steady state case with negligible birth and death, equation 2.25 can be
rewritten as:
𝜕

𝜕

𝜕𝑥

𝜕𝐿

𝜕

(𝑣𝑥 𝑛) = − ( 𝑛) = − (𝐺𝑛)
𝜕𝐿 𝜕𝑡
𝜕𝐿
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where 𝐺 is the linear growth rate equal to 𝜕𝐿/𝜕𝑡. Equation 2.27 describes the PSD along
both the spatial and size coordinates. In practice, the spatial distribution is insignificant as
most applications are implemented under ideal conditions. Therefore, equation 2.26 and
2.27 are usually averaged over the external coordinate so to describe a more specific region
of the system.83 This concept is applied to both batch and continuous MSMPR crystallizers.
For a batch case that assumes perfect mixing, negligible agglomeration/breakage, and size
independent growth, the PBE can be expressed as:
𝜕𝑛
𝜕𝑡

𝜕𝑛

+ 𝐺 𝜕𝐿 = 0
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For a continuous MSMPR with the same assumptions and if there are no crystals in the
inlet stream, the population equation balance can be expressed as:
𝜕𝑛
𝜕𝑡

𝜕𝑛

𝑛

+ 𝐺 𝜕𝐿 + 𝜏 = 0
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where 𝜏 = 𝑉/𝑄, 𝑉 is the operating volume of crystallizer and 𝑄 is the inlet and outlet flow
rate. The residence time (𝜏) becomes an important parameter controlling or affecting the
final crystal properties. For a continuous MSMPR operating under steady state conditions
equation 2.29 simplifies to:
𝜕𝑛

𝑛

𝐺 𝜕𝐿 + 𝜏 = 0
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This equation can be integrated to solve for the CSD with the appropriate boundary
conditions.34,41,83
𝐼𝑛𝑖𝑡𝑖𝑎𝑙 𝐶𝑜𝑛𝑑𝑖𝑡𝑖𝑜𝑛: 𝑛(0, 𝐿) = 𝑛(𝐿) = 𝑛0
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𝐵𝑜𝑢𝑛𝑑𝑎𝑟𝑦 𝐶𝑜𝑛𝑑𝑖𝑡𝑖𝑜𝑛: 𝑛(𝑡, 0) = 𝐵𝑛𝑢𝑐

2.36
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The given equations that represent batch and continuous MSMPR crystallization can now
be coupled with various definitions for nucleation and growth rates, as well as with the
respective mass balances. Numerous solution methods exist to solve the PBM for a
crystallization system. Two of the most common and efficient solution methods are the
method of moments (MOM) and the QMOM. The two methods will be discussed in the
proceeding sections with QMOM used as the method of choice throughout thesis work.
2.7.1

Method of moments (MOM)

Solving the various forms of equation 2.25 permits the calculation of the CSD and other
crystal properties. The PBE also serve as a tool for modeling and understanding the
different mechanisms occurring during crystallization. Because a crystallization does not
produce monodispersed crystals, information about the crystal size distribution is usually
expressed as an average. The most common method of solving PBEs is by using a moment
transformation. The moment of a distribution is expressed as:
∞

𝜇𝑘 = ∫0 𝐿𝑘 𝑛 𝑑𝐿

2.37

The different moments of the distribution are representative of different physical properties.
The zeroth moment represents the number of crystals; the first represents the sum of the
characteristic lengths of the all crystals in the distribution; the ratio of the first and zeroth
moment represents the mean size of the crystals; the third moment multiplied by crystal
density represents the total concentration of crystals in the slurry.83 Substituting equation
2.33 into equation 2.28 yields:
𝑑𝜇𝑘
𝑑𝑡

+ 𝑘𝐺𝜇𝑘−1 = 0

2.38

Equation 2.34 is consistent since 𝑘 = 0 represents the zeroth moment, or total particles,
and would not be affected by growth.
Moment transformation of the PBE converts the system of equations into a set of
ordinary differential equations (ODEs) that describe the evolution of the moments of a
distribution and can be relatively simple to solve; often having analytical solutions. As
opposed to the original partial differential equation (PDE), which is computationally
cumbersome to solve. However, it requires the set of ODEs to be in the closed form;
meaning the moments are to be described only as a function of themselves. The closure

33
condition becomes very restricted and limits the types of growth functions and
agglomeration kernels implemented.84,85 For example, the necessary and sufficient
condition for closure of a growth-only crystallization process is:
𝐺(𝐿) = 𝑎 + 𝑏𝐿

2.39

where 𝑎 and 𝑏 are independent of the crystal size, 𝐿. The case of 𝑏 = 0, is the well-studied
size independent growth scenario (equation 2.28).34,83 Fortunately, in practice this growth
rate condition is relevant, given that crystallization properties are usually examined as an
average of the distribution and not on an individual basis.
2.7.2

Quadrature method of moments (QMOM)

The QMOM technique is much like MOM, except QMOM can handle a much broader
range of growth functions and agglomeration kernels. QMOM replaces the closure
requirement that restricts MOM by approximating the closure condition. The technique
uses the summation of abscissas (𝐿𝑖 ) and weights (𝑤𝑖 ) to approximate and completely
specify the low-order moments of the unknown distribution, 𝑛(𝐿). The MOM technique is
not able to accurately specify the low-order moments unless the equations meet the closure
condition or some other type of simplification is made.85 Moreover, the QMOM
approximation becomes completely independent of the growth function and agglomeration
kernel.84
𝑘
𝜇𝑘 = ∫ 𝐿𝑘 𝑛(𝐿)𝑑𝐿 = ∑𝑁
𝑖=1 𝐿𝑖 𝑤𝑖

𝑘 = 0, … , 2𝑁 − 1

2.40

Equation 2.36 is the quadrature approximation of the moments for 𝑁 quadrature points.
Substituting equation 2.36 into equation 2.28 yields:
𝑑𝜇𝑘
𝑑𝑡

𝑘−1
+ 𝑘𝐺 ∑𝑁
𝑤𝑖 = 0
𝑖=1 𝐿𝑖

𝑘 = 0, … ,2𝑁 − 1

2.41

The number of quadrature points used determines the number of nodes used to approximate
the integral, i.e., the distribution. 𝑁 also determines the moments whose evolutions are
being tracked and used to solve the weights and abscissas, i.e., the first 2𝑁 moments
determine the first 𝑁 weights and abscissas.
The most efficient and commonly used technique to solve for the weight and abscissas
is the Product Difference (PD) algorithm.86 The PD algorithm minimizes the error
committed by replacing terms in the PBM with their quadrature approximation. The
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algorithm works by using the moment sequence (𝑁 moments) to construct a tridiagonal
Jacobian matrix (of rank 𝑁/2) whose eigenvalues and eigenvectors correspond to (𝑁/2)
weights and abscissas.84,85 Although the QMOM procedure does not directly provide the
CSD, the abscissas are related to the particle class sizes and the weights are related to the
volume fraction in the respective class size. In general, increasing the number of quadrature
points (or nodes) decreases the error of the approximation. However, 𝑁 = 3, has been
found to be the best tradeoff between accuracy and the size of the problem.84,85,87,88 A more
complex and detailed example of the use of the QMOM technique will be discussed in the
proceeding sections.

Optimization
Optimization of a process can be examined from both a physical sense, i.e., running
experiments and adjusting process parameters to achieve improved results, and a
mathematical sense, i.e., developing a model that accurately predicts the process and then
optimizing the input variables so to achieve desired final properties. In the mathematical
sense, optimization of a crystallization process requires the kinetic information discussed
in Section 2.2, a PBM that considers the relevant process mechanisms and an efficient
solution method to accurately predict the process as discussed in Section 2.6. The PAT
tools discussed in Section 2.4 can also provide insight that can be used to improve models
and ultimately lead to better optimization results. Optimization of crystallization properties
like shape, size, yield, and purity via optimal heating/cooling profiles, anti-solvent addition
profiles, and addition location(s) has been well studied in the literature.7,14,15,18,51 Although
well studied, optimization of a crystallization system can be a very complex problem
depending on the mechanisms incorporated in the PBM and the solution method chosen.
Even when expressed in terms of moments, the optimization problem would represent the
minimization of a nonlinear system. Nonlinear systems can have several local minima and
finding the global minima is not easily achievable. Several approaches exist to handle these
cases.89
A typical optimization problem for crystallization is the maximization of the mean
crystal size. The manipulative variable is either the temperature or anti-solvent addition
profile for a cooling process or anti-solvent process, respectively. For batch process, the
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batch time can either be fixed or a manipulative variable as well; the equivalent for
continuous processes would be the residence time. Fixing the batch or residence time
significantly reduces the computationally burden of the optimization problem and is
common practice. The optimization formulation for the maximization of mean crystal size
via temperature profile of a batch process can be expressed as:
min(−ℒ10,𝑒𝑛𝑑 )
𝑥(𝑘)

2.42

subject to:
𝑇𝑚𝑖𝑛 ≤ 𝑇(𝑡) ≤ 𝑇𝑚𝑎𝑥
𝑟𝑚𝑖𝑛 ≤

𝑑𝑇
𝑑𝑡

≤ 𝑟𝑚𝑎𝑥

𝐶(𝑡𝑒𝑛𝑑 ) ≤ 𝐶𝑚𝑎𝑥 (𝑡𝑒𝑛𝑑 )

2.43
2.44
2.45

𝑥 represents the vector of the variable to be optimized. It contains 𝑘 elements which is the
number of discretization of the variable representing the number of stages the variable is
divided into to describe the process.90 Each optimization problem has its own optimal level
of discretization for the manipulative variables. Significantly below this optimal 𝑘 value
the optimal solution may be inaccurate and significantly above this optimal 𝑘 can make
convergence infeasible. The objective function is −ℒ10,𝑒𝑛𝑑 and represents the moment
based final number mean diameter.91 It is expressed as the ratio of the first and zero moment:
𝜇

−ℒ10,𝑒𝑛𝑑 = 𝜇1,𝑒𝑛𝑑
0,𝑒𝑛𝑑

2.46

Optimization problems are subject to constraints the allow the optimal variable to be
achievable in a practical application. Otherwise the unconstraint optimal solution is likely
either infeasible or unrealistic in application. In this example case, there are three
constraints on temperature, heating/cooling rate, and yield. 𝑇𝑚𝑖𝑛 , 𝑇𝑚𝑎𝑥 represent the lower
and upper bounds for the temperature. 𝑟𝑚𝑖𝑛 , 𝑟𝑚𝑎𝑥 represent the lower and upper bounds for
heating/cooling rates. 𝐶(𝑡𝑒𝑛𝑑 ) represents the concentration in solution at the end of the
batch process and 𝐶𝑚𝑎𝑥 (𝑡𝑒𝑛𝑑 ) represent the maximum allowable concentration at the end
of the batch experiment.
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2.8.1

Multi-objective optimization (MOO) framework

A multi-objective optimization (MOO) framework arises from the desire to achieve
multiple, many times conflicting, objectives. A typical conflict of interest is to increase the
crystal mean size (ℒ10,𝑒𝑛𝑑 ) while decreases the aspect ratio (𝐴𝑅) of crystals. Larger crystals
with smaller aspect ratios have improved processing properties. It has been shown that an
MOO framework for increasing the mean size while simultaneously decreasing the aspect
ratio can be implement for a batch cooling crystallization.7 Another practical example is
to minimize the coefficient of variation of the distribution, minimize the nucleation and
maximize growth. Broad distributions are lead to downstream processing difficulties,
specifically they prevent uniform dosing of pharmaceuticals. A MOO framework has
proven to be more effective than a single objective in reducing fines leading to increased
growth and a narrower distribution.92 An example of a multi-objective optimization (MOO)
framework for the case of maximizing crystal mean size while decreasing aspect ratio is
formulated as follows:
min(−ℒ10,𝑒𝑛𝑑 | 𝐴𝑅)
𝑥(𝑘)

2.47

subject to equations 2.39, 2.40, and 2.41. Equation 2.43 can be rewritten as:
min(−𝑤1 ℒ10,𝑒𝑛𝑑 + 𝑤2 𝐴𝑅)
𝑥(𝑘)

2.48

where 𝑤1 and 𝑤2 represent the weighting of each objective. By varying the weightings, a
set of solutions can be obtained, depicting the tradeoff between the objectives. This is
known as the Pareto optimality and plotting set of optimal solutions is known as the Pareto
optimality. Along the Pareto frontier, a move from a single point along the curve results in
a favorable reduction in one objective and an undesirable increase in the other objective.93
Numerous optimization algorithms exist to implement desired optimization schemes.
There are ideal algorithms for linear, quadratic and nonlinear problems. However,
discussions of these algorithms are outside the scope of this thesis work. For details of
various optimization algorithms, the readers are referred to Numerical Optimization by
Nocedal & Wright (2006).94 The interior point algorithm is employed in the proceeding
sections and is described by Nocedal & Wright (2006) and Byrd et al. (1999). 94,95
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Process intensification (PI)
PI is the combination of innovative processing techniques and technologies to improve
overall process efficiency, increase yield of desire final product, and produce final product
of desired properties. While there exist many definitions for PI, generally it includes:
increasing productivity and selectivity through multi-scale designs and intelligent
intensification of unit operations, designing novel equipment based on scientific process
knowledge (e.g., multi-functional reactors, microtechnology), and the development and
implementation of multi-scale modeling frameworks to appropriately predict, design and
control processes. The aim of PI is to advantageously increase or decrease process
complexity allowing for the elimination of large, cumbersome, costly, and energyintensive processes; replacing them with smaller, less-expensive, and more efficient ones.
The smaller operation decreases the operational footprint resulting in greener, safer
processes (due waste and exposure minimization), and improved control and
automation.96,97 PI via hybridization of unit operations (or multi-functional equipment)
reduces the overall number of unit operations; leading to reduced capital and energy costs.
By increasing overall yield, the consumption and waste of raw materials is also reduced,
further adding to savings in operational costs. In the pharmaceutical indsutry, the increased
savings can be used to further drug discovery, research and development. Microscale
technology offers improved mixing dynamics resulting in reduced maldistribution or local
hotspots in a process, increase heat transfer, and an improved the design space (offers
operating conditions unattainable in convential equipment).96,97 In crystallization,
improved mixing leads to improve yield and improved uniformity throughout the product
properties.
To date, PI has been mostly exploited in reaction chemistry. Examples include: the heat
exchanger (HEX) reactor shown to decrease process time and byproduct formation, the inline monolithic reactor shown to decrease equipment size by two orders of magnitude,
spinning disk reactor shown to 90%+ reduction in process time, inventory and impurity
levels, and the reactive distillation which uses the heat of reaction to vaporize reaction
products resulting in the distillation of the products (separation).98-101 Figure 2.6 shows a
methyl acetate process that was reduced from 28 unit operations to 3, a prime example of
PI.
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Figure 2.6 PI of Eastman Chemical methyl acetate plant: (left) conventional process, (right)
intensified process. Reprinted with permission from [96]. Copyright 2002 American Chemical
Society.

Early adoption of PI was not widespread because of a number of barriers, particularly in
the pharmaceutical industry. Barriers to PI included: industrial growth strategies that focus
on mergers and acquisitions rather than innovation, an R&D focus on new products as
opposed to new manufacturing methods, fear of being first and waiting for innovation to
pass regulation before attempting implementation, lack of familiarity and exposure to such
techniques, lack of standardized lab-scale PI equipment, lack of modeling capability and
concerns over scale-up.96

However, in the last five years, examples of end-to-end

integrated continuous manufacturing of pharmaceuticals have been presented with
integration of drug synthesis, purification (e.g., crystallization, extraction), filtration,
formulation, automation and control.102-105
Many of the PI techniques implemented in pharmaceutical processes have been driven
by innovation in the technology (i.e., in equipment), specifically the emergence of
microtechnology for use in reaction applications. Very few PI techniques in the
pharmaceutical industry have revolved around innovation in the processing technique.
Moreover, there is a need to address the integration of upstream and downstream processes.
Spherical crystallization has a long history as a size enlargement technique for particulate
processes, and has the potential to be the key processing technique to integrate and intensify
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drug substance and drug product. The remaining chapters of this thesis will focus on SC
and its application as a PI technique.

Conclusions of the literature review
The discussion presented in this chapter covered crystallization fundamentals, techniques,
modes of operation, as well as PAT and modeling to provide the sufficient background
necessary to comprehend the proceeding chapters. Various modes of operation for SC
processes are implemented in the following chapters to assess their PI capabilities. Each
mode of operation incorporates PAT tools for process monitoring and understanding. A
PBM designed to track both constituent and agglomerate properties for superior process
development will also be presented. The coupling of downstream continuous unit
operations with a continuous crystallization process is also discussed to complete the
overall PI theme.
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3. A REVIEW OF SPHERICAL CRYSTALLIZATION

Introduction
Spherical crystallization originates from SA techniques used in the 1960’s to preferentially
agglomerate and recover common commodity materials. Early examples include the
agglomeration of barium sulfate106, calcium carbonate107, graphite107,108, coal31 and sand.109
In these early applications, the process was an agglomeration in suspension technique. The
key was to identify suitable agglomeration agents, called the bridging liquid or binder, to
agglomerate suspended particles. In the early 1980’s, SA expanded into pharmaceutical
applications where simultaneous precipitation (via crystallization) and agglomeration
became of interest, and the term SC was adopted.22,30 Spherical crystallization is a particle
size enlargement technique designed to improve processing properties (flowability,
compressibility) while maintaining or improving micromeritic properties (size, size
distribution, dissolution rate).110 The technique is of interest in the pharmaceutical industry
because of the frequently undesired functional properties of APIs. Moreover, in
conventional pharmaceutical operations, designing particles of enhanced micromeritic and
functional properties would require multiple unit operations (e.g., milling, granulation).
However, with SC those additional downstream unit operations can be eliminated while
other operations (i.e., filtration, washing, drying) become more efficient.111,112
Spherically crystallized particles of salicylic acid were first studied by Kawashima et
al.22,113 and reported improved properties including particle size, angle of repose,
compressibility, and tablet hardness. Since then many other compounds have exhibited
improved physio-mechanical properties from SC over conventional crystallization
including the following APIs: tolbutamide114, bucillamine115, aceclofenac116, cefotaxime
sodium117, carbamazepine118, and ibuprofen.119 The improvement in the compression
properties is believed to come from the higher tensile strength of compressed agglomerated
crystals. Agglomerates are composed of numerous small crystals of very high surface area
to volume ratios. This internal structure, along with their sphericity, increases the number
of contact points of spherical agglomerates and enhances inter-particle bonding upon
compression; leading to increased strength.119,120 Due to the nature of their internal
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structure, spherical agglomerates can also have desirable biopharmaceutical characteristics.
Spherical agglomerates of fine crystals have exhibited significantly improve dissolution
rates for some APIs.116,121,122 Bioavailability and dissolution are properties largely
dependent on particle size. The size of the agglomerated crystals and the porosity of the
agglomerates can allow for improved dissolution rates.

Spherical crystallization methods
Spherical crystallization can be achieved in five different ways: spherical agglomeration
(SA), quasi-emulsion solvent diffusion (QESD), ammonia diffusion (AD), crystallo-coagglomeration (CCA), and neutralization technique (NT).23,123 SA depends on the
miscibility of the solvents in the system and solubility of the solute. This technique
typically employs three solvents: a (good) solvent to dissolve the solute; an anti-solvent,
miscible with the solvent, to precipitate the solute; and a bridging liquid, of high affinity
for the solute and immiscible with anti-solvent (and solvent system), to preferentially wet
the solute crystals.23,123 There are instances in which the solvent itself promotes
agglomeration and behaves as the bridging liquid, in which only two solvents are
necessary.119,123 QESD requires two solvents. The solute is dissolved in the solvent and
added to the anti-solvent. Emulsion droplets then form if the affinity between the solute
and solvent is much greater than the affinity between the solvent and anti-solvent. The
emulsion formation is followed by counter-diffusion where concentration gradients cause
the solvent diffuses out of the droplets into the anti-solvent and vice versa. Counterdiffusion reduces the solubility of the solute in the droplet inducing supersaturation and
crystallization. Residual solvent within the droplet serves as the bridging liquid, promoting
agglomeration and maintaining sphericity.125,126 AD uses a system of three partially
immiscible with ammonia-water as the solvent and bridging liquid, an organic solvent as
the anti-solvent, and a hydrocarbon to promote immiscibility and agglomeration. The
immiscibility of the solvents creates emulsions which then follow a process like QESD and
two-solvent SA. This technique is typically used with amphoteric drugs.23,123,127 CCA is
the crystallization and agglomeration of a solute (drug) with another solute (drug or
excipient) using a bridging liquid. The second solute may remain in solution, particularly
in the case of excipients. The technique is very useful for poorly compressible materials as
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the inclusion of excipients can improve compressibility. However, given that the physiochemical properties of drugs and excipients differ drastically, and the selection of an
appropriate solvent system is often very challenging.23,128 For simplicity, the CCA method
maybe be referred to as co-agglomeration. Lastly, with NT, crystal formation is induced
neutralization of a basic solution containing dissolved acid and subsequent agglomeration
is caused by the addition of a bridging liquid.23,123,129 QESD and SA are the most common
applications of SC and their mechanisms are illustrated in Figure 3.1.

(a)

(b)
Figure 3.1 Schematic diagrams showing: (a) QESD and (b) SA. Adapted with permission from
[130] Copy Right 2015 American Chemical Society.

While SC offers many benefits from product quality to PI, it also increases process
complexity which may be disadvantageous or too difficult to design due to lack of
fundamental understanding. One of the most common challenges in designing a SC process
is the selection of the appropriate solvent system for both crystallization and agglomeration,
particularly finding a suitable bridging liquid.131 APIs with polymorphs pose an even
bigger challenge to selectively precipitate and agglomerate the desired form without
transformation.131,133 Moreover, SC is only attainable under a certain range of operating
conditions which can require an extensive amount of experiments to identify.23 The
proceeding sections will explore SA, discussing the process parameters which influence
final product properties, agglomeration mechanisms, differences in operating modes and
modeling of the process.
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Spherical crystallization via SA
SA can consist of simultaneous crystallization and agglomeration or the agglomeration in
suspension of fine crystals to produce spherical agglomerates. For SA applications,
crystallization is usually carried out through an anti-solvent method, sometimes referred to
as “drowning-out”, “salting-out” or “solvent change.” Anti-solvent crystallization methods
involve the addition of a miscible anti-solvent to a solution (solute dissolved in solvent)
which reduces the solubility of the solute and induces crystallization. When fine crystals
are desired or a very low solution to anti-solvent ratios (SASR), a reverse addition
technique is used where the solution is added to the anti-solvent which causes “crashingout” or “oiling out” to produce fine crystals. Reverse addition is commonly used for SA
processes, since agglomerates of fine crystals possess advantageous functional and
biopharmaceutical properties. However, the high degree of supersaturation generated by
this approach can also form emulsions and cause some agglomeration. In such cases, the
agglomeration caused by crystallization often goes unnoticed because of the agglomeration
caused by the bridging liquid.

Figure 3.2 Salicylic acid particles (left) spherically agglomerated (scale bar = 10mm), (right)
crystals via conventional crystallization (scale bar = 200m). Reprinted with permission from [22].
Copyright 1982 The American Association of the Advancement of Science.
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In cases with simultaneous crystallization and agglomeration, the bridging liquid is
present at the onset in either the solution or anti-solvent, typically in the solution. Due to
the immiscibility of the bridging liquid in the solvent system, bridging liquid droplets or
emulsions are created that contain solution. The emulsions make the process resemble
QESD.28 However, further agglomeration of the emulsions takes place. In agglomeration
in suspension cases, the bridging liquid is added after the crystallization process. Addition
of bridging liquid post crystallization, allows for various crystallization techniques to be
employed for the formation of the crystals.134 Figure 3.2 shows images of crystals of
salicylic acid (right) which have been spherically agglomerated in a water-ethanol solvent
system using chloroform as the bridging liquid (left). The following section will review
operating parameters affecting SA.

Parameters affecting spherical agglomeration
Many operational parameters have significant impact on a SA process and the quality of
its final product. One of the key considerations in developing a SA process is the choice of
bridging liquid. The main characteristic is its ability to wet the crystals of interest, in
suspension. Chow & Leung (1996) proposed some general rules for solvent and bridging
liquid selection which explicitly detailed the dependency on the miscibility of the solvent,
anti-solvent and bridging liquid, and mentioned the use of the contact angle between the
bridging liquid and crystals as a measurement to assess compatibility of a bridging
liquid.135 In addition to the solvent-bridging liquid system, other operational parameters
that must be considered include: the solvent addition method and rate; bridging liquid
addition method, rate, and amount; agitation rate, temperature and residence time.30 These
operational parameters not only the affect the precipitation process but also the
agglomeration rate and resultant particle properties.
3.4.1

Effect of solvent system

As discussed previously, the miscibility of the solvent system is of critical importance in
establishing a functional SA process. Moreover, there critical concentrations of each
solvent that dictate the feasibility. As an evaluation tool, ternary phase diagrams of the
solvent, anti-solvent, and bridging liquid have been developed and various points along the
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phase diagram have been explored to assess the feasible regions for the compositions for
each solvent. From the first reported SA study to more recently, ternary phase diagrams
have been consistent in their ability to identify the compositions at which miscibility is
optimal and within that the compositions at which SA is achieved. Examples of ternary
phase diagrams are available for the following compounds: salicylic acid22, tolbutamide131,
acebutolol hydrochloride123, fenbufen136, cefotaxmine103, benzoic acid137, simvastation122,
and etodolac.138 Figure 3.3 shows the ternary phase diagram for benzoic acid SA in a waterethanol-toluene solvent system. The region of SA feasibility is only a small portion of the
ternary phase diagram. The lines depict the region of optimal miscibility while the points
represent feasible operating compositions for agglomeration. As evident from the ternary
phase diagram, for benzoic acid the ideal miscibility and agglomeration feasibility regions
consist of a large anti-solvent composition (water), and small solvent (ethanol) and
bridging liquid (toluene) compositions. This finding is observed generally for water
insoluble compounds.

Figure 3.3 Solvent phase diagram for ethanol, water, toluene at 𝑇 = 20℃ . Reprinted with
permission from [137] Copyright 2011 Elsevier.

While ternary phase diagrams aid in developing the SA experiments, selecting the
appropriate bridging liquid takes precedence. Testing solvents for their wettability of the
solute of interest is a good starting point. The Washburn’s test, which measures the
capillary rise of liquid in a column of packed power, is one method of evaluating wettability.

46
The test measures the contact angle of the liquid with the crystals interest, perfect wetting
is equivalent to a contact angle of zero.29 Amaro-González & Biscans (2002) investigated
different solvents to serve as the bridging liquid for the SA of lobenzarit. They observed
and experimentally validated that the most suitable wetting agent was that of the lowest
contact angle produced by the Washburn’s test. In their experiments, n-hexane had the
lowest contact angle and produced larger, compact, and good sphericity agglomerates of
narrow size distribution.29 While n-hexane produced the best agglomerates, other bridging
liquid test also produced agglomerates of lesser quality; proving that the Washburn’s test
can be a good tool for bridging liquid selection and optimization. Other studies in the
literature have shown different bridging liquids to produce very different final product
properties. Differences observed include yield, strength, size, size distribution and
sphericity. Along with a low contact angle with the solid, other properties of a bridging
liquid should be a low solubility in the anti-solvent, low solubility for the solid, and a high
interfacial tension between the liquid and anti-solvent.139
3.4.2

Effects of solvent addition methods

The order in which the various solutions and solvents are mixed together can vary.
Different addition methods examples include: (i) the addition of the anti-solvent to the
solution to induce crystallization then bridging liquid addition to induce agglomeration140,
(ii) the addition of solution to an anti-solvent/bridging liquid mixture to induce
simultaneous crystallization and agglomeration140, and (iii) the addition of bridging liquid
to the solution then the addition of the bridging liquid-solution mixture to the anti-solvent
to induce simultaneous crystallization and agglomeration.26,137 When comparing method 1
and method 2, method 2 produced more compact and spherical agglomerates with much
less fines left in suspension.26 Method 3 has not been explicitly compared to the other
methods in the literature, however it is a commonly used method due to its ability to
produce dense agglomerates of very fine crystals.137,139 A recent study of the SA of
atorvastin calcium showed that method 3 produced agglomerates of improved flowability
and compressibility compared two method 1.141 The solvent addition method also becomes
important for polymorphic systems. Several studies have shown that the solvent
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composition at the onset of nucleation determines the polymorph formed.131,133,141 The
addition method should be tailored to the produce the polymorph of interest.
Along with the addition method, the rate of addition also impacts the crystallization
and agglomeration behavior, resulting in different final properties. The general observation
is the decrease in agglomerate size with increasing feed rates.30,137 The smaller size is
attributed to the increased supersaturation achieved by the higher feed rate. The
morphology of the crystals and shape of the agglomerates was observed to be unaffected
by feed rate. Mechanical strength tests showed that the fracture force of agglomerates
increased with increasing feed rates. This observation could be related to the internal
structure of the agglomerate being composed of smaller crystals can create stronger bonds
upon compression. In agglomeration-only studies, bridging liquid addition post
crystallization (method 1), increasing the feed rate of the bridging liquid also produced
smaller final agglomerates. The increased feed rate promotes dispersion of the bridging
liquid into small droplets creating smaller agglomerates.142 It is important to note that the
effect of droplet size is also correlated to the agitation rate and the size of the primary
crystals undergoing agglomeration.
3.4.3

Effect of bridging liquid content

After establishing the solvent system, operating region with in the phase diagram and
addition method, the amount of bridging liquid added (within the region of feasibility)
becomes of the most important process parameter in tuning the final product
properties.26,110,141-143 The bridging liquid content is usually quantified as the bridging
liquid to solute ratio (BSR) on a volume basis. The BSR range is highly dependent on the
system of study, and is found empirically. Each system has a critical BSR range that
determines agglomeration feasibility and efficiency. Below this range, there is no
significant agglomeration, and above this range a paste-like product is produced. The
widely-observed trend for a wide range of compounds is increasing agglomerate size with
increasing BSR within the critical range.29,137,139,142-147 Increasing the BSR within the
critical range increases the amount of bridging liquid available for agglomeration.
Increased bridging liquid availability in turn increases the probability of cohesion and
deformability. The increased cohesion and deformability allows for higher agglomeration
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efficiency resulting larger, more spherical agglomerates.137 The increased deformability
also creates more compact agglomerates leading to increased agglomerate strength using
increasing BSR. Lastly, the higher availability of bridging liquid with increasing BSR
reduces, and ultimately eliminates, fine crystals in the system leading to a narrower size
distribution.142,146
3.4.4

Effect of agitation rate and duration

The hydrodynamics of the SA system must be sufficient to allow for mixing and particle
collisions to take place. Furthermore, an optimized solvent system with the appropriate
BSR will not produce spheres without the adequate amount of mixing. Like the BSR, the
agitation rate has a lower and upper bound. Operating below the lower bound leads to
maldistribution of the bridging liquid often causing phase separation and flocculation.
Operating above the upper bound can lead to the disruption of the agglomeration process
causing breakage of agglomerates. The agitation rate bounds are much broader than those
of the BSR, for this reason there have not been studies that specifically aim to identify
those bounds. However, studies have shown that within the apparent optimal bounds
increasing the agitation rate to a certain point leads to rapid agglomerate growth and
increased agglomerate size, followed by a rapid decrease in agglomerate size due to
compaction with further increase in the agitation rate.22,26,116-118,143,148,149 The agitation rate
can serve as the design variable that leads to the desired agglomerate size.
Studies have shown the agitation rate plays an important role in the dispersion of the
bridging liquid droplets and the suspension of the agglomerates. An increase in agitation
rate leads to smaller droplet sizes.142 Collisions between crystals, bridging liquid droplets
and wet crystals are higher with increasing agitation rates, increasing the probability of
agglomeration.29 Final product properties influenced are also influenced by the agitation
rate. Properties affected include the agglomerate size distribution, porosity and
compressive strength. The increased shear forces at higher agitation rates leads greater
compaction and consolidation, producing denser agglomerates of reduced porosity,
improved flowability and sphericity, and increased compressive strength.116-118,143
Compaction and consolidation also contribute to the observed decrease in agglomerate size
with increases in agitation rate. While most studies report a decrease in the mean size with
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increasing agitation rates, there are cases that report a broadening of the overall size
distribution with increasing agitation.117 A recent study by Wu et al. (2015), observed a
decrease in the critical BSR with increasing agitation speed.141 This finding suggests that
due to the more uniform distribution of bridging liquid at higher agitation rates, particle
wetting and agglomeration become more efficient therefore requiring less bridging to
obtain agglomerates. Consolidation of agglomerates at higher agitation rates can also lead
to less entrapment of bridging liquid within the agglomerate pores making it available for
further agglomeration with other particles. In addition to agglomeration, the agitation rate
can also affect crystallization, influencing the nucleation and growth mechanisms of the
primary crystals; higher agitation rates can cause higher nucleation or secondary nucleation
and lead to formation of smaller primary crystals.34
A disadvantages of high agitation rates is the short contact times between colliding
particles. Reduced contact times can inhibit agglomeration leading to smaller agglomerates
and changes in the size distribution.117 Very high agitation rates can reduce the efficiency
of the agglomeration process due to disruptive forces overcoming the adhesive forces
during a particle-particle collision. In extreme cases, even already adhered particles can
be broken have excessive agitation. However, studies in this regard are limited because the
focus of the literature has been to optimize the process and extreme cases have rarely been
explored. Generally, the SA processes are operated in a regime where disruptive forces can
be ignored.
The duration under agitation, or residence time, is another important parameter
effecting SA product properties. In a couple studies, a modest increase in the agglomerate
size has been observed with an increase in residence time.150,150 Longer durations under
agitation can also lead to consolidation which in some instances can liberate entrapped
bridging liquid promoting continued coalescence. Eventually, an equilibrium size is
reached once the particles are sufficiently dense and can no longer consolidate, or there is
no more bridging liquid available for continued coalescence. As with increased agitation
rate, increased residence time can also impact properties like porosity and compressive
strength. Studies of salicylic and benzoic acid SA have shown decreases in porosity and
increases in sphericity and compressive strength with longer residence times.111,139 With
longer residences times, once the bridging liquid is consumed, collisions between
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agglomerate particles with each other, impeller, and vessel wall cause deformation that
leads to compaction followed by densification of the agglomerates.150 The results suggest
that a minimum batch time for agglomeration exists for each system. However, above the
minimum, for sufficiently long residence times an equilibrium size is reached after which
further increasing the residence time will have minimal effects.
3.4.5

Effect of temperature

Cooling crystallization has long been one of the predominant techniques for creating
supersaturation and inducing nucleation and growth in crystallizing systems. Temperature
changes can significantly change the solubility and dictate the supersaturation of a
crystallization process; directly impacting crystal properties.34 More importantly for SA
processes, temperature also affects the relative solubility of the solvent mixture. Resulting
in changes in the ternary phase diagram which can alter miscibility and availability of
bridging liquid in the system. Therefore, temperature changes can influence the
agglomeration process.
Interpreting the effects of temperature on SA processes can be complicated because of
competing mechanisms. For example, Kawashima et al. (1984) studied the effect of
temperature on the SA of salicylic acid in an ethanol-water-chloroform solvent system.
With an initial increase in temperature, there was a decrease in agglomerate size;
potentially due to the dissolution from the surface of the agglomerates. However, with
further increases in temperature, the size of the agglomerates increased and the size
distribution broadened.113 The results identified that changes in temperature affect the
solubility of both the solid and the bridging liquid in the system. As the temperature
increased, the solubility of chloroform decreased slightly while the solubility of the solid
increased significantly; reducing the amount of solid crystallized. Thus, the amount of
bridging liquid available for agglomeration increased relative to the amount of solid
leading to larger agglomerates at higher temperature. The constituent particles within the
agglomerates were also observed to increase with increasing temperature. Larger primary
particles are related to the growth driven tendency of crystallization processes at higher
temperatures. At lower temperatures, the crystallization process has a nucleation driven
tendency resulting in smaller particles and the immiscibility of the bridging liquid is
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increased. The combination of smaller particles and increased bridging liquid availability
results increase agglomerate size due to continued coalescence. This effects have also been
observed for carbamazepine agglomerates.118 Both studies also noted a decrease in
agglomerate bulk density and sphericity with an increase in temperature.
Contrarian results exist that report decreases in agglomerate size with increasing
temperature for benzoic acid and cefotaxime.110,139 Yield has also been reported to decrease
with increasing temperature which is usually the case for crystallization processes.
Changes in the constituent particles with temperature were consistent through the studies
depending on whether the process driven by growth (higher temperature, larger particles)
or nucleation (lower temperature, smaller particles).
3.4.6

Effect of primary crystal properties

For agglomeration in suspension process (post crystallization) the properties of particles
can also affect the final process outcome. The properties of interest being morphology and
particle size and their impact on agglomerate properties. Studies of salicylic acid have been
conducted comparing the SA of smaller crystals with equant morphology with larger
crystals of acicular morphology.142 The results showed larger crystals, due to their
morphology, agglomerated less efficiently with reduce sphericity than the smaller isotropic
crystals. Suggesting that the compaction process, which usually improves sphericity and
helps eliminate fines, was not effective for the larger acicular particles. Moreover, multiple
studies found a higher initial particle size results in a lower surface area reducing
deformability and coalescence efficiency.142,144 Smaller particles have also been shown to
require less bridging liquid for efficient agglomeration.109 The adhesive forces between
smaller particles are much stronger than for larger particles; making disruptive forces less
effective, and agglomeration more efficient. The finding is somewhat counterintuitive and
may be system not be generalized. Given the higher surface area of smaller particles, a SA
process should more bridging liquid to achieve the appropriate amount of wetting.
One process parameter related to the initial particles is slurry density or solids
concentration prior to agglomeration. Blandin et al. (2003) observed, below a certain solids
concentration (𝐶𝑠 ), increasing 𝐶𝑠 led to a faster agglomeration process with larger final
agglomerates of salicylic acid. For further increases in 𝐶𝑠 , above the limiting 𝐶𝑠 , no change
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in the final agglomerate size was observed. However, the porosity of the final agglomerates
did decrease with increasing 𝐶𝑠 within the range studied.143 The porosity results suggest
that, at higher solids concentrations, more contact points are available for collisions
contributing to the compaction process, and thereby, decreasing porosity.
3.4.7

Effect of combined process parameters

To achieve the desired final properties, a combination of process parameters can be
adjusted. Blandin et al. (2003) established some empirical equations (3.1, 3.2) relating
solids concentration (𝐶𝑠 ), BSR (𝐵𝑆𝑅), and agitation rate (𝑁) to the final agglomerate size
(𝐿𝑛𝑏 ) and the coefficient of variation (𝐶𝑉𝑛𝑏 ) for size distribution. When fit to experimental
data, the equations found the BSR to be the most significant parameter, followed by the
agitation rate.143 Empirical equations of this type can potentially be used to design and
predict the final properties for any system as parameters 𝛼 and 𝛽 are material specific. It is
also important to note that process parameters can be combined to intensify their effects on
the process and final product properties. For example, increasing addition rates of solution
or bridging liquid decreases the agglomerate size. This effect can be combined with an
increase in agitation rate, which has also shown to decrease agglomerate size, to further
decrease the attainable agglomerate size.
𝐿𝑛𝑏 = 𝛼𝐶𝑠0.3 𝑁 −0.6 𝐵𝑆𝑅 2.1

3.1

𝐶𝑉𝑛𝑏 = 𝛽𝐶𝑠0.4 𝑁 0.4 𝐵𝑆𝑅 −0.6

3.2

Mechanisms in spherical agglomeration
Many studies in the literature have thoroughly developed an understanding of how process
parameters affect a SA process and its final agglomerate properties. Effects on properties
like agglomerate size, size distribution, sphericity, porosity, compressibility and
flowability are well understood from an operational perspective. However, most of the
studies have been empirical with less emphasis on the understanding the complex
mechanisms occurring during SA. To better design, model and control SA systems
mechanistic understanding is imperative.
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Kawashima & Capes (1974) took a quantitative approach to understanding the kinetics
of the SA of sand.152 Although many assumptions and experimental pitfalls limited their
results, the study found the agglomeration kinetics in their system to be well described by
a first-order rate process. Other early studies also concluded agglomerate growth as a firstorder process. The studies described agglomerate growth as growth via layering
mechanism and correlated the rate constant to process parameters like agitation rate,
primary particle size and concentration of bridging liquid.109,113,146,153 Bemer (1979) took a
mechanistic approach to understanding SA process by analyzing the agglomeration in
suspension of powdered glass in a carbon tetrachloride-water-glycerol solvent system.
Measuring the agglomerate size at different times in a batch process, Bemer (1979) was
able to suggest four main size enlargement regimes which occur during an agglomeration
process: flocculation, zero growth, fast growth and the equilibrium regime.154 The
flocculation regime refers to the formation of loose flocs of particles initially created by
the addition of bridging liquid. During the zero-growth regime, immediately following the
flocculation regime, the particle mean size remains unchanged largely due the reduced
availability of bridging liquid following flocculation. The zero-growth regime can vary
depending on the agglomeration system (compound, solvents) and the operating conditions.
The zero-growth regime is followed by a fast growth regime, where loose flocs are
transformed into closely packed pellets by consolidation and further agglomeration occurs
via coalescence due to bridging liquid moving to the surface of the flocs. Finally, an
equilibrium is reached in which the mean size remains unchanged or reduces slightly due
to further consolidation.154 Later, Kawashima et al. (1981) developed another quantitative
relationship between the final agglomerate size and the contact angle and interfacial tension
of the bridging liquid with the particles, the size of the primary particles and their bridging
liquid saturation (related to porosity).144 These studies formed the basis of the mechanistic
understanding literature.
The initial flocculation regime, also known as the wetting phase, describes the initial
interaction between particles and bridging liquid droplets. It has been proposed the particles
and droplets interact via two mechanisms, depending on the relative size of one another:
(i) a distribution mechanism occurs when droplets are smaller than the crystals, and (ii) an
immersion mechanism occurs when the liquid droplets are larger than the particles.29,155
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The distributive mechanism describes the distribution of the bridging liquid droplet on the
surface particles; coating the particles and forming agglomerates upon collision with other
particles. The immersive mechanism describes the immersion of the particles into the
bridging liquid droplet; as more particles become immersed by a droplet, they agglomerate
and consolidate within the droplet until the droplet is fully saturated with particles. Similar
mechanisms have been proposed for the ‘nucleation’ phase during granulation.156,157 In
granulation, the immersive mechanism is known to produce granules of higher sphericity,
more density, and narrower size distributions when compared to the distributive
mechanism. Other studies compare growth mechanisms in SA to granulation as
well.113,139,142 However, care must be taken when directly relating granulation and SA
mechanisms as the continuous phases are different; a solid particle bed in granulation, a
liquid suspension in SA.
In a more focused study, Subero-Couroyer et al. (2006) used a visualization flow cell
under an optical microscope to investigate the wetting phase more thoroughly.142 The
experimental setup allowed a closer observation of the interactions between bridging liquid
droplets and particles. However, the study was limited to only immersive cases as the
droplets were considerably larger than the particles. In the study, particles of salicylic acid
were observed to enter chloroform droplets due to the high affinity of chloroform for the
particles.29,142 The results suggest that the immersive mechanism is determined by the
droplet size and the affinity between the droplets and particles. When attempting to scale
the experiments from a flow cell to a stirred vessel, using an imaging probe for visualization,
distinguishing between droplets and particles proved to be difficult. However, flocculation
was clearly evidenced at the onset, further validating flocculation as the initial agglomerate
growth regime.142 The presence of flocculation made the it difficult to assess whether the
mechanisms occurring were distributive or immersive; although, it is likely a combination
of both mechanisms. At high agitation rates, the droplet sizes were observed to be smaller
and better dispersed through the system. At well-dispersed conditions, the agglomeration
rate was observed to be faster, provide much smaller agglomerates. Again, no conclusive
interpretations could be made as smaller droplets could lead to a change in mechanism
from immersive to distributive. Some studies in the literature have explored the use of a
micro force balance to investigate the forces, geometry and interactions between bridging
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liquid and particles.158,159 While promising, the studies were also isolated small scale
investigations that likely will not transfer well in a stirred vessel.
Blandin et al. (2000, 2003) developed an in-situ visualization tool to monitor the SA
process and studied all phases of agglomerate growth proposed by Bemer (1979).143,154,160
After the flocculation and zero growth phases, the fast growth and equilibrium phases are
dominated by coalescence and compaction. In their study of a reactive crystallization and
SA, Blandin et al. (2003) observed a decrease in the mean agglomerate size immediately
following the flocculation period.143 This period of decreasing agglomerate size correlates
well with the zero-growth regime outlined by Bemer (1979) and is attributed to the
compaction of flocs due to the hydrodynamics in the system. After a minimum size is
reached due to compaction, rapid growth of the agglomerates is observed due to
coalescence. This observation, again, agrees with those of Bemer (1979) and is attributed
to bridging liquid being squeezed to the surface of agglomerates during compaction.137 The
increased availability of bridging liquid promotes the rapid-growth regime via coalescence.
A more recent study has also confirmed this finding for a benzoic acid in ethanol-watertoluene system.137 As the bridging liquid is consumed, the size distribution narrows. Once
the bridging liquid is completely consumed, the agglomerate size plateaus.143 Moreover,
all fine particles were eliminated by the end of the process. Agreeing with other studies
that suggest smaller particles, due to their higher surface area, are more susceptible to
wetting and agglomeration.142 This also suggest that the agglomeration kinetics for fine
particles is much higher than that for large particles. It has been observed that fine crystals
form flocs or nuclei at a higher rate during the flocculation phase as well.150 The study by
Blandin et al. (2003) served as the first example of the use of in-line PAT tools to gain
process insight.
Post processing scanning electron microscopy (SEM) images of agglomerates from
Blandin et al. (2003), showed possible “compaction and rearrangement” and “adhesion”
coalescence mechanisms taking place during fast growth and equilibrium growth regimes.
When coalescence was driven by compaction and rearrangement, primary particles were
arranged in a compact manner, giving very spherical and dense agglomerates. When
coalescence was driven by adhesion, the previously mentioned growth via layering
mechanism takes place.137,146,153 Layers of particles become apparent in the structure of
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agglomerates, delimited by porous/breakable areas. Particles that underwent the adhesion
mechanism also fractured easily due the voids in their structure. At-line and post processing
agglomerate strength studies showed significantly higher compressive strength for dried
agglomerates compared to agglomerates from the liquid suspension.143 This is a common
observation due to the volatility of bridging liquid and the slight solubility of the compound
in the bridging liquid. The bridging liquid bonds that bind the wet agglomerates in
suspension are replaced by solid crystalline bridges during the drying process due to
evaporation of the bridging liquid.112 The differences in agglomeration strength from in
suspension to dried point out changes occurring in the internal structure of the agglomerate
post processing. Suggesting that the use of in-line PAT tools should be even more
prominent so that mechanisms are studied and interpreted correctly.
Due to the deformable nature of the agglomerates upon initial wetting, disruptive forces
during coalescence due to shear are more likely than breakage of agglomerates.111 However,
there are conflicting views on whether a breakage mechanism exist for SA processes. At
high agitation rates, breakage may be factor and can lead to fragmentation of particles and
agglomerates.137 Without conclusive evidence of occurrence during SA, a comprehensive
mechanistic study of breakage in SA does not exist.

Modeling spherical agglomeration
The first few attempts to model SA resulted in first order approximations for agglomeration
kinetics.22,30,109,145-147,150,152 These approximations did not differ from other rates processes
as agglomerate growth was estimated as a growth rate (length/time) as opposed to an
agglomeration rate (based on an agglomeration kernel/rate). Growth rate approximations
do not truly describe the agglomeration mechanisms since it does not account for
coalescence. Since then, several modeling approaches have been developed for SA systems.
Much of the modeling work has focused on agglomeration in suspension systems to reduce
the complexity of the problem; focusing solely on developing more accurate and physically
relevant agglomeration kernels. The literature is divided between studies of crystallization
that exhibit agglomeration and studies of agglomeration suspension. The modeling studies
discussed henceforth extend the initial modeling work and focus on the development of
agglomeration kernels and PBMs that improve the predictability of SA process.

57
3.6.1

Modeling agglomeration in suspension processes

Bemer’s (1979) study on the SA of powdered glass also included a modeling perspective.
Based on the previously mentioned experimental observations, a PBM was developed to
predict the changes in the agglomerate size distribution (ASD). In the study, it was
observed that traditional granulation (agglomeration via coalescence/consolidation only)
PBMs predicted continuous agglomerate growth; contradictory to experimental
observations. To overcome the inaccuracies of coalescence only models, a model that
included coalescence from collisions, growth mechanisms (e.g., layering) and breakage
mechanisms (e.g., crushing) was developed. Referred to as the “coalescence-breakage”
model, the coalescence term was redefined from a coalescence frequency and efficiency
model; the model worked well at predicting steady-state ASDs.154 However, as previously
mentioned, the suggestion that there is a breakage mechanism during SA has yet to be
validated experimentally and cannot be generalized to all systems.
Most of the common agglomeration kernel depend solely on the size of the interacting
particles. Given the mechanisms occurring in SA, describing agglomeration solely on the
size of the particles would depict experimental results. Madec et al. (2003) developed a
multidimensional kernel that used a Monte Carlo solving approach.161 The kernel, specific
to agglomeration in suspension systems, incorporated the composition of bridging liquid,
which made the model more representative of experimental agglomeration mechanisms
discussed in Section 3.3 and 3.4. As mentioned in Section 3.4.3, there is an optimal range
for the ratio of bridging liquid to solute volume (BSR); below or above this critically
optimal range would produce loosely compacted agglomerates or paste-like amorphous
agglomerates, respectively.130,140,162 Equation 3.3 represents the agglomeration kernel used
in the study.
𝛼

𝛽 = 𝛽0 (𝐿3𝑖 + 𝐿𝑗3 ) ((𝑐𝑖 + 𝑐𝑗 ) (100 −
volume of liquid
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1−𝑐𝑜𝑝𝑡
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𝑐𝑜𝑝𝑡
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58
Here, 𝛽 is the agglomeration rate, 𝛽0 is the agglomeration rate constant, 𝐿𝑖 (𝐿𝑗 ) is the size
of the agglomerating particles, 𝑐𝑖 (𝑐𝑗 ) is the composition of bridging liquid in each particle,
𝛿 is the weight coefficient for the solid particles, 𝛼 is the weight coefficient for the liquid
droplets, and 𝑐𝑜𝑝𝑡 is the optimal bridging liquid composition. The composition function
(last term in equation 3.3) is derived such that the collisions can only occur between
particles with sufficient, not excess, bridging liquid composition, i.e., 𝑐𝑖 = 0 and 𝑐𝑖 = 100
will not yield a collision. The weighting coefficient for the solid particles is a function of
the optimal bridging liquid composition and weighting coefficient of the droplets (equation
3.5) to assure that an agglomeration event cannot occur until wetting has occurred.161 This
unique incorporation of the bridging liquid composition served as the efficiency term by
which the process would reach equilibrium. The multidimensional kernel (size,
composition) resulted in simulations of the ASDs which could better predict the growth
mechanisms explained in experimental literature.154 The study was limited to
agglomeration only systems (no nucleation, growth) and required some prior knowledge
of the system composition. Moreover, the study did not consider the hydrodynamics of the
system, the internal structure of the agglomerates, and did not track the population of
bridging liquid droplets. To address some these issues, a coupled simulation approach
using computational fluid dynamics (CFD) and Monte Carlo to track droplet and particle
populations was suggested referring to a previous study by Madec et al. (2001).163
As outlined in Section 3.4, the key mechanisms of agglomeration in suspension are: 1)
bridging liquid droplets capture solid particles and form agglomerate nuclei, 2) compaction
of the agglomerate nuclei occurs due to collisions causing a rapid decrease in mean
diameter, 3) growth via coalescence and consolidation then occurs due to the
hydrodynamics and process conditions (i.e., agitation rate and BSR), and 4) the limit of
compactibility determines when agglomeration ends.111,143,154 Based on experimental
observations, a “growth via coalescence only” model was developed by Blandin et al.
(2005).111
𝜕Ψ(𝐿,𝑡)
𝜕𝑡

= 𝑅𝐴 (𝐿, 𝑡)

3.6

In equation 3.6, Ψ represents the number density function and 𝑅𝐴 represents the
agglomeration rate distribution. The agglomeration model considered the size (𝐿) and
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concentration of the agglomerating particles ( 𝑁𝑖 or 𝑁𝑗 ) . The agglomeration rate
distribution can be broken down into its agglomeration rate (𝑟𝑎𝑔𝑔 ), a function of the
meeting probability ( 𝑓 ), the agglomeration efficiency ( eff ) and the concentration of
particles (𝑁𝑖 or 𝑁𝑗 ) in the process (equations 3.7-3.10).
𝑟𝑎𝑔𝑔 (𝑙, 𝑡) = 𝐾(𝑖, 𝑗, 𝑡)𝑁𝑖 (𝑡)𝑁𝑗 (𝑡)

3.7

𝐾(𝑖, 𝑗, 𝑡) = 𝑓(𝑖, 𝑗, 𝑡)eff(𝑖, 𝑗, 𝑡)

3.8

2
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̅̅̅̅̅̅̅̅
̅̅̅̅̅̅̅̅2 1/2
𝑓(𝑖, 𝑗, 𝑡) = 𝐶𝑐𝑜𝑙𝑙 𝛼(𝑖, 𝑗, 𝑡) (4 ) (𝑆𝑖 + 𝑆𝑗 ) [𝑢(𝑆
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3.9
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3.10

𝑜𝑡ℎ𝑒𝑟𝑤𝑖𝑠𝑒
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𝑖

𝑗

3.11

In equation 3.9, 𝑓, is described by a function of the target efficiency (𝛼), characteristic size
of size distribution class (𝑆𝑖 , 𝑆𝑗 ), and collision velocity (𝑢).164 The target efficiency is a
function of the agglomerate and fluid densities as well as the fluid viscosity. The collision
velocity is calculated from the particle-fluid relative velocity and is a function of energy
dissipation. In equation 3.10, the agglomeration efficiency, eff, is defined as the ratio of
adhesive to disruptive force. The disruptive force (𝑓𝑠𝑒𝑝 ) is a function the shear stress,
dissipation energy, and the corresponding characteristic area. The adhesive force (𝑓𝑎𝑑ℎ ) is
a function of the deformation energy, which is calculated by the agglomerate strength
(based on porosity, BSR) and the collision energy (based on primary particle size,
interfacial energy, binding force). The adhesive force is then proportional to the
deformation, porosity, binding force, and area to volume ratio (equation 3.11).111 The
simulations from the proposed model showed very good predicting ability, agreeing with
experimental data when the necessary parameters were fit to the data. An additional benefit
of the model is the incorporation of the system hydrodynamics and properties like porosity
and deformability, predicting final properties another than size. One downside is the model
development is very extensive and complex to understand. Additionally, the work did not
provide values for all parameters making it difficult to assess its validity or extend it to
other systems.
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The key difference between the “coalescence-breakage” model and the “growth via
coalescence only” model is the latter ignores breakage and fragmentation due to the
experimental observations. Agglomerates created through an agglomeration in suspension
process remain soft and do not fragment/break, but rather deform and compact upon
collisions. Madec’s et al. (2003) multidimensional agglomeration model directly addresses
the agglomeration mechanism by incorporating the bridging liquid content in each
agglomerate. If the agglomerate is saturated with bridging liquid an agglomeration event
will not occur or if two particles do not contain bridging liquid, then an agglomeration will
also not occur. Some limitations in their model include the negligence of hydrodynamics
and the solving method as stochastic method can be computational heavy.
3.6.2

Modeling simultaneous crystallization and agglomeration

While a majority of the SA modeling work covers agglomeration in suspension, many of
the experimental SA studies are combined crystallization and agglomeration studies.137,139
There is an opportunity to further improve modeling in this area by using the experimental
understanding of the combined nucleation, growth, and agglomeration mechanisms.
However, the inclusion of crystallization mechanisms such as nucleation and growth
occurring simultaneously with agglomeration requires innovative model development and
further understanding of the interplaying kinetics. David et al. (1991) began tackling this
issue by formulating an agglomeration rate kernel that incorporated particle concentration,
supersaturation, energy dissipation, crystallizer size and size of agglomerating crystals.165
A SA process, particles are constantly changing in size until an equilibrium is reached.
This change in particle size changes the hydrodynamic experience, or collision mechanism,
for each particle. David et al. (1995, 2003) followed their initial work by developing a
multi-layer agglomeration model that considers the efficiency of agglomeration based on
the collision mechanism (i.e., Brownian, laminar, or turbulent).166,167
𝛽𝑖,𝑗,𝑏 = 𝑘𝐴𝑏 𝐺
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In equations 3.12-3.14, 𝛽𝑖,𝑗,𝑏 , 𝛽𝑖,𝑗,𝑙 , and 𝛽𝑖,𝑗,𝑡 are the agglomeration rates at the Brownian,
laminar, and turbulent scales, respectively. 𝑘𝐴𝑏 , 𝑘𝐴𝑙 , 𝑘𝐴𝑡 , are the agglomeration rate
constants at the Brownian, laminar and turbulent scales, respectively. 𝐺 is the growth rate
and 𝑆𝑖 (𝑆𝑗 ) is the size of agglomerating particles. In equation 3.13, 𝑃 is the dissipated power
per unit mass and 𝜈 is the kinematic viscosity. In equation 3.14, 𝑓 is the Marchal’s relative
size function, 𝑁 is the stirring speed, 𝐷 is the particle diffusivity, and 𝜆𝑐 is the Taylor
microscale. Per David et al. (1991, 1995, 2003), Brownian collisions occur at or below the
Batchelor microscale, laminar collisions occur above the Batchelor microscale and below
the Kolmorgorov microscale, and turbulent collisions occur between the Kolmorgorov and
Taylor microscale.165,166,167

As particles increase in size, their collision mechanism

(microscale/flow field) changes from Brownian (equation 3.12) to laminar (equation 3.13)
to turbulent (equation 3.14). Above the Taylor microscale, equation 3.14 reduces to zero
as the size of agglomerates becomes too large and the system is too turbulent to produce a
successful agglomeration event.167 The agglomeration rate kernels accounted for changes
in the collision mechanism and was a function of the supersaturation and temperature
through the growth rate which served as the efficiency term. Agglomeration is enhanced
by inter-particle growth or agglomerative bond formation; when supersaturation increases,
the strength of the liquid bridge between two particles increases leading to subsequent
inter-particle growth and higher agglomeration efficiency.37 It is important to note that the
work of David et al. (2003) was not specific to agglomeration in suspension systems, but
rather crystallization processes that exhibit agglomeration. This distinction is important
because crystallization processes that exhibit agglomeration do not necessarily follow the
same mechanisms or kinetics as agglomeration in suspension processes; since there is no
bridging liquid addition. However, as shown experimentally, the effects of hydrodynamics,
particle size and particle concentration are relevant to both.
Another area of opportunity is in the development of models that have ability to track
the changes of the primary (internal) particles and multiple populations. Ochsenbein et al.
(2015) developed a coupled PBM that tracked two populations during agglomeration in
suspension for the agglomeration of needle-like crystals.168,169 The coupled PBM
framework is composed of a 2-D PBE that describes the 2-D growth of the needle-like
primary crystals. The primary crystal population is coupled to a PBE that describes the
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agglomeration of the needle-like crystals. The unique coupling of the PBM allowed the
derivation of a 2-D agglomeration kernel, considering both characteristic lengths of the
agglomerating particles as well as their orientation.
In all the modeling studies presented here, experimental observations drove the model
development by describing and identifying critical mechanisms occurring during the
agglomeration process. Different agglomerate growth regimes observed during
experimentation lead to the development of a combined coalescence and breakage model
to better predict those growth regimes.154 Experimentally observed differences in
agglomeration mechanisms as particles in size and fluid flow led to the development of a
multilayer agglomeration kernel to describe changes in the hydrodynamics.167
Consideration of more physically relevant mechanisms led to the incorporation the
composition of bridging liquid in individual agglomerates as the efficiency term in a
multidimensional agglomeration kernel.161 Accounting for both mechanistic phenomena
(e.g., deformability, collision efficiency, and compaction) and process conditions (e.g.,
energy dissipation, BSR, particle size) led to the development of a comprehensive model
with the ability to predict size and porosity.111 However, no generalization on the best
model can be made as all the studies were very system specific. A challenge with the
development of these more sophisticated models is validation. As the number of
mechanisms represented by a model increases, so do the number of equations and
parameters.

Continuous spherical crystallization
As outlined earlier, SA creates advantages in micromeritic properties of suspended
particles that lead to the improved recovery of high-value solid particles. These advantages
provide the opportunity for improved process design and efficiency, making SA a PI
technique. Combining the inherent advantages of SA with the advantages of continuous
operations can significantly improve process efficiency, adaptability and productivity. The
first example of continuous SA was the preparation spherical wax matrices of
sulfamethoxazole by Kawashima et al. (1982).30 Their study focused on understanding the
fundamental agglomeration mechanisms in a single-stage mixed suspension, mixed
product removal (MSMPR) crystallizer. The most important observed difference between
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batch and continuous SA was in the different growth regimes. Unlike batch, which
undergoes a zero-growth period and then a fast growth period before leveling off at an
equilibrium size, a continuous process undergoes a fast growth period immediately before
undergoing a size reduction period then finally leveling off at an equilibrium size.30,154 The
initial fast growth period in a continuous process is a result of the buildup of bridging liquid
and agglomerating particles during startup. However, as operation continues, the size
reduction period can be attributed to the removal of particles and bridging liquid at a more
balanced rate, i.e., steady state. With respect to most other process parameters, the same
trends exist in terms of their effect on final agglomerate properties. Tahara et al. (2015)
also used a single-stage MSMPR crystallizer for a SC technique via emulsion solvent
diffusion (ESD).170 Although a ESD technique differs from SA, their system used a solvent
recycling technique that can potentially be incorporated into SA systems to allow for higher
yield from the crystallization process. A MSMPR operates at a single point in the phase
diagram which reduces yield, including a solvent recycle stream allows for yield closer to
that of a batch system.

Conclusions
Spherical crystallization provides a direct path towards upstream and downstream
integration of pharmaceutical unit operations. The technique can tailor micromeritic
properties of crystals to produce final products of superior attributes. The enhanced
micromeritic and flow properties potentially allow for a reduction in the number of unit
operations during industrial processing, reducing time and costs. These attributes make the
technique inherently a PI technique.
For the subset of SC techniques reviewed here, i.e., SA, studies show that there are
many process parameters that influence the final agglomerates properties. Many of them
focus on the optimization of the operating conditions to achieve desired product
functionality. However, this has largely been carried out on a trial and error basis due to a
lack of mechanistic understanding and PAT tools. Figure 3.4 details the various process
considerations for developing a SA experiment. From solvent selection to final product
properties there are many key decision variables that ultimate lead to a successful SA
procedure, yielding desired properties. A bridging liquid should exhibit good wettability
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(measured by capillary rise or Washburn’s test) and low contact angle with the solid of
interest. It should also be immiscible with the suspension solvent system to allow for
preferential wetting of the solid particles. The combination of bridging liquid and
crystallization solvent can influence the crystal polymorph and morphology so the method
of bridging liquid addition and crystallization should be examined carefully. The size,
morphology, and concentration of solids in the system can affect the optimal process
parameters as well. The desired final agglomerate properties should dictate the critical
operating range for all process parameters as changes in processing parameters can lead to
a wide range of final product properties. Identifying the critical BSR and sufficient
agitation rate appeared to be of top priority throughout the literature.
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Solvent selection

• Contact angle, wettability,
miscibility
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Figure 3.4 Workflow of process considerations when developing a spherical agglomeration
process.

An understanding of the mechanisms occurring during the agglomeration process is
imperative to control and predict final product properties. Studies have been reported which
have given important insights into the mechanisms occurring during SA citing coalescence,
consolidation, growth via layering, deformation, collision efficiency, microscale dependent
collisions, composition of bridging liquid in agglomerate, fragmentation, and breakage.
Models have been proposed that take into consideration these agglomeration phenomena.
However, more mechanistic and modeling studies are required to enable experimental
design and the tailoring of specific product properties. Moreover, models that can track the
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different populations/phases (i.e., primary crystals, agglomerates, droplets) are needed so
that physically relevant agglomeration kernels can be developed that take into
consideration the effects of process conditions (i.e., agitation rate, BSR). Moving forward,
a mechanistic understanding should be enhanced due to the emergence of sophisticated online analysis techniques and PAT tools (e.g., PVM, FBRM). Combined with the traditional
off-line characterization methods, on-line PAT provides an opportunity to further enhance
our understanding of the SA mechanisms and their effects on final product properties.
Most research thus far, has been carried out using batch systems. However, continuous
SA processes have also been successfully reported. The pharmaceutical industry is
experiencing a paradigm shift from batch to continuous processing. Continuous processing
has the potential to significantly reduce plant size and footprint while generating a more
consistent product at higher levels of productivity. Combining the PI benefits of SA with
continuous processing can be the future of pharmaceutical manufacturing.
While this review focused only the SA subset of SC there are also many potential
benefits from some of the other techniques. Co-agglomeration of APIs and excipients, can
allow direct incorporation of final formulation blends into the spherical agglomerates. Coagglomeration of API and excipients adds another PI attribute to SC that can lead to direct
compression of agglomerates. This technique could further reduce the required number of
unit operations and costs in pharmaceutical manufacturing. QESD is also a technique that
has been employed in the co-agglomeration. QESD can allow the incorporation of API and
excipients of different hydrophobicity into spherical agglomerates, providing a method of
overcoming differences in wettability.
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4. FURTHER UNDERSTANDING OF AGGLOMERATION
MECHANISMS IN SPHERICAL CRYSTALLIZATION
SYSTEMS THROUGH PAT TOOLS

Introduction
Spherical crystallization of active pharmaceutical ingredients is a technique used to alter
and improve micromeritic properties of the crystals during or post the crystallization
process. While there are different SC techniques, a commonly used technique in the bulk
chemical industries is SA.152,162 Spherical agglomeration requires the use of an appropriate
bridging liquid that preferentially wets suspended particles causing agglomeration that
under suitable hydrodynamics (agitation/mixing) produce spherical agglomerates. General
guidelines for the selection of the appropriate bridging liquid and solvent system have been
developed for common chemical compounds and pharmaceutical powders. 135 To further
develop initial studies, investigations into the effects of the different operating parameters
governing a SA process have been studied in detail. The effects of operating parameters
such as the amount of bridging liquid, identification of the critical bridging liquid range,
batch or residence time, agitation rates, solute concentration, polymorphic effects, and feed
rate have been well studied in the literature.22,26,29,30,131,133,137,141,143
Blandin et al. (2003) and Subero-Couroyer et al. (2006) incorporated an in-situ
visualization probe in their salicylic acid SA experiments to study bridging liquid injection
time and wetting period.142,143 Their imaging probe allowed for real time tracking of
agglomeration mechanisms. Blandin et al. (2003) used the probe to monitor and measure
particle size in-situ. Most of the study focused on the effects of process parameters on the
agglomerate size and porosity. Subero-Couroyer et al. (2006) used the probe to identify
mechanisms such as flocculation during the binder injection period and compaction. The
study also investigated the effect of different initial particle sizes on the agglomeration
process by comparing crystallized particles of salicylic acid with salicylic acid particles
available commercially. While some insights as to how the agglomeration mechanism
differs with different primary particles size was suggested, the operating conditions at
which the differences in mechanisms occur were not clearly identified. Nonetheless, these
two studies mark some of the few cases using process analytical technologies (PAT) tools
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to study SA mechanisms. A recent few studies focused on understanding the differences in
final agglomerate properties for different bridging liquid addition methods and different
primary crystal properties.26,29,116,140,141,144 However, these studies did not clearly elucidate
differences in the agglomeration mechanism for different bridging liquid addition methods,
likely due to having not employed PAT tools. Incorporating in-line PAT tools in SA
processes has proven to be difficult due to fouling of the probes.29,142
As SC becomes more prevalent in pharmaceutical applications, process development
will require knowledge of the effects primary crystal properties, interactions between
crystals and bridging liquid, and mechanisms of various bridging liquid addition methods.
A study on the differences in mechanisms for different bridging liquid addition methods is
currently lacking. Moreover, a definitive mechanistic relationship between the primary
crystal size and bridging liquid droplet size has yet to be established. Lastly, an analysis of
flow characteristics as it pertains to the agglomeration mechanism has not been divulged.
In this work, PVM and FBRM probes are used to determine the properties of the
primary crystals, examine the interactions between crystals and bridging liquid droplets,
and assess the most suitable bridging liquid addition method for the SA of benzoic acid.
For different bridging liquid additions methods, the PVM will elucidate the respective
agglomeration mechanism. Particle size of bridging liquid droplets and primary crystals
are characterized by the FBRM to establish the relationship between primary crystal size
and bridging liquid droplet size that lead to different mechanisms. Characterization of final
agglomerates for various flow properties will be related to mechanistic findings to provide
guidelines for experimental design.

Materials and methods
4.2.1

Materials

Benzoic acid (≥99.5% purity, Sigma Aldrich) was used as the model compound for all
experiments in this study. Benzoic acid typically exhibits thin plates or needle-like
morphologies during crystallization; hence has been extensively used as a model
compound for SA throughout the literature.26,139 The solvent system consisted of ethanolwater-toluene. Ethanol (pure, 200 pf, USP grd, Decon Labs) served as the solvent in which
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to prepare benzoic acid solutions, deionized water served as the anti-solvent, and toluene
(≥99.5% assay, Fisher Scientific) as the bridging liquid.
4.2.2

Experimental setup

All experiments were carried out in a 500-mL lab scale jacketed crystallizer. Agitation was
controlled by an overhead stirrer with a three-blade retreat curve impeller. At the agitation
rates studied (300-500 rpm) particles were observed to be well suspended. Peristaltic
pumps (Cole-Palmer) and platinum cured silicon tubing (MasterFlex L/S) fed solution,
antisolvent and bridging liquid into the crystallizer. All liquids fed to the crystallizer were
added at the surface, equidistant from the impeller and crystallizer wall. The chord length
distribution and particle counts were monitored using a Mettler-Toledo Particle Track
G400 (FBRM) and in-situ images of the process was taken using a Mettler-Toledo
ParticleView V19 (PVM).
4.2.3

Methods

Benzoic acid solutions were prepared by dissolving benzoic acid in ethanol at 40 °C. The
solution was then allowed to cool down to room temperature (20 °C) prior to the start of
the experiment. The saturation temperature of the maximum concentration (0.375 g/mL)
was 15 °C. Three different bridging liquid addition methods were studied to assess their
respective agglomeration mechanism. The benzoic acid concentrations (BA conc.) of the
solution feed studied were 0.15, 0.25, and 0.375 g/mL. The SASR studied were 0.175, 0.35,
and 0.50. The BSR was equal to 1 for all experiments. The conc., SASR, and BSR were
kept constant for each method to evaluate their mechanistic differences.
(i) Bridging liquid addition method 1 (BAM1): The bridging liquid is dissolved in the
benzoic solution. To ensure homogeneity, the bridging liquid-solution mixture is
stirred for a minute. Then the bridging liquid-solution mixture is fed (2 mL/min) to
the crystallizer which contains water to induce simultaneously crystallization and
agglomeration. The stirring speed is maintained at 500 RPM through the
experiment.
(ii) Bridging liquid addition method 2 (BAM2): The benzoic acid solution is fed (2
mL/min) to the crystallizer containing water to initiate crystallization. The
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crystallization process proceeds until the particles counts (FBRM) plateau. The
bridging liquid is then fed (2 mL/min) to the crystallizer to induce agglomeration.
In this case, the crystallization and agglomeration processes are decoupled. During
the crystallization period the agitation rate is kept at 300 RPM to avoid agitation
induced shear or secondary nucleation. The agitation rate is increased to 500 RPM
upon bridging liquid addition.
(iii) Bridging liquid addition method 3 (BAM3): The benzoic acid solution and
bridging liquid are simultaneously fed to the crystallizer. In this method, the
solution is fed at 2 mL/min while the bridging liquid is fed per the BSR. For an
experiment at a benzoic acid conc. of 0.15 g/mL and a SASR of 0.175 the benzoic
acid weight percentage by volume would be 10%. Since the BSR = 1, the bridging
liquid flowrate is set to 0.20 mL/min.
Total batch time for some experiments varied as the total amount of solution feed varied.
For BAM1, the batch time for SASR = 0.175, 0.35, and 0.50 was 67, 95, and 113 min,
respectively. For all BAM2, the crystallization process was carried for 120 min and the
agglomeration process 30 min. The crystallization process was carried out for a long period
to ensure the crystals had reached an equilibrium prior to agglomeration. For BAM3, the
batch time for SASR = 0.175, 0.35, and 0.50 was 75, 130, and 167 min, respectively. The
differences in batch time does not affect the mechanistic studies. Due to the decoupling of
crystallization and agglomeration in BAM2, results from BAM2 are used to identify
significant relationships between crystal size and agglomerate properties. The method is
also used to study bridging liquid droplets. For bridging liquid droplet studies, the
experiments were carried at the same experimental conditions but on a solute-free basis
(no crystallization).
Offline images of the spherical agglomerates were taken using a Nikon SMZ1500
microscope. ImageJ was used to determine the ASD based on the Feret diameter. A
Freeman FT4 Powder Rheometer was used to characterize the flow properties of the
resulting agglomerates. The FT4 uses a blade that rotates and move down and up through
a particle bed at a defined helix angle and speed. The instrument then measures the torque,
force, and height as it traverses the particle bed. Given the blades ability to condition the
particle bed through gentle clockwise slicing flow patterns, every test starts in a
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homogeneous, low stress packing state. This conditioning process makes the FT4 ideal for
comparative studies since all samples will have a similar start condition. Actual flow
studies occur under a counter-clockwise aggressive flow pattern or for compressibility a
vented piston is used to apply force on the particle bed.171-173 Flow properties studied
include: compression percentage (CPS), stability index (SI), flow rate index (FRI), and
conditioned bulk density (CBD). The porosity of the final agglomerates was measured
using the combination of an AccuPyc II 1340 Pycnometer and GeoPyc 1360 Envelope
Density Analyzer.

Results and discussion
Table 4.1 details the experimental conditions. The BA conc. and SASR are the only
variables varied for each experiment. The BSR and agitation rate (RPM) were set to values
found suitable in the literature, BSR = 1 and RPM = 500.26,137 The theoretical
supersaturation (S) for each experiment was calculated from solubility data in the
literature.137,187 The SC procedure in this study is carried out using a reverse anti-solvent
addition where the solution is fed to anti-solvent. This type of procedure results is a
supersaturation profile which is not easily quantified. Therefore, S expressed as the ratio
of g of benzoic acid in g of the solvent mixture (ethanol-water-toluene) to the solubility of
benzoic acid in the solvent mixture (g/g). At a constant BA Conc., S doesn’t have a linear
response to changes in SASR. This observation is typical of benzoic acid in ethanol-water
mixtures and has been detailed in the literature.187 The bridging liquid to anti-solvent ratio
(BASR) is also provided based on the BSR. The BASR is specified because it is the main
parameter in the bridging liquid droplet studies. The table also details the success rate of
the different bridging liquid addition methods. BAM2 was the most successfully at
producing spherical agglomerates. BAM1 showed some success both also produced
elongated agglomerates while BAM3 produced only elongated agglomerates. Experiments
3, 8 and 9 did not produce agglomerates for any of the methods. For experiment 3 and 9, it
was observed that the high solubility at SASR = 0.5 was too high to produce the sufficient
crystallization (experiment 3) or adequate immiscibility of the bridging liquid (experiment
9). For experiment 8, the supersaturation was too high, yield high nucleation and resulting
in insufficient bridging liquid at a BSR = 1.
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Table 4.1 Experimental conditions
S
Exp. BA Conc. SASR BASR
BAM1 BAM2 BAM3
0.02
2.2
0.15 0.175
✕
1
✓
✓
0.03
2.5
0.15
0.35
✕
✕
2
✓
0.05
1.5
0.15
0.5
3
0.03
3.5
0.25 0.175
✕
4
✓
✓
0.06
4.0
0.25
0.35
✕
5
✓
✓
0.08
2.4
0.25
0.5
✕
✕
6
✓
0.04
4.8
0.375 0.175
✕
7
✓
✓
0.08
5.5
0.375
0.35
8
0.11
3.2
0.375
0.5
9
✓spherical agglomerates produced, ✕ elongated agglomerates, - no agglomerates

4.3.1

Bridging liquid addition method 1 (BAM1)

Figure 4.1 shows the progression of Exp. 1 via BAM1 (i.e., bridging liquid is dissolved in
solution). For BAM1, as the solution is fed to crystallizer bridging liquid droplets
containing solution are formed due to the immiscibility of the solvent mixture. Droplet
formation and stabilization is then proceeded by nucleation within the droplets; evidenced
by changes in the turbidity of the droplet. As crystals grow through solvent diffusion they
break the droplet barrier. This is apparent through a breakout period where bridging liquid
droplets are no longer visible. It is important to notice the crystal morphology. Due to the
slow nature of solvent diffusion through the droplet/water interface, long needle-like
crystals for formed. As the crystals grow in length the bridging liquid droplet is distributed
along the surface of the crystal which accounts for the disappearance of the droplets. The
agglomerated needle-like particles formed within one droplet are now wet agglomerates
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that go through further coalescence with other wet agglomerates. Figure 4.2 illustrates the
mechanisms involved in this method.
a)

b)

c)

d)

Figure 4.1 PVM images of BAM1 for Exp. 1 (a) emulsion formation and stabilization (b)
crystallization and break out (c) coalescence (d) completion

Bridging liquid
droplet
stabilization

Droplet turbidity
increases

Diffusion controlled
crystal growth
through droplets

Coalescence of
agglomerates

Figure 4.2 Schematic of agglomeration mechanism for BAM1
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It is important to mentioned that this bridging liquid addition method did produce a
significant amount of fouling on both the FBRM and PVM probes. While the PVM probe
could provide images that detail the mechanisms, fouling of the FBRM made it impossible
to record any significant particle counts or size data for this method; especially during the
agglomeration period.
4.3.2

Bridging liquid addition method 2 (BAM2)

Figure 4.3 shows the progression of Exp. 1 via BAM2 (i.e., bridging liquid is introduced
into the system after the crystallization). It is important to note the difference in crystal
morphology from this method versus the previous method. Due to benzoic acid’s low
solubility in water, the high supersaturation generated by solution addition leads to the
formation of fine plate-like crystals and some minor agglomeration. As the bridging liquid
is introduced, flocculation of the fine crystals around the bridging liquid droplets occurs.
Flocculation is also referred to as the wetting phase in SC. This observation is a key
difference between the BAM1 and BAM2. Flocculation was not observed in BAM1
because the droplets are stabilized prior to crystallization and nucleation and growth occurs
with the droplet. As the particles grow out of the droplet, their surfaces contain bridging
liquid so there is no wetting phase for BAM1. After the flocculation period, the system
goes through a consolidation period where the agglomerates become much more compact
and begin to take their spherical shape. The crystal morphology of this method (i.e., small
plate-like crystals) most likely leads to the better compaction and sphericity observed in
the PVM images. The consolidation phase also leads to the movement of bridging liquid
from the agglomerate core to the surface, and ultimately, liberation into the continuous
phase. Thus, further coalescence of agglomerates is observed. The consolidation and
bridging liquid liberation phase leading to further coalescence can be observed in Figure
4.4. These results agree well with the empirical findings in early literature.154,155,160 Figure
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4.5 illustrates all the mechanisms involved in this method. The consolidation phase was
also not observed for BAM1.
a)

b)

c)

d)

Figure 4.3 PVM images of BAM2 for Exp. 1 (a) crystallization (b) flocculation (c) consolidation
(d) coalescence and completion
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Figure 4.4 PVM of consolidation and agglomeration of multiple agglomerates and the liberation
of bridging liquid droplets (Exp. 1)

Fine crystal
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formation (agglomerate nuclei)
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Further
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availability

Figure 4.5 Schematic of agglomeration mechanism for BAM2

4.3.3

Bridging liquid addition method 3 (BAM3)

Figure 4.6 shows the progression of Exp. 1 via BAM3 (i.e., bridging liquid and solution
are simultaneously introduced to anti-solvent). Here both very small crystals and droplets
form at the onset. Although not entirely depicted in the images presented here, generally,
the onset of the process includes a combination of crystals, crystals in droplet from ethanolwater emulsions, bridging liquid droplets, and bridging liquid droplets with crystals via
immersion. However, the life span of droplets and emulsions are short and the process is
governed by slow crystal growth that leads to long needle-like crystals, like BAM1. While
the constituent particles are like those of BAM1, the final agglomerates have a much
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different morphology. BAM3 results in elongated agglomerates that are not spherical in
shape. This observation could be attributed to the significantly slower addition of bridging
liquid for this method which results in agglomeration via layering of needle-like crystals
as opposed to coalescence. Thus, the elongated agglomerates.

a)

b)

c)

d)

Figure 4.6 PVM images of BAM3 for Exp. 1 (a) droplet formation and crystallization (b) crystal
growth and wetting (c) agglomeration via layering (d) completion
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crystals
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Figure 4.7 Schematic of agglomeration mechanism for BAM3

a)

b)

c)

Figure 4.8 Offline images of agglomerates from Exp. 1 a) BAM1 b) BAM2 c) BAM3

Both BAM1 and BAM3 produce the same crystal morphology although the agglomeration
mechanism ultimately differs. This observation is an indication that presence of the
bridging liquid influences the crystallization process. The bridging liquid reduces the rate
of supersaturation generation given that the bridging liquid increases the solubility of the
system as appose to crystallizing with pure anti-solvent as with BAM2. Figure 4.7
illustrates the mechanisms involved in this method. Agglomerates from each method for
experiment one are show in Figure 4.8. Given the elongated nature of the agglomerates
produced via BAM3 (Figure 4.8c), this method was not considered for characterization.
4.3.4

Comparison of agglomerate properties from BAM1 vs BAM2

4.3.4.1 ASDs of BAM1 vs BAM2
Properties of spherical agglomerates from BAM1 and BAM2 were compared to assess how
final product properties are effected by the bridging liquid addition method. Figure 4.9
shows the ASD for experiments 1, 4, 5 and 7. Aside from experiment 4, agglomerates made
via BAM1 are shown to have broader and multi-nodal distributions. While agglomerates
made via BAM2 have a uniform distribution with a long tail. These observations are a
direct result of the difference in mechanisms between the two methods.
Agglomerates made via BAM1 are shown to have a fine agglomerate population and a
large agglomerate population evidenced by the multi-nodes. The fine agglomerate
population is likely a result of the size distribution of droplets formed at the beginning of
the process. Smaller bridging liquid droplets that crystallize and coalesce with other smaller
droplets lead to finer agglomerate formation. While large droplets can coalesce with larger
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droplets to create very large agglomerates. Experiment 4 and 7 do not show significant fine
agglomerate nodes nor very large agglomerate nodes, which suggests a more even
distribution during droplet formation when compared to experiment 1 and 5. This could
also suggest that the solvent composition (miscibility) and BSR of these experiments are
optimal compared to the others. Except for experiment 4, agglomerates made via BAM1
also tend to be significantly larger than those of BAM2. Larger agglomerates can also be a
result of the apparent larger constituent particles of BAM1 as evidence by the PVM images.
Due to fouling of the FBRM for BAM1, this observation was difficult to quantify in terms
of particle size. Lastly, since BAM1 did not show a consolidation mechanism, the
mechanism could also be responsible for the very large agglomerate size.
Agglomerates made via BAM2 are shown to have a much smaller size distribution.
This observation is due to the smaller constituent particles and the consolidation
mechanism that follows the flocculation phase. The tailing displayed in the ASD of
agglomerates made via BAM2 is a result of continued coalescence of agglomerates after
the consolidation phase which liberates bridging liquid from the core to the surface of
agglomerates (Figure 4.4). The small dark spots in the background of Figure 4.4 are
liberated droplets.
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Figure 4.9 ASD of experiments 1,4, 5, and 7 for BAM1 and BAM2

4.3.4.2 Flow properties of BAM1 vs BAM2
Flow properties for agglomerates from both bridging liquid addition methods were also
measured. The first set of flow studies were stability and variable flow. For stability studies
using the FT4, the blade traverses downward through the particle bed at a set rotation speed
for seven different tests (100 mm/s). The ratio of the energy required to traverse the particle
bed during the seventh test to the energy required during first test is a measure of the
stability of the particles. This ratio is called the Stability Index (SI). An SI = 1, or within
the range 0.90 to 1.10, shows good agglomerate stability. As Figure 4.10a depicts,
experiments 5 and 7 of BAM1 and experiments 2, 4, and 7 of BAM2 have acceptable
stability. The rest display an SI below 0.90. The cause of instability is due to the deagglomeration of the particles. Experiment 1 via BAM2 has a particularly low SI which
can be attributed the de-agglomeration of large agglomerates into their primary
agglomerates. As shown in Figure 4.4, BAM2 tends to over-agglomerate after the
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consolidation phase due the liberation of bridging liquid. However, the liberated bridging
liquid may be insufficient to create strong bonds between two agglomerates leading to deagglomeration during flow studies.
For variable flow studies using the FT4, the blade traverses downward through the
particle bed at decreasing rotational speeds for four different tests (100, 70, 40, 10 mm/s).
The ratio of the energy required to traverse the particle bed during the fourth test to the
energy required during the first test is called the Flow Rate Index (FRI), and is a measure
of how sensitive the agglomerates are to being made to flow. An FRI between 1.5 and 3.0
displays average sensitivity to flow while an FRI = 1 is indicative of insensitivity to flow.
As Figure 4.10b depicts, all experiments that display good stability also display average to
low sensitivity to flow. This observation is typical of large particles and confirms the
benefit of SC. For particles of low SI, particularly experiments 1 and 6 via BAM2, the FRI
cannot be interpreted given the likelihood of de-agglomeration occurring.
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Figure 4.10 a) SI vs agglomerate dia., b) FRI vs agglomerate dia., c) CPS vs agglomerate dia., d)
CPS vs p for agglomerates from BAM1 & BAM2
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For compression studies using the FT4, a vented piston applies pressure the particle
bed. The percentage in the height of the particle bed is Compression % (CPS). Figure 4.10cd show the CPS vs agglomerate diameter and porosity (p) vs agglomerate diameter. For
BAM1, CPS decreases with increase in agglomerate size. The decrease in CPS is related
to the apparent increase in constituent particle size evidenced in PVM images. For BAM2,
CPS increases as agglomerate size increases up to 1500 um. Larger agglomerates (>1500
um) display low compressibility. The low compressibility of smaller agglomerates (<1000
um) and larger agglomerates (>1500 um) is related to consolidation and continued
coalescence mechanisms exhibited by this method. However, no significant or
generalizable trends are observed between the CPS and agglomerate size for BAM2. For
BAM1, the batch time could have impacted the compressibility as the compressibility
decreases with increasing batch time for experiments 1, 4, 5 and 7. The porosity (p) was
observed to decrease with increasing agglomerate size. Experiments of high porosity but
low compressibility signal that the constituent particles are difficult to rearrange and are
tightly packed even at high porosity. These results suggest the relationship in CPS and p
are more likely correlated to the properties of the constituent particles. The following
suggestions will focus on BAM2 and the relationship between primary crystal size and
agglomerate properties.
4.3.5

Relationship between crystal CLD and ASD for BAM2

Understanding the relationship between the crystal size and agglomerate size is critical in
optimizing a SA process for both crystal and agglomerate properties. Since BAM2
decouples crystallization and agglomeration, each mechanism can be studied separately
and their effect on one another becomes more apparent. Figure 4.11a-b shows the chord
length distributions (CLD) and square weighted mean chord length (SWMCL) of
experiments 4,5, and 6 from the FBRM. For these experiments, the BA conc. of the solution
feed is 0.25g/ml and SASR = 0.175, 0.35 and 0.50, respectively. Experiment 4 had the
largest SWMCL and least number of particles in the CLD. At low SASR, as solution is
added to the crystallizer the change in solubility as a function of SASR is not significant.
Experiment 4, therefore, has much longer growth period than experiments 5 and 6. At
higher SASR, like in experiments 5 and 6, as solution is feed into the crystallizer the
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solubility increases rapidly and diminishes the supersaturation along with nucleation and
growth. For this reason, as SASR increases the particle size decreases. Experiment 5 also
exhibits the highest supersaturation likely driving the process towards nucleation and
leading to a smaller SWMCL and higher counts. Figure 4.11c-d shows CLD and SWMCL
of experiments 1,4, and 7. For these experiments, the SASR = 0.175 and BA conc. of the
solution feed is 0.15, 0.25 and 0.375 g/ml, respectively. As the CLD depicts, the particle
count increases significantly with increases BA conc. as expected. Experiment 7 with the
highest BA conc. produced crystals of the smallest SWMCL. Experiment 4 produced larger
crystals and higher counts than experiment 1 due to the faster depletion of supersaturation
at the lower concentration of experiment 1 (0.15 g/mL).
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Figure 4.11 (a) CLD of Exp. 4, 5 and 6 and (b) SWMCL of Exp. 4, 5, and 6 for constant
concentration (0.25 g/ml) with varying SASR. (c) CLD of Exp. 1, 4, and 7 and (d) SWMCL for
constant SASR (0.175) with varying concentration.

With knowledge about the primary crystal properties from the crystallization process,
an understanding of the relationship between primary crystal CLD and ASD can be
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developed. Figure 4.12 shows the size distributions of the agglomerates for the experiments
4, 5, and 6 (constant concentration with varying SASR). As the figure shows, the
experiments with the smallest primary crystal size produce agglomerate distributions with
the smallest mean size. The experiment with the largest primary crystal size produced the
agglomerates with the largest mean size. The images of agglomerates produced (Figure
4.13a-c) show a vast qualitative difference. The smaller agglomerates have less sphericity
and appear to be less compact with evident void spaces. The larger agglomerates are of
high sphericity and appear more dense/compact.
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Figure 4.12 (a) ASD for constant BA conc. (0.25g/ml) and varying SASR (b) ASD for constant
SASR (0.175) and varying BA conc.

a) AR – 1.10

b) AR – 1.76

c) AR – 1.44

d) AR – 1.12

e) AR – 1.10

f) AR – 1.44

Figure 4.13 (top) Agglomerates corresponding to Exp. 4, 5, and 6 left to right (bottom)
agglomerates corresponding to Exp. 1, 4, and 7 left to right.
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Figure 4.13d-f shows the size distributions of the agglomerates for the experiments 1,
4, and 7 (constant SASR with varying concentration). The trend here is the same as
previous scenario. The experiments that produced the smallest primary particles, produced
the smallest agglomerates. The agglomerates show the same qualitative difference
observed in the previous scenario. The smaller agglomerates have less sphericity and
appear to be less compact with evident void spaces. The larger agglomerates also show
higher sphericity and appear to more compact.
In comparing the spheres from Figure 4.12 and Figure 4.13, it is evident that the
agglomeration efficiency is much better for experiments 1,4 and 7. This observation
suggests that variations in the SASR affect the sphericity and agglomeration efficiency of
the process. As the SASR increases, the miscibility of the bridging liquid increases and
leads to a reduced amount of bridging liquid in the continuous phase. Therefore, the SASR
effects the miscibility and operating point in the ternary (ethanol-water-toluene) phase
diagram.
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Evaluating the performance properties of the agglomerates from BAM2 experiments
shows a higher correlation with the size of the primary crystals as opposed to the
agglomerate size. For example, Figure 4.14 shows the CPS and CBD vs Crystal SWMCL.
Both figures can be divided up into two regions: primary crystals above and below 175μm.
In the region below 175μm, as the primary crystal size increases the CPS and agglomerate
size decrease while the CBD increases. From a mechanistic perspective, agglomerates in
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this region undergo continued consolidation as primary crystal size increases,
consolidating to a minimum CPS and agglomerate size and maximum CBD. In the region
above 175μm, as the primary crystal size increases the CPS and CBD remain relatively
constant while the agglomerate size continues to increase. From a mechanistic perspective,
agglomerates in this region have reached a maximum consolidation leading to constant
values in CPS and CBD as primary crystal size increases. However, as evidence in Section
3.2, the consolidation phase liberates bridging liquid which leads to continued coalescence
and a larger agglomerate size. The results also suggest that as primary crystal size increases
it becomes more difficult to compress and compact the resulting agglomerates. Smaller
primary crystals have a greater ability to rearrange and compact during the consolidation
phase as opposed to larger ones. These results provide a much clear picture than when only
comparing performance with agglomerate size as in Figure 4.10. Moreover, it was observed
in Figure 4.12 and Figure 4.13 that the sphericity increases with increase in primary crystal
and agglomerate size. To further investigate to these differences in the agglomerate quality
as a function of primary crystal size, the interaction between primary crystal size and
bridging liquid droplet size is examined in the following section.
4.3.6

Interaction between crystals and bridging liquid droplets

To understand the influence of bridging liquid droplet size and primary crystal size on the
final agglomerate size some experiments from Table 4.1 use BAM2 were run for bridging
liquid droplet only scenarios. The experimental conditions were the same except without
the crystallization process. Bridging liquid was fed to an ethanol-water mixture at the
appropriate BASR and the resulting droplets were measured by an FBRM. Figure 4.15a-b
shows the CLD for both crystals and droplets from experiments 1 and 4. The crystal
SWMCL for these experiments were 288μm and 380μm, respectively, while the droplet
SWMCL was 49μm. In both scenarios, the bridging liquid droplet SWMCL was at least
5X smaller than the primary crystal SWMCL. The resulting agglomerates from both
experiments are very large and qualitatively show excellent agglomeration efficient,
sphericity, and compaction (Figure 4.13a, d-e). Figure 4.15c-d shows the CLD for both
crystals and droplets from experiments 5 and 6. The crystal SWMCL for these experiments
were 121μm and 96μm, respectively, while the droplet SWMCL for each was 58μm and
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50μm. In both scenarios, the bridging liquid droplet SWMCL was close to 2X smaller than
the primary crystal SWMCL. The resulting agglomerates from both experiments are much
smaller, less spherical and appear to be less compact (Figure 4.13b-c, f).
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The results here reveal the critical relationship between the primary crystal and
bridging liquid droplet. As the ratio between crystal SWMCL and droplet SWMCL
decreases the crystal-droplet interaction goes from distributive to immersive. The
difference in crystal-droplet interaction is responsible for the CPS, P and CBD differences
observed in Figure 4.10 and Figure 4.14. Experiments 5 and 6 showed much higher CPS
and P compared to experiments 1 and 4. In Figure 4.14, Experiments 1 and 4 show a higher
CBD compared to experiments 5 and 6. The images shown in Figure 4.13 qualitatively
back these findings. Ratios of crystal to droplet SWMCL for four experiments (Exp. 1, 4,
5 and 6) are given in Table 4.2. For benzoic acid, the critical crystal to droplet size ratio
(CPSR) is suggested to CPSR = 4. For a distributive crystal-droplet interaction, the crystal
size should be at least 4X greater than the droplet size. For an immersive interaction, the
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crystal size should be less than 4X the droplet size. Due to the polydispersity of both
crystals and droplets of the droplets, it is likely that both immersive and distributive
mechanisms occur at the same time. However, at the suggested CPSR one mechanism will
be significantly more dominant than the other. The droplet experiments in this study did
not differ significantly in SWMCL given the constant feed and agitation rates. These
parameters can be adjusted to further reduce/increase the droplet size.
Table 4.2: Crystal vs bridging liquid droplet mean size
Exp.
1
4
5
6

Crystal
SWMCL
288
380
120
96

Droplet
SWMCL
49
49
58
50

Ratio

Resulting Agglomerate

5.9
7.8
2.1
1.9

Large, spherical, compact
Large, spherical, compact
Small, irregular, loose
Small, irregular, loose

Conclusions
This study uses PAT tools to provide insight and knowledge of the different phases of SC.
Different bridging liquid addition methods were studied to assess how the agglomeration
period differs for each bridging liquid incorporation method. BAM1 undergoes an
emulsion dispersion and stabilization phase followed by crystallization of needle-like
particles within the droplets. Once the particles grow in length, they breakout of the droplet
and begin to coalescence other particles. BAM2 undergoes a wetting phase post
crystallization. The wetting phase is characterized by the flocculation of particles. The flocs
then go through a consolidation phase forms agglomerates and liberates bridging liquid to
the surface of the agglomerate. The newly available bridging liquid then promotes
continued coalescence. BAM3 undergoes simultaneous emulsion formation and
crystallization. Due to the slow bridging liquid feed, this method undergoes a layering type
of agglomeration mechanism that results in elongated agglomerates. Spherical
crystallization via crystallization followed by agglomeration (BAM2) proved to be the
most robust in terms of successfully producing spherical agglomerates as well as flow
properties. This study also clearly outlines the role of droplet size and primary crystal size
in the final agglomerate size. A critical crystal to droplet size ratio was established to
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determine whether a crystal-droplet interaction would be dominated by an immersive or
distributive mechanism.

5. MODELING AND OPTIMIZATION OF SPHERICAL
AGGLOMERATION IN SUSPENSION THROUGH A COUPLED
POPULATION BALANCE MODEL

This chapter is reprinted with minor modification with permission from Peña, R., Burcham,
C. L., Jarmer, D. J., Ramkrishna, D., & Nagy, Z. K. (2017). Chemical Engineering Science,
167, 66–77. Copyright 2017 Elsevier.

Introduction
Since its introduction, the PBM has been widely used and accepted as the model
formulation method for simulation and prediction of the size distribution and other
properties of particulate systems.83,174 PBMs allow for systems that include any or all of
the following mechanisms: nucleation, growth, breakage and agglomeration. Following the
initial work by Smoluchowski175 (1917) on the rate of aggregation for spherical particles,
there have been many contributions for systems that exhibit agglomeration including
dispersion (bubble) coalescence176,177, granulation178,179 and particle aggregation during
crystallization.165,180,181 The shared limitation in the models between many of the previous
studies is the loss of information of constituent particles. This limitation presents obstacles
in the estimation of the kinetic parameters (nucleation and growth rate vs agglomeration
rate) and in developing an understanding of the influence of process conditions on each in
population (constituent particles vs agglomerates). Having information regarding the
constituent particles would allow for improved particle design through more accurate
parameter estimation, simulation, optimization, and control; particularly for the
increasingly popular technique of agglomeration in suspension.
Agglomerating fine particles in suspension, using a bridging liquid, to improve particle
properties and downstream process efficiency has been known since the late 1960s.
Initially the technique was used mostly in bulk chemical industries (e.g., coal
beneficiation162). Since then agglomeration in suspension techniques have been geared
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towards application in the pharmaceutical industry to improve filtration and downstream
processing of APIs during crystallization by eliminating granulation and milling unit
operations.27,28,29 In this respect the technique is often referred to as SC. Interest in the
application of SC in pharmaceutical processes has increased through the continued
development and understanding of the operating conditions22,30,123, choice of binding
agent26, kinetics152 and mechanisms28,137,139,143 that govern experimental outcomes. Peña
and Nagy130 studied and showed the benefits of SC as a PI technique, whereby both internal
(primary crystals) and external (agglomerates) properties can be controlled experimentally
through a decoupled CSC approach; providing the means by which both biopharmaceutical
(bioavailability, dissolution) and manufacturing (flowability, filtration, drying) properties
can be simultaneously adapted to meet desired quality specifications. This technique opens
the door for combined experimental and modeling approaches for the optimization and
control of both the primary crystal and agglomerate properties in SC processes. However,
many of the PBMs currently in literature would fail to accomplish this because of the
limitations and loss of constituent particle information.
The limitations in previously developed PBMs are related to the complex
crystallization phenomena occurring during SC processes. For previous models,
agglomeration was either an incidental process occurring along with nucleation and growth
during crystallization or the main process occurring in seeded or seed-fed systems with
negligible nucleation and growth. This allowed for empirical agglomeration models often
independent of system properties and solely dependent on fitting to experimental data.182
The models are limited in accuracy, very system dependent and have difficulty capturing
all the influencing process parameters on the system. Moreover, they only take into
consideration the evolution of the agglomerates and not that of the constituent primary
crystals. As previously mentioned, from the mechanistic point of view there are numerous
studies in the literature that propose agglomeration mechanisms. However, there has yet to
be a comprehensive correlation between the proposed mechanisms of SC, which include
nucleation, growth and agglomeration, and the appropriate agglomeration kernel. This has
largely been influenced by the inherit loss of information in the PBMs and the lack of PAT
tools to help determine and validate proposed mechanisms.17
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Bemer (1979) was one of the first to study agglomeration in suspension from both an
experimental and modeling approach.154 His work led to further implementations of
combined experimental and modeling studies. David et al. (2003) developed a multi-layer
agglomeration model that considers the efficiency of agglomeration based on the collision
mechanism (i.e., Brownian, laminar, or turbulent).167 As particles change in size their
collision mechanism or flow field can change from Brownian to laminar to turbulent, as
particle size increases. In their model, the kernel accounted for changes in the collision
mechanism and was also a function of the supersaturation and temperature through the
growth rate which was used as the efficiency term. It is known that agglomeration is
enhanced by inter-particle growth or agglomerative bond formation; when supersaturation
increases the subsequent inter-particle growth between two particles that come in contact
increases allowing for higher agglomeration efficiency.37 Madec et al. (2003) simplified
the agglomeration model by incorporating a more relevant process parameter into the
kernel, specifically their work accounted for the composition of bridging liquid in an
agglomerate.161 It has been shown that there is a critically optimal range for the ratio of
bridging liquid to solute volume (BSR); below or above this critically optimal range would
produce loosely compacted agglomerates or paste-like amorphous agglomerates,
respectively.27,137,139 This unique incorporation of the bridging liquid composition served
as the efficiency term by which the process would reach equilibrium.
The most comprehensive study in this area is that of Blandin et al. (2005) In this
combined experimental and modeling study, key aspects of agglomeration in suspension
are noted:
(i) The agglomeration mechanism is a three-step process; a) bridging liquid droplets
capture solid particles and form agglomerate nuclei, b) compaction of the agglomerate
nuclei due to collisions with other particles causes a rapid decrease in the mean
diameter, c) growth and consolidation then occur due to the hydrodynamics and process
conditions of the system (i.e., collisions, BSR),
(ii) Agglomeration is only efficient in the critical BSR range; the agglomerate size
increases with a strong dependence on BSR, weak dependence on solids concentration
and inverse dependence on agitation rate,
(iii) Porosity decreases as mean diameter reaches equilibrium.

91
(iv) Agglomeration stops once the agglomerates become too compact to deform.111
Based on these fundamental experimental observations an agglomeration model
considering the size and concentration of the agglomerating particles, with the
agglomeration kernel expressed as a function of the meeting probability and agglomeration
efficiency of the process, was developed. The meeting probability was described by a
function of the target efficiency, agglomerate sizes, and collision velocity.164 The
simulations from this work agreed with experimental data when the necessary parameters
were fit to the data. By identifying the critical experimental mechanisms, Blandin et al.
(2005) could develop a comprehensive model that accounted for both the mechanistic
phenomena (e.g., deformability, collision efficiency, and compaction) and process
conditions (e.g., energy dissipation, BSR, primary particle size). Although this model
showed significant superiority over many others observed in the literature, it still has the
limitation of losing the information of the constituent particles. Moreover, the model relies
on the assumption that the initial particles participating in the agglomeration are
monodispersed. Table 5.1 summarizes various kernels found in the literature used for
agglomeration in suspension modeling with 𝑟 defined as the radius of the particle and is
interchangeable with the characteristic length.
Table 5.1 Common agglomeration kernels
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To overcome the issues of loss of information a coupled PBM formulation is required.
A coupled PBM formulation could simultaneously tracks the evolution of the primary
crystals and the evolution of the agglomerates. The relationship between primary crystal
properties and their effect on final agglomerate properties would thereby be more evident
and more efficient than in traditional approaches. To the best of our knowledge, the only
previous work that presented this approach is that of Ochsenbein et al. (2015).169 In their
study, Ochsenbein et al. (2015) focused on the agglomeration of needle-like crystals in
suspension. Through a coupled PBM framework Ochsenbein et al. (2015) could develop a
PBE to describe the evolution of the primary crystals by a two-dimensional growth rate to
represent the needle like structure of the crystal. Then another PBE was used to describe
the evolution of the agglomerates as a function of the primary crystals. For the
agglomeration kernel, they derived their own modified kernel that included both
characteristic lengths of the primary crystals participating in the agglomeration. The new
PBM formulation also allowed for the development of new parameters that add value to
the simulations due to their experimental relevance. However, the work of Ochsenbein et
al. (2015) neglected nucleation, something common to previously developed PBMs with
agglomeration. The coupled PBM framework will be extended herein.
The contribution of this work is the extension of the coupled PBM framework for
application in the simulation and optimization of an agglomeration in suspension system.
A coupled PBM framework has been developed for a semi-batch, reverse addition, antisolvent crystallization system with agglomeration. Reverse addition anti-solvent
crystallization techniques entail the addition of solution to the anti-solvent. The technique
is carried out for low SASR to produce very fine crystals due to very high supersaturation
generation. The system includes nucleation and growth of primary crystals and subsequent
agglomeration. The purpose of the work is to exploit the advantages presented by a coupled
PBM framework; for example, the ability to optimize for specific primary and agglomerate
sizes. This presents an opportunity to find optimal operating conditions that meet both
bioavailability and manufacturability demands. It also allows for the ability to develop a
first principles based parameter for agglomeration efficiency and a first principles based
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estimate for porosity. Additionally, through the retention of the information of the primary
particles, the interplay between the effects of operating conditions on the properties of the
primary crystals versus the agglomerates will be clear.

Model development for agglomeration in suspension
Modeling the agglomeration in suspension system is decomposed into three populations:
all primary crystals, un-agglomerated crystals and agglomerates. The system of coupled
PBEs will be coupled with a mass balance equation to enable the modeling of the CSD
properties and ASD properties simultaneously. The model will allow us to relate the CSD
and ASD properties to micromeritic properties (e.g., porosity and agglomeration
efficiency). The PBM will incorporate nucleation, growth and agglomeration mechanisms.
This coupling allows for a PBE that describes the entire primary crystal population whether
part of an agglomerate or not. However, the PBE does not track the location of the primary
crystals. The inability to track the location of the primary crystals creates a difficulty in
assessing the exposure of each individual crystal to supersaturated fluid; especially, once
it is incorporated into an agglomerate. Hence, for simplicity, it is assumed that primary
crystal growth rate is independent of its in environment (i.e., particles partaking in
agglomeration have the same growth kinetics as particles remaining in suspension). This
assumption is a limitation of the model but studies the literature have shown that
agglomerate strength is dependent on supersaturation of the system due to growth of
crystals within an agglomerate (agglomerative bond).37
The set of PBEs are as follows:
𝜕
𝜕𝑡

𝜕

[𝑉(𝑡)𝑛𝑡𝑐 (𝑥, 𝑡)] = − 𝜕𝑥 (𝐺(𝑥)𝑉(𝑡)𝑛𝑡𝑐 (𝑥, 𝑡)) + 𝛿(𝑥)𝑉(𝑡)𝐵

5.1

In equation 5.1, 𝑛𝑡𝑐 (𝑥, 𝑡) is the volumetric number density (no. m-4) representing the
primary crystals in the system; regardless of whether the crystal is part of an agglomerate
or not (total crystals). 𝐺 (m s-1) is the growth rate, 𝐵 (no. m-3s-1) is the nucleation rate, 𝛿(𝑥)
(m-1) is the Dirac delta function, and 𝑉(𝑡) (m3) is the suspension volume. 𝑥 (m) represents
the characteristic length and 𝑡 is the batch time.
𝜕
𝜕𝑡

[𝑉(𝑡)𝑛𝑐𝑠 (𝑥, 𝑡)] = −

𝜕
𝜕𝑥

(𝐺(𝑥)𝑉(𝑡)𝑛𝑐𝑠 (𝑥, 𝑡)) + 𝛿(𝑥)𝑉(𝑡)𝐵 − 𝐷𝑐𝑠,𝑎𝑔𝑔 (𝑥)

5.2
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∞

𝐷𝑐𝑠,𝑎𝑔𝑔 (𝑥) = 𝑉(𝑡)𝑛𝑐𝑠 (𝑥, 𝑡) ∫0 𝛽(𝑥, 𝜆)𝑛𝑐𝑎 (𝜆, 𝑡)𝑑𝜆

5.3

In equation 5.2, 𝑛𝑐𝑠 (𝑥, 𝑡) is the volumetric number density (no. m-4) representing the unagglomerated crystals (crystals in suspension). This equation differs from the first equation
by the third term (𝐷𝑐𝑠,𝑎𝑔𝑔 (𝑥) (no. m-1s-1)) which represents the death (disappearance) of
crystals due to agglomeration (equation 5.3). The death of crystals can occur through
crystal agglomeration with other crystals or agglomerates. This is denoted by the
volumetric number density 𝑛𝑐𝑎 (𝜆, 𝑡) (no. m-4) which represents both crystals and
agglomerates of a characteristic size 𝜆. In equation 3, 𝛽(𝑥, 𝜆) represents the agglomeration
rate (m3 no.-1s-1) of a particle of characteristic size 𝑥 with a particle of characteristic size 𝜆.
𝜕
𝜕𝑡

[𝑉(𝑡)𝑛𝑎 (𝑥, 𝑡)] = −

𝐵𝑎,𝑎𝑔𝑔 (𝑥) =

𝑥2 𝑥
∫
2 0

𝜕
𝜕𝑥

(𝐺(𝑥)𝑉(𝑡)𝑛𝑎 (𝑥, 𝑡)) + 𝐵𝑎,𝑎𝑔𝑔 (𝑥) − 𝐷𝑎,𝑎𝑔𝑔 (𝑥)
3 1⁄3

𝛽((𝑥3 −𝜆 )

3

,𝜆)𝑛𝑐𝑎 ((𝑥3 −𝜆 ),𝑡)𝑉(𝑡)𝑛𝑐𝑎 (𝜆,𝑡)
3 2/3

(𝑥3 −𝜆 )
∞

5.4

𝐷𝑎,𝑎𝑔𝑔 (𝑥) = 𝑉(𝑡)𝑛𝑎 (𝑥, 𝑡) ∫0 𝛽(𝑥, 𝜆)𝑛𝑐𝑎 (𝜆, 𝑡)𝑑𝜆

𝑑𝜆

5.5
5.6

In equation 5.4, 𝑛𝑎 (𝑥, 𝑡) is the volumetric number density (no. m-4) representing the
agglomerates produced from the birth (𝐵𝑎,𝑎𝑔𝑔 (𝑥) (no. m-1s-1)) and death (𝐷𝑎,𝑎𝑔𝑔 (𝑥) (no.
m-1s-1)) of agglomerates from crystal-agglomerate and agglomerate-agglomerate
agglomeration. 𝛽(𝑥, 𝜆) is the same as the term in equation 5.3 and represents the
agglomeration rate. It is important to note that traditionally the agglomeration birth and
death terms are expressed with volume as the internal coordinate. However, since all the
other mechanisms are expressed with respect to characteristic length a modification is
made to express this in terms with respect to characteristic length following modification
steps from the literature.12,85,88 Equations 5.2 and 5.4 are coupled through equation 5.7.
𝑛𝑐𝑎 (𝑥, 𝑡) = 𝑛𝑐𝑠 (𝑥, 𝑡) + 𝑛𝑎 (𝑥, 𝑡)

5.7

Equation 5.7 is simply the addition of the un-agglomerated crystals and the agglomerates
denoted by the number density function 𝑛𝑐𝑎 (𝑥, 𝑡) (no. m-4). This combined population is
used to account for crystal-crystal and crystal-agglomerate interactions and reduce the
number of terms in the birth and death terms in equations 5.1-5.6. Equation 5.1 is
intentionally made to stand alone based on the assumption of uniform kinetics for all
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populations tracked in the system. The set of equations will all be coupled by the mass
balance which will ultimately determine nucleation and growth kinetics.

Solution method
Most of the SC systems in literature are semi-batch with limited modeling work. For this
reason, a semi-batch system with combined cooling and reverse addition anti-solvent is
modeled. To account for the volume change in a semi-batch system the number density
functions are expressed as a redefined number density (𝑛̃(𝑥, 𝑡) = 𝑉(𝑡)𝑛(𝑥, 𝑡)).15,184 The
modified PBM will be as follow:
𝜕

𝜕

𝜕𝑡
𝜕

𝑛̃𝑡𝑐 (𝑥, 𝑡) = − 𝜕𝑥 (𝐺(𝑥)𝑛̃𝑡𝑐 (𝑥, 𝑡)) + 𝛿(𝑥)𝑉(𝑡)𝐵

5.8

𝜕

𝜕𝑡
𝜕

̃𝑐𝑠,𝑎𝑔𝑔 (𝑥)
𝑛̃𝑐𝑠 (𝑥, 𝑡) = − 𝜕𝑥 (𝐺(𝑥)𝑛̃𝑐𝑠 (𝑥, 𝑡)) + 𝛿(𝑥)𝑉(𝑡)𝐵 − 𝐷
𝜕

𝜕𝑡

̃𝑎,𝑎𝑔𝑔 (𝑥)
𝑛̃𝑎 (𝑥, 𝑡) = − 𝜕𝑥 (𝐺(𝑥)𝑛̃𝑎 (𝑥, 𝑡)) + 𝐵̃𝑎,𝑎𝑔𝑔 (𝑥) − 𝐷

5.9
5.10

𝑛̃𝑐𝑎 (𝑥, 𝑡) = 𝑛̃𝑐𝑠 (𝑥, 𝑡) + 𝑛̃𝑎 (𝑥, 𝑡)

5.11

̃𝑐𝑠,𝑎𝑔𝑔 (𝑥) = 𝑛̃𝑐𝑠 (𝑥, 𝑡) ∫∞ 𝛽(𝑥, 𝜆)𝑛̃𝑐𝑎 (𝜆, 𝑡)𝑑𝜆
𝐷
0

5.12

𝐵̃𝑎,𝑎𝑔𝑔 (𝑥) =

𝑥2

𝑥
∫
2 0

3 1⁄3

𝛽((𝑥3 −𝜆 )

3

̃ 𝑐𝑎 ((𝑥3 −𝜆 ),𝑡)𝑛
̃ 𝑐𝑎 (𝜆,𝑡)
,𝜆)𝑛
3 2/3

(𝑥3 −𝜆 )

𝑑𝜆

̃𝑎,𝑎𝑔𝑔 (𝑥) = 𝑛̃𝑎 (𝑥, 𝑡) ∫∞ 𝛽(𝑥, 𝜆)𝑛̃𝑐𝑎 (𝜆, 𝑡)𝑑𝜆
𝐷
0

5.13
5.14

The above set of PBEs can be solved using the QMOM approximation for the redefined
moments. 12,85,88,185
∞

𝑘
𝜇̃𝑘 = ∫0 𝑥 𝑘 𝑛̃(𝑥, 𝑡)𝑑𝑥 ≈ ∑𝑁
𝑖=1 𝑤𝑖 𝐿𝑖

5.15

The quadrature approximation transformed set of PBEs can be written as:
̃ 𝑡𝑐,𝑘
𝑑𝜇
𝑑𝑡
̃ 𝑐𝑠,𝑘
𝑑𝜇
𝑑𝑡

𝑘−1
= 𝑘 ∑𝑁
𝑖=1 𝑤𝑡𝑐,𝑖 𝐿𝑡𝑐,𝑖 𝐺(𝐿𝑡𝑐,𝑖 ) + 𝛿(𝑘)𝑉(𝑡)𝐵
𝑘−1
= 𝑘 ∑𝑁
𝑖=1 𝑤𝑐𝑠,𝑖 𝐿𝑐𝑠,𝑖 𝐺(𝐿𝑐𝑠,𝑖 ) + 𝛿(𝑘)𝑉(𝑡)𝐵 −

̃𝑐𝑠,𝑎𝑔𝑔 (𝑤𝑐𝑎,𝑖 , 𝐿𝑐𝑎,𝑖 , 𝑤𝑐𝑠,𝑖 , 𝐿𝑐𝑠,𝑖 , 𝑘)
𝐷
̃ 𝑎,𝑘
𝑑𝜇
𝑑𝑡

5.16

5.17

𝑘−1
̃
= 𝑘 ∑𝑁
𝑖=1 𝑤𝑎,𝑖 𝐿𝑎,𝑖 𝐺(𝐿𝑎,𝑖 ) + 𝐵𝑎,𝑎𝑔𝑔 (𝑤𝑐𝑎,𝑖 , 𝐿𝑐𝑎,𝑖 , 𝑘) −

̃𝑎,𝑎𝑔𝑔 (𝑤𝑐𝑎,𝑖 , 𝐿𝑐𝑎,𝑖 , 𝑤𝑎,𝑖 , 𝐿𝑎,𝑖 , 𝑘)
𝐷

5.18
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𝑘
𝑁
̃𝑐𝑠,𝑎𝑔𝑔 (𝑤𝑐𝑎,𝑖 , 𝐿𝑐𝑎,𝑖 , 𝑤𝑐𝑠,𝑖 , 𝐿𝑐𝑠,𝑖 , 𝑘) = ∑𝑁
𝐷
𝑖=1 𝑤𝑐𝑠,𝑖 𝐿𝑐𝑠,𝑖 ∑𝑗=1 𝑤𝑐𝑎,𝑗 𝛽(𝐿𝑐𝑠,𝑖 , 𝐿𝑐𝑎,𝑗 )

5.19

𝑘

1
3
3
𝑁
3
𝐵̃𝑎,𝑎𝑔𝑔 (𝑤𝑐𝑎,𝑖 , 𝐿𝑐𝑎,𝑖 , 𝑘) = 2 ∑𝑁
𝑖=1 𝑤𝑐𝑎,𝑖 ∑𝑗=1 𝑤𝑐𝑎,𝑗 (𝐿𝑐𝑎,𝑖 + 𝐿𝑐𝑎,𝑗 ) 𝛽(𝐿𝑐𝑎,𝑖 , 𝐿𝑐𝑎,𝑗 ) 5.20
𝑁
̃𝑎,𝑎𝑔𝑔 (𝑤𝑐𝑎,𝑖 , 𝐿𝑐𝑎,𝑖 , 𝑤𝑎,𝑖 , 𝐿𝑎,𝑖 , 𝑘) = ∑𝑁
𝐷
𝑖=1 𝑤𝑎,𝑖 𝐿𝑎,𝑖 ∑𝑗=1 𝑤𝑐𝑎,𝑗 𝛽(𝐿𝑎,𝑖 , 𝐿𝑐𝑎,𝑗 )

5.21

𝜇̃𝑐𝑎,𝑘 = 𝜇̃𝑐𝑠,𝑘 + 𝜇̃𝑎,𝑘

5.22

The set of PBEs is solved with the product difference (PD) algorithm and the number of
quadrature points used is 𝑁 = 3 which solves for the weights (𝑤𝑖 ) and abscissas (𝐿𝑖 ).
Details regarding the PD algorithm can be found in the literature.84,86,185 Matlab ® ode15s
is used to solve the set of ODEs.

Mass balance and kinetics
The mass balance equations used in the model for the semi-batch reverse addition antisolvent crystallization of benzoic acid is derived as:
𝑑𝑉
𝑑𝑡

= 𝐹𝑠

𝑑𝐶𝑆
𝑑𝑡

=

𝑑𝑥𝑆𝐴𝑆𝑅
𝑑𝑡

𝑀=

5.23

(𝐶𝐵𝐴0 −𝐶𝑠 )
𝑉

𝐹𝑠 −

̃ 𝑡𝑐,2
3𝜌𝑐 𝑘𝑣 𝐺𝜇
𝑉

𝐹

= 𝑉𝑠

0

̃ 𝑡𝑐,3
𝜌𝑐 𝑘𝑣 𝜇
𝑉

5.24
5.25
5.26

where 𝑉(mL) is the volume of mother liquor mixture, 𝐹𝑠 (mL min-1) is the flow rate of
solution being added to the system, 𝐶𝑆 (g mL-1) is the solute (benzoic acid) concentration,
𝐶𝐵𝐴0 (g mL-1) is the solute concentration in the solution being fed, and 𝑥𝑆𝐴𝑆𝑅 is the solution
to anti-solvent ratio. In equation 5.24, 𝜌𝑐 is the density of the crystal and 𝑘𝑣 is the shape
factor and are fixed at 1.316 (g mL-1) and 0.524, respectively. For simplicity, it is assumed
that the solvent mixture density change is negligible. 𝑀(g/mL) represents the magma
density of the slurry.
The nucleation and growth rate kinetics for traditional anti-solvent crystallization of
benzoic acid were used for this study and taken from the literature.186
𝐵 = 𝑘𝑏 (𝒩)(1 + 𝑖 ∗ 𝑀)(𝑆 − 1)𝑏(𝒩)

5.27
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𝐺 = 𝑘𝑔 (𝒩)(𝑆 − 1) 𝑔(𝒩)

5.28

𝐶

𝑆=𝐶𝑆

5.29

𝑠𝑎𝑡

Here the nucleation and growth kinetics depend on supersaturation, 𝑆, (which is generated
by changes in the 𝒮𝒜𝒮ℛ and temperature) and agitation rate, 𝒩. The variable 𝑖 is an
empirical parameter that influences the extent to which a system is driven by primary or
secondary nucleation. The 𝑖 parameter is not given in the reference and hence will be used
to do a parameter study on the effect of secondary nucleation on the results of the model
formulation. The dependence of the rate constants on the agitation rate is shown in Table
5.2.
Table 5.2 Empirical kinetic constants retrieved from [186]
𝓝 - agitation rate (rpm)

𝒌𝒈 (𝟏𝟎−𝟔 )

𝒈

400

1.5

3.1

1.2

1.6

600

2.6

3.5

3.2

1.9

800

3.2

3.8

3.6

2.3

𝒌𝒃 (𝟏𝟎𝟕 )

𝒃

There are limited complete studies of the solubility of benzoic acid in ethanol-water
mixtures for various concentrations and temperatures except for O’Grady (2007).187 In the
study, various solubility experiments for benzoic acid at different temperatures and
ethanol-water mixtures were carried out. The data from his work is taken and fit to a third
order polynomial with respect to both temperature and 𝒮𝒜𝒮ℛ using the Matlab function
fit. Figure 5.1, the y-axis (left) and z-axis (right) are read as the concentration of benzoic
acid in ethanol expressed in g per mL.
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Figure 5.1 (top) Solubility data retrieved from [187] of benzoic acid in ethanol-water mixture with
respect to temperature. (bottom) Resulting solubility surface as a function of SASR and temperature.
The SASR from O’Grady were expressed as volume ratios for the solubility surface.

The agglomeration kernel used for this study is a homogeneous kernel derived from
the combination of the Brownian diffusion kernel and the Zauner and Jones183 and will be
referred to as the Brownian+ kernel. It is expressed as:
1
2

𝛽(𝐿𝑖 , 𝐿𝑗 ) = 𝑎 (𝑏 + 𝑐𝜀 −

𝑘𝑎 (𝐿 +𝐿 )
𝑑𝜀) 𝑆 𝑒 𝐿𝑖 𝐿 𝑗
𝑖 𝑗

2

5.30

The first portion of the agglomeration kernel is composed of the parameters and process
conditions defined by Zauner and Jones183 where 𝑎, 𝑏, 𝑐, 𝑑 and 𝑒 are constants, 𝜀 is the
energy dissipation and 𝑆 is the supersaturation. The energy dissipation is defined as follows:
𝜀=

𝑁𝑝 𝑑𝑠5 𝒩 3
𝑉

5.31
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where 𝑁𝑝 is the stirrer power number, 𝑑𝑠 (m) is the diameter of the stirrer and 𝒩 is the
agitation rate over 𝑉, the volume of the slurry.142 The second part of the kernel is the
Brownian portion that takes into account the surface area effect of the two particles
partaking in the agglomeration and is divided by the product of the two particles which
allows for a determination effect; as the particles get larger the effect of the Brownian
portion of the kernel is reduced. This is appropriate as this model allows the agglomeration
rate to decreases as the particles get larger, a common behavior seen in agglomeration in
suspension techniques like SC.

Agglomeration efficiency and porosity
As pointed out by Ochsenbein et al. (2015), one of the advantages of the coupled PBM is
that it allows for the development of physically relevant parameters.169 One parameter is
the agglomeration efficiency. The coupled PBM framework allows for the population of
all primary crystals, un-agglomerated crystals and agglomerates to be tracked, allowing for
the determination of the efficiency of the agglomeration process with regards to the total
number of crystals contained in the agglomerates.

Figure 5.2 Schematic of the different populations being tracked by the coupled PBM framework.

Figure 5.2 is a schematic representation of the three populations being tracked by the
coupled PBM framework. As the figure depicts, the primary crystals population consist of
each individual crystal outlined in green within the green dashed box, the individual

100
crystals left in suspension consist of those crystals circled in blue dotted lines and lastly
the agglomerates consist of those particles circled in red solid lines. Expressed in terms of
volume, Figure 5.2 illustrates that the ratio of the volume of agglomerates to the volume of
total primary crystals is a measure of the extent of agglomeration:
𝑉

% 𝑜𝑓 𝑎𝑔𝑔𝑙𝑜𝑚𝑒𝑟𝑎𝑡𝑒𝑑 𝑐𝑟𝑦𝑠𝑡𝑎𝑙𝑠 = 100 (𝑉𝑎 )
𝑡𝑐

5.32

This definition can be very easily defined using the moments of the PBM (𝜇̃𝑡𝑐,𝑘 , 𝜇̃𝑐𝑠,𝑘 , 𝜇̃𝑎,𝑘 ).
Specifically, the third moment of each PBE which is a volume based moment can be used
to express the agglomeration efficiency as:
̃
𝜇

𝒜ℰ = 100 (𝜇̃ 𝑎,3 )
𝑡𝑐,3

5.33

Porosity is a property of interest in agglomeration and granulation because it can have on
other properties like dissolution and compressibility. Many times, a final desired porosity
can determine the experimental conditions.

Figure 5.3 Schematic of agglomerates with similar characteristic lengths but different internal
properties (i.e., porosity).

Figure 5.3 illustrates how the porosity of an agglomerate decreases as subsequent
agglomeration continues over time. Due to the one-dimensional PBE, reconstructing the
size of the agglomerate from the characteristic length assumes that the particle produced
from an agglomeration event is a sphere. This assumption causes high porosity initially
(see agglomerate on left in Figure 5.3) which is what occurs experimentally. As subsequent
agglomeration continues the assumption of a sphere becomes more reasonable and the
porosity decreases in the very same manner seen experimentally (left to right in Figure 5.3).
Expressed in terms of volume Figure 5.3 states that volume of the pore (𝑉𝑝 ) is equal to the
volume of agglomerates minus the difference between the volume of primary crystals and
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volume of un-agglomerated crystals. The porosity determined by dividing this difference
by the volume of agglomerates.
𝑉𝑝 = 𝑉𝑎 − (𝑉𝑡𝑐 − 𝑉𝑐𝑠 )
𝜀𝑝 = 1 −

5.34

(𝑉𝑡𝑐 −𝑉𝑐𝑠 )

5.35

𝑉𝑎

Like the agglomeration efficiency, the porosity can be calculated with respect to the
moments of the coupled PBM (𝜇̃𝑡𝑐,𝑘 , 𝜇̃𝑐𝑠,𝑘 , 𝜇̃𝑎,𝑘 ).
𝒫 =1−

̃ 𝑡𝑐,3 𝜇
𝜇
̃ 𝑐𝑠,3
−̃
̃ 𝑡𝑐,0 𝜇
𝜇
𝑐𝑠,0

̃ 𝑎,3 ⁄𝜇
̃ 𝑎,0
𝜇

= 1−

𝒱𝑡𝑐,30 −𝒱𝑐𝑠,30

5.36

𝒱𝑎,30

The set of coupled PBEs and defined parameters are to be used in an optimization
framework where internal properties like crystal mean size and external properties like
agglomerate mean size can be optimized for subject to constraints on agglomeration
efficient and yield, and other quality attributes or process constraints.

Optimization framework
Three optimization scenarios were analyzed: (i) minimizing primary crystal size, (ii)
maximizing primary crystal size, and (iii) attaining bioavailability and manufacturability
targets. For simplicity, the total particle mean size using the first and zeroth moment of the
respective populations were used, ℒ𝑡𝑐,10 and ℒ𝑎,10. The batch time is fixed at 300 min (~5
hr) which is typical for agglomeration in suspension systems like benzoic acid SC. The
optimization variables are the dynamic operating profiles for temperature (𝒯(𝓉)), agitation
rate (𝒩(𝓉)) and solution flow rate (ℱ𝓈 (𝓉)). The level of discretization for the optimization
variables is 10. All the scenarios were subject to the same variable bounds and constraints.
The bounds were chosen based on the range of the available solubility and kinetic data.
𝜕𝒯

The framework includes constraints on cooling/heating rate, ( 𝜕𝓉 ), solution addition
(𝒮𝒜𝒮ℛ), agglomeration efficiency, (𝒜ℰ), yield, (𝒞𝑓𝑖𝑛𝑎𝑙 ) and initial flow rate, (ℱ𝓈 (0)).
Since a reverse addition anti-solvent crystallization system was chosen for this study the
constraint on the initial flow rate assures that a certain crystal mass will be generated
otherwise the optimizer may try to crystalize one large particle towards the end of the batch.
The optimization problem for the first two scenarios can be written as:
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𝑚𝑖𝑛

𝒯(𝑡),𝒩(𝑡),ℱ𝓈 (𝑡)

−ℒ𝑡𝑐,10 𝑜𝑟 ℒ𝑡𝑐,10

5.37

𝑠. 𝑡.
16 ≤ 𝒯(𝑡) ≤ 28 °𝐶

5.38

400 ≤ 𝒩(𝑡) ≤ 800 𝑅𝑃𝑀

5.39

0 ≤ ℱ𝓈 (𝑡) ≤ 2.5 𝑚𝑙/𝑚𝑖𝑛

5.40

−0.4 ≤

𝜕𝒯
𝜕𝑡

≤ 0.4°𝐶/𝑚𝑖𝑛

5.41

0.25 ≤ 𝒮𝒜𝒮ℛ ≤ 0.40

5.42

𝒜ℰ ≥ 50%

5.43

𝒞𝑓𝑖𝑛𝑎𝑙 ≤ 0.75𝒞𝑚𝑎𝑥

5.44

ℱ𝓈 (0) ≥ 1.0 𝑚𝑙/𝑚𝑖𝑛

5.45

The new variable 𝒞𝑓𝑖𝑛𝑎𝑙 is the final concentration of solute in solution while 𝐶𝑚𝑎𝑥 is
the maximum concentration if all the solution is added to the system and no crystallization
occurred. As written the constraint requires a 25% yield. The optimization problem is
solved using the “interior point” method of fmincon in Matlab. The objective function of
the optimization problem for the last scenario can be written as:
𝑚𝑖𝑛

𝒯(𝑡),𝒩(𝑡),ℱ𝓈 (𝑡)

2

𝑊1 (ℬ𝑇 − ℒ𝑡𝑐,10 ) + 𝑊2 (ℳ𝑇 − ℒ𝑎,10 )

2

5.46

ℬ𝑇 and ℳ𝑇 represent bioavailability and manufacturability targets. For this scenario, the
optimization problem is a multi-objective framework with 𝑊1 and 𝑊2 being the weights
for each objective. The weights in equation 5.46 are shown as a generalization for situations
in which bioavailability or manufacturability is more heavily weighted than the other. In
this work, 𝑊1 and 𝑊2 each have values of one. This scenario is restricted to the same
constraints previously described.

Results and discussion
5.7.1

Minimizing primary crystal mean size

The first scenario of interest is the minimization of the particle size. Minimization of
primary crystal mean size is relevant in many industrial scenarios and helps with
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micromeritic properties in pharmaceutical applications like bioavailability and dissolution.
This scenario will also serve to illustrate the capabilities of the coupled PBM approach.
The moments of this scenario illustrate the ability to keep track of all the populations in the
PBE set. Figure 5.4 shows the zeroth moment for the three populations. The zeroth moment
is representative of the total particle count. In Figure 5.4, the total particle count for the
primary crystals in the system increases as solution is fed and the system becomes
supersaturated. For this scenario, an inflection point occurs (at 105) indicating a significant
increase in nucleation and a plateau is reached (at 220 min) indicative of zero
supersaturation (zero nucleation).
Focusing on the zeroth moment of the un-agglomerated crystals and the agglomerates,
an initial increase in un-agglomerated crystals that correlates with that of the primary
crystals when the system first nucleates is evident. There is a delayed increase in the
agglomerate counts since agglomeration cannot begin until there are crystals present. At
38 min, the un-agglomerated crystals count begins to spike but is then quickly reduced due
to agglomeration. Since agglomerate formation can occur from crystal-crystal, crystalagglomerate and agglomerate-agglomerate interactions, the zeroth moment of the
agglomerates continues to decrease further; even though there is no longer nucleation
(zeroth moment of primary crystals plateaus). The difference in magnitude of the primary
crystals and un-agglomerated crystals in the beginning is also an indication of
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Figure 5.4 The zeroth moment for each population in the PBE set for the minimization of Ltc,10.

104
Figure 5.5 shows the third moment for the three populations. As the system begins to
nucleate and grow the volume of the primary crystals increases steadily until the
supersaturation is depleted. Comparing both Figure 5.4 and Figure 5.5 suggests that most
of the particle volume is created at the onset with low total counts followed by secondary
nucleation shown by the jump in the total counts but only a slight increase in total volume.
The volume of un-agglomerated crystals is significantly smaller than the volume of
primary crystals and agglomerates suggesting that most of the agglomeration happens at
after the infliction (increase in nucleation) in primary crystals counts. The third moment of
the three populations shows the same trend for all optimization scenarios investigated and
hence will not be shown for other scenarios. Comparing Figure 5.4 and Figure 5.5 can be
misleading given that in Figure 5.4 the total count of un-agglomerated crystals is increasing
along with that of primary crystals, while in Figure 5.5 the total volume of un-agglomerated
crystals rapidly decreases and is significantly smaller than that of the primary crystals. This
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can be clarified by looking at the mean sizes of the three populations.
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Figure 5.5 The third moment for each population in the PBE set for the minimization of Ltc,10.

The mean size optimization profiles of the three populations for this scenario are shown
in Figure 5.6. The mean size is expressed as the first moment divided by the zeroth, 𝐿𝑡𝑐,10 .
The minimum primary particle size achievable in this scenario is 2.5 µm. While the crystals
left in suspension have a mean size of 0.1 µm and the agglomerates are of a mean size of
28.8 µm. The small size of the un-agglomerated crystals again suggests that the increase
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seen in the total counts relates to secondary nucleation, which in turn corresponds to a small
particle size and very small/negligible volume. The agglomerate mean size and the primary
crystal mean size follow the trend observed from the zeroth moment. When the primary
crystal mean size plateaus the agglomerate mean size increases otherwise they follow the
same pattern as the primary crystal mean size increases the agglomerate mean size
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Figure 5.6 Primary crystal mean size (Ltc,10), un-agglomerated crystals mean size (Lcs,10) and
agglomerate mean size (La,10) for Scenario 1.

Figure 5.7 shows the optimal flowrate, temperature and agitation rate profiles for the
minimization of the primary crystals mean size. Flowrate is initialized at its upper bound,
the temperature profile starts near its lower bound and the agitation rate is initialized at its
upper bound. High nucleation or crashing out is characteristic of reverse addition antisolvent crystallization. Thus, the optimizer begins the process by nucleating from the
addition of solution to the anti-solvent, at lower temperatures and high agitation rate to
promote nucleation and generate small crystals. This period lasts the first 15 min and allows
for the system to reach a supersaturated state quickly.
Immediately following the initial period, the flow rate of solution is decreased to its
lower bound, the temperature begins to decrease further and the agitation rate is decreased
to 600 RPM. These changes allow the system to decouple the effects of solution addition,
temperature and agitation on nucleation. Whenever solution addition is increased,
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temperature is slightly increased and whenever solution addition is decreased, temperature
is slightly decreased allowing for nucleation to be controlled by flowrate or temperature.
This keeps the system supersaturated and in a nucleation phase, evident by the continued
decrease in the primary crystals mean size, until the plateau in primary crystals is reached
at 220 min. Nucleation is reduced in this period by an increase in temperature and solution
addition. This period is continued until the end of the batch. This final addition of solution
satisfies the SASR constraint and decreases supersaturation. Figure 5.8 shows the operating
curve along the solubility surface for this scenario.
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Figure 5.7 Optimal flowrate, temperature and agitation rate profiles for the minimization of Ltc,10.

Figure 5.8 Operating curve along the solubility surface for the minimization of primary crystal size.
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5.7.2

Maximizing primary crystal mean size

Maximizing particle size also has industrial relevance in that some systems exhibit low
downstream processing efficiency when the particle size is too small. For this scenario,
Figure 5.9 shows the primary crystal count very quickly reaching a plateau (100th min)
indicative of the system avoiding secondary nucleation. A similar behavior in the zeroth
moment of un-agglomerated crystals and agglomerate population is observed. The initial
spike in the number of un-agglomerated crystals increases similarly to the primary crystals,
however once the primary crystal counts plateau the counts of un-agglomerated crystals
decreases sharply. This is followed by an increase and then a decrease in the agglomerate
counts as the system transitions from crystal-crystal agglomeration to agglomerate-crystal
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Figure 5.9 The zeroth moment for each population in the PBE set for the maximization of Ltc,10.

Figure 5.10 shows the optimization results for the maximization of the primary particle
size. The maximum achievable primary particle size is 41.8 µm. While the unagglomerated crystals left in suspension have a mean size of 61.6 µm and the agglomerates
are of a mean size of 117.8 µm. With regards to the growth of the primary crystals and
agglomerates the trends are like that of the first scenario. The mean size of the primary
crystals remains constant after the 100th min which aligns with the plateau in primary
crystals counts indicative of little supersaturation or growth beyond this point. As in the
previous scenario, the agglomerate mean size increases when the primary crystal mean size
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is constant or when increasing. Interestingly, the un-agglomerated crystal mean size
continues to increase even after the 100th min point. This is due to the agglomeration kernel
used to describe the system. The Brownian+ kernel favors the agglomeration of smaller
particles. Hence, once the system plateaus with regards to counts and has depleted
supersaturation; agglomeration will favor smaller particles, which is the reason for the
increase in mean size of un-agglomerated crystals, due to the removal of fine crystals from
this distribution. This is also the reason why the increase in the mean size of unagglomerated crystals increases with a higher order trend versus the agglomerate mean size
which increases with a linear trend. Every small crystal that leaves the un-agglomerated
crystals population increases the percentage of large crystals left behind while only
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Figure 5.10 Primary crystal mean size (Ltc,10), un-agglomerated crystals mean size (Lcs,10) and
agglomerate mean size (La,10) for Scenario 2.

Figure 5.11 shows the optimal process profiles for this scenario. The solution flow rate
is initiated at 1.0 mL/min and quickly increased to the upper bound while the temperature
is increased linearly to the upper bound (30 °C). As seen in Figure 5.12 (solubility surface),
the system is not supersaturated at the onset, and thus the delayed start in counts and mean
size. As the solution flow rate is increased to 2.5 mL/min and the temperature is held
constant, the system becomes supersaturated and crystals begin to nucleate and grow. The
addition of solution is continued through the 75th minute until the system again becomes
undersaturated. A steady decrease in temperature follows, bringing the system back to a
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supersaturated state. An increase in nucleation results as evident by the sharp increase in
counts and subtle decrease in mean size. The process completes with another cycle of
increasing temperature and decrease in agitation rate. This effectively serves to reduce the
amount of supersaturation that is consumed due to nucleation and drives growth. This is
evident by the increase in primary crystal mean size before the system plateaus and the
temperature is brought to saturation.
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Figure 5.11 Optimal flowrate, temperature and agitation rate profiles for the maximization of Ltc,10.

Figure 5.12 Operating curve along the solubility surface for the maximization of primary crystal
size.
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5.7.3

Multi-objective optimization for bioavailability and manufacturability

Optimizing for both bioavailability and manufacturability targets is the unique scenario
that is made feasible by the proposed coupled PBM framework. Prior to evaluating the
attainability of bioavailability and manufacturability targets, the maximization of
agglomerate particles is evaluated to understand the range and limitation to the maximum
agglomerate size; although the optimal profiles are not shown here. The maximum
attainable agglomerate size for the fixed batch time and operating conditions used here is
154.4 µm. The minimum and maximum size for the primary crystal were 2.5 and 41.8 µm,
respectively. Given these results, the bioavailability target, 𝐵𝑇 , for the mean size is set to
10 µm and the manufacturability target, 𝑀𝑇 , is set to 50 µm.
Figure 5.13 shows the results of the mean sizes for the bioavailability and
manufacturability targets. Both the bioavailability and manufacturability target sizes were
attained within 1 µm. 𝐵𝑇 = 10.1 and 𝑀𝑇 = 49.9 µm. The trends of mean size profiles
described for the previous scenario is similar in this scenario. When the primary crystals
mean size is increasing or constant the agglomerate mean size increases. While the primary
crystal mean size is constant the un-agglomerated crystal mean size increases because
agglomeration favors smaller particles due to the agglomeration kernel used in this case.
All the mean sizes decrease when nucleation occurs due to the increase in smaller counts
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Figure 5.13 Primary crystal mean size (Ltc,10), un-agglomerated crystals mean size (Lcs,10) and
agglomerate mean size (La,10) for Scenario 3.
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Figure 5.14 shows the optimal process profiles for the solution flow rate, temperature
and agitation and Figure 5.15 shows the operating line along the solubility surface.
Analyzing these figures together, it is obvious that the optimal profile is a combination or
interpolation of the previous two scenarios. One apparent difference is the number of
temperature cycles observed in this scenario driven by the need to balance both nucleation
and growth of the primary crystals so to attain both targets. From a solution flow rate
perspective, the system is initiated and carried in the same manner as the previous scenario
of maximizing primary particle size. The solution flow rate is initiated at 1.0 mL/min and
then increased to the upper bound while the temperature is increased linearly to the upper
bound (30 °C). As in the previous scenario, the system is undersaturated until the solution
flow rate is increased (Figure 5.15). A temperature cycling phase then commences at a very
low solution addition. This temperature cycles and low solution addition balance
nucleation and growth allowing for both the bioavailability and manufacturability targets
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Figure 5.14 Optimal flowrate, temperature and agitation rate profiles for the bioavailability and
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Figure 5.15 Operating curve along the solubility surface for the bioavailability and
manufacturability targets.

The agitation profile is similar for all three scenarios indicating that agitation rate is
impacting the nucleation and growth kinetics more than the agglomeration kinetics. Overall
the trend in agglomerate size with respect to changes in agitation rate did not match those
reported in the literature.26, 27,123 This is most likely due to the set of nucleation and growth
kinetic models used as both have an agitation rate dependence. The influence temperature
profiles also had an impact on this results since most SA experiments had previously been
conducted at constant temperature.
Table 5.3 Summary of optimization results with constraint values.
Parameters

Min Ltc,10

Max Ltc,10

BT/MT

Ltc,10 (µm)

2.5

41.8

10.1

La,10 (µm)
AE
Yield
SASR

28.8
96.5%
0.25
0.39

117.8
77.5%
0.31
0.40

49.9
75.6%
0.41
0.37

Table 5.3 summarizes the optimization results. All scenarios met the agglomeration
efficiency (larger than 50%), yield (25% or greater) and SASR constraints (between 0.25
and 0.40). The bioavailability and manufacturing target scenario required the lowest
amount of solution to the system but produced the highest yield. This is most likely due to
the greater number of temperature cycles. The scenario to minimize primary crystal mean
size had lowest yield most likely due to prevention of growth in the system. This scenario

113
also had the highest agglomeration efficiency which is also related to the high amount of
nucleation in this scenario and the fact that agglomeration favors smaller particles.

Porosity profiles
Figure 5.16 shows the porosity profiles from the optimization scenarios. As detailed in the
model development section, this approach to estimating porosity is unique and derived
from the moments of the distributions. The benefits of calculating porosity in simulations
is the ability to design process around the ideal porosity for specific dissolution and
compression properties. The porosity is not included in the optimization studies as it would
require an appropriate scaling parameter to make physical sense. The porosity for the
different scenarios show similar final values with different profiles. The porosity profile
for the maximization of primary crystal size increases initially and then decreases as the
system continues to agglomerate without supersaturation or nucleation (Figure 5.9 and
Figure 5.10). The profiles for the minimization of primary crystal size and target
bioavailability and manufacturability both follow similar cycles of increasing and
decreasing porosity, which correlates well with the temperature and nucleation cycles seen
in optimal profiles and total counts.
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Figure 5.16 Porosity profiles for all three optimization scenarios.
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Effects of secondary nucleation
The parameters used for the presented results were taken from literature values. However,
the empirical parameter 𝒊 found in the nucleation rate expression is not found in the
literature and was not fit to experimental data prior to this study. A study to understand the
effects of this parameter on the simulation and optimization results was conducted. Table
5.4 shows the differences in the results for minimization and maximization of primary
crystal for 𝒊 equal to 1 and 0.01.
Table 5.4 Comparison of optimization results with different 𝒊 values

Empirical Parameter
𝒊=1
𝒊 = 0.01

Min Ltc,10

Max Ltc,10

Ltc,10 / La,10 (µm)

Ltc,10 / La,10 (µm)

2.5/ 28.8
19.8 / 145.8

41.8 / 117.8
89.6 / 156.1

The results from shown in Table 5.4 show that a lower 𝒊 value results in a significantly
larger achievable minimum and maximum primary crystal mean size. Modulating 𝒊 varies
the extent of secondary nucleation in the system. A lower 𝒊 value decreases the extent of
secondary nucleation which in return allows more supersaturation to be consumed by
growth.
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Figure 5.17 Primary crystal mean size (Ltc,10), un-agglomerated crystal mean size (Lcs,10) and
agglomerate mean size (La,10) when 𝑖 = 0.01 for both minimization (top) and maximization (bottom)
of primary crystal size.

Figure 5.17 shows the mean size profiles for both the minimization and maximization
of primary crystal size. The mean size profiles show a significant difference from that of
the system with a higher value for 𝒊. Most notably, changes in the mean size for the
agglomerate follow more closely the changes in mean size of the primary crystals. The
agglomerate mean size stays relatively constant, increases and decreases with the same
trend as primary crystal mean size. This shows the impact that secondary nucleation can
have on the final agglomerated size. The trends observed with lower values for 𝒊 are more
reasonable when compared to the experiments in the literature137,139, but will need to be fit
to experimental data to attain a system specific value.
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Conclusions
In this work, a coupled PBM with nucleation, growth and agglomeration was developed.
Three populations of interest are tracked: primary crystals, un-agglomerated crystals and
agglomerate populations. Tracking these populations separately gives access to otherwise
unattainable information in traditional PBMs. This allows for optimization frameworks and
process design efforts tailored to the property specifications for each population.
An optimization framework has been developed to achieve optimal flowrate,
temperature and agitation rate profiles for a reverse addition, anti-solvent crystallization
system of benzoic acid with agglomeration. The results of this work show that operating
parameters can be optimized to achieve the desired primary and/or agglomerate properties.
The framework allows for bioavailability (primary crystal size) and manufacturability
(agglomerate particle size) optimization. Moving forward this model formulation will
allow for the development of better, more relevant kinetic and agglomeration parameters.
Given that each population is tracked separately, kinetic parameters can be fit separately
without having to lump all the kinetics into one population; thereby increasing accuracy of
the parameter fit. Agglomeration kernel identification would greatly improve with this
model formulation, and can begin the shift from purely empirical kernels to combination
kernels that relate the physical mechanisms and operating conditions more accurately.
Moving forward the proposed model formulation will be fit to data from various
agglomeration in suspension systems to assess its capability to predict product properties.
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6. PROCESS INTENSIFICATION THROUGH CONTINUOUS
SPHERICAL CRYSTALLIZATION USING A TWO-STAGE
MIXED SUSPENSION MIXED PRODUCT REMOVAL (MSMPR)
SYSTEM

This chapter is reprinted with minor modification with permission from Peña, R., & Nagy,
Z. K. (2015). Crystal Growth and Design, 15(9), 4225–4236. Copyright 2015 American
Chemical Society

Introduction
Crystallization, originally conceived as a purification and separation process, has become
a predominant technique in particle design technology. It is a unit operation in process
systems in a broad range of industries including pharmaceuticals, bulk and fine chemicals,
food, and electronics.32 In most solid-liquid separation processes, crystallization is the
characteristic and property-determining step. Given that it is also one of the initial steps, it
has a major impact on downstream processes (e.g., filtering, drying, milling, handling,
storage).1
Crystallization greatly influences API purification, final product properties, dosage
form and the efficiency of intermediate unit operations leading to the final dosage form.
Milling and granulation are unit operations that often follow crystallization with the
purpose of improving crystal properties either for better bioavailability or for improved
processing characteristics (e.g., flowability, compressibility). However, milling and
granulation have some inherited inefficiencies and although the overall crystal size can
improve, it is often at the expense of a wider crystal size distribution (granulation) and poor
process properties (milling).
In the past, the pharmaceutical industry’s manufacturing processes have been limited
in efficiency due to their batch nature, costing the industry as much capital investment and
development time as drug discovery. However, due to expiring patents and the fluctuating
cost of energy most companies have begun to face the economic burden of inefficient
manufacturing.23 Of current interest in the industry is to move manufacturing processes
from batch to continuous operation. Batch crystallization is a versatile, recipe based, mode
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of operation that can be adapted for specific product properties and used for different
products. Batch crystallizers are also relatively inexpensive compared to systems using
other methods of operation and are simple to use. However, continuous operation allows
for lower overall capital investment, production that is more efficient and reproducible,
easier scalability, and better waste or off-specification product management.25,83 Scale up
of batch operations is not as straightforward as that of continuous operations because they
occur at unsteady state and require greater understanding of the effects of the differences
in scales. Continuous operation, although easier to scale, makes the process design more
difficult because of all the interplaying parameters. Also according to standard economy
of scale considerations it is only viable when production rates are very large (> 50
tons/day).32 More recently, throughput requirements for continuous operations have been
outweighed by considerations that are related to achieving operating conditions and levels
of product consistency that are unattainable in the batch operations currently available;
providing accepted benefits to continuous processes independently of the scale and
production rate.
Common to most pharmaceutical products is the use of many unit operations, which is
characteristic of batch operation and solid dosage formulations. This can decrease the
overall yield and efficiency of the manufacturing process and often makes it difficult to
maintain product safety and quality. Instead, intensifying the processes involved in
pharmaceutical formulations can greatly improve efficiency. One method of improving
product properties post-crystallization, reducing unit operations and easily implementing
continuous manufacturing strategies is through PI. PI presents several advantages for the
pharmaceutical industry including lower capital and operating costs, less handling, transfer
and storage of intermediate products, and more robust and energy efficient operation.
Implementing CSC allows for the elimination of downstream particle property enhancing
unit operations like milling, grinding and granulation, and promotes the move from batch
to continuous operation.
CSC of a model drug compound was first carried out by Kawashima et al. (1982) after
Kawashima & Capes (1974) realized that resulting products from SA had very good flow
properties.30,152 In their work, a model continuous mixed suspension, mixed product
removal (MSMPR) crystallizer consisting of one stage was fed an aqueous suspension. The
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critical parameters were identified as agitation rate, suspension feed rate, and bridging
liquid feed rate.22 Since Kawashima et al. (1982) very little work has been done on CSC.
An abundance of work exists on SC in batch operation. The first batch spherical
crystallization (BSC) was carried out by Kawashima et al. (1982) who crystallized salicylic
acid in ethanol by pouring the solution into a water-chloroform mixture and found the
critical parameters to be similar to that in a continuous system: agitation rate, temperature,
bridging liquid content, and residence time.22 There are also very few references that make
use of PAT tools for monitoring SC. This could be due to the increased difficulty of process
monitoring when complex mechanisms like nucleation, growth, and agglomeration are
happening simultaneously. However, the use of PAT tools for crystallization processes has
been widely discussed in the literature17,46,188 and has proven to be beneficial in the
monitoring of both liquid-phase and solid-phase dynamics during crystallization. Blandin
et al. (2003) provides the best example of the benefits of in-situ monitoring of a SC
process.143
Rasmuson & co-workers26,137,139 have done research on how changes in the key
operating parameters of BSC affect the final product properties. In most of their work the
solute was benzoic acid, the good solvent was ethanol, and the poor solvent was water.
Longer residence times30, or duration under agitation137, produced stronger and highly
spherical agglomerates. Katta & Rasmuson26 also found that the agglomerate size increased
with increasing solute concentration. Lower concentrations produced more fines and
porous spherical agglomerates. Other properties found to be important in BSC include the
feed rate of the solution into the poor solvent; an increase in feed rate led to decrease in
agglomerate size. This is due to the difference in the rate of supersaturation generation at
low versus high feed rates. Thati & Rasmuson139 studied the effect of temperature on the
SA process, and found that agglomerate size increased with a decrease in temperature. The
decrease in solubility at lower temperatures increased supersaturation, which increased
nucleation and subsequent inter-particle growth between colliding particles. There has also
been a wide range of studies on the physiochemical, mechanical, and micromeritic
properties of the spherical agglomerates to assess the possibility of direct tableting of the
agglomerates.28,118,123,134,137,139,189,190 However, none of the aforementioned studies looked
into the interplay between the operating conditions and the trade-off between the size
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distribution and properties of spherical agglomerates and the size distribution of
constituting internal crystals. In almost all previous SC systems, crystallization and
agglomeration occurred simultaneously; offering little or no control in tailoring the internal
crystal size versus external agglomerate size. In this work, a novel two-stage CSC system
is proposed in which the nucleation and growth processes are separated (in the first stage)
from the agglomeration mechanism (in second stage), enabling precise and independent
control of the internal CSD and ASD. This can enable the simultaneous control of product
properties (e.g., dissolution profile) and processing requirements (e.g., flowability,
compressibility). A FBRM was used to help identify the initiation and extent of the
agglomeration process, although in-situ imaging microscope might be more suitable.

Spherical crystallization mechanisms
Kawashima et al. (1995) found that SC is also possible in two solvent systems and
proposed the SC mechanism for both two and three solvent systems. In both systems, the
proposed mechanism is the formation of an emulsion droplet of good solvent in which the
drug is precipitated via diffusion of the good solvent to the poor solvent.124 The difference
in the techniques is the presence or absence of agglomeration. Figure 6.1 illustrates the SC
mechanism for two and three solvent systems. Two solvent systems are usually emulsion
based SC techniques where emulsions are formed by the immiscibility between the poor
and good solvent (e.g., oil in water or water in oil) or by the good solvent’s inherently
greater affinity for the solute. Chadwick & Davey made spherical particulates from water
in oil emulsions using a water-soluble compound and cooling as the method of
supersaturation generation.126 Spherical particulates can also be produced using anti-
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solvent crystallization whereby counter diffusion of the poor solvent and good solvent into
and out of the emulsion droplet promotes crystallization or ESD.

Figure 6.1 Agglomeration mechanism for different spherical crystallization techniques (c and d
adapted from [28], d adapted from [23]).

The mechanism for three solvent systems is like two solvent systems except
agglomeration is present. The third solvent is the bridging liquid. The bridging liquid
preferentially wets the precipitated solute particles.26,123,139,152 Collisions between wet
particles causes the particles to adhere and create agglomerates. This method is commonly
referred to as SA. Spherical particulates produced by ESD are usually smaller and more
porous than the particulates produced by SA while agglomerates produced by SA are
usually bigger and stronger. SA has more applicability as it does not require the creation
and subsequent stability of emulsion droplets like ESD. Kawashima et al. (2003) states the
SC mechanism taking place changes from SA to ESD as the SASR, essentially the
concentration, is decreased.28 Krishna et al. (2012) and Kovačič et al. (2012) propose
methods to decide the best SC mechanism for different types of systems.123,191
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Blandin et al. (2003) and Rasmuson & Thati (2011) found that the size of the spherical
agglomerates significantly increases with increased bridging liquid content.111,137 The BSR
determines the bridging liquid content. Amaro-González & Biscans (2002), SuberoCouroyer et al. (2006), and Rasmuson & Thati (2011) established that there is a critical
range for the BSR for which below the minimum spherical agglomerates will not form and
above the maximum a paste like product will form.

29,142,137

Figure 6.2 illustrates the

progression of an agglomerate, for both fine crystals and emulsions, as the BSR is increased.
Initially, when an amount of bridging liquid is added at a ratio of BSR 1 below the critical
ratio (BSRcric) the agglomeration process begins and crystals (or emulsions) adhere and
form agglomerates although there may be loose crystals still in the suspension. As the
bridging liquid ratio is increased to the BSRcric the agglomerate is more firmly held together,
more particles adhere to one agglomerate and there are no longer loose particles in
suspension. At a ratio BSR3 above the BSRcric a bridging liquid layer begins to form around
the agglomerate. When the bridging liquid ratio is increased to BSR4, the bridging liquid
layer reaches its maximum. At ratios above BSR4, there will be excess bridging liquid in
the suspension, which causes the formation of bridging liquid droplets (Figure 6.2e).
Further increase in the bridging liquid ratio can cause phase separation where the particles
(or agglomerates) become surrounded by bridging liquid, which is suspended in the
continuous phase (Figure 6.2f). In the case of excess bridging liquid, a more amorphous
agglomerate is produced that behaves in a paste-like manner.

Figure 6.2 Agglomerate formation as bridging liquid content is increased. Adapted from [162].
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The contribution of the work presented herein is CSC in a two-stage MSMPR
crystallizer. The purpose of the proposed setup is to achieve two of the current major
focuses of the pharmaceutical industry, which are PI and continuous manufacturing. PI
occurs through the SC technique that will produce spherical particulates with the potential
to be directly compressed. Continuous manufacturing in the proposed MSMPR setup will
improve the process efficiency while reducing the handling of intermediate products and
reducing the number of unit operations in a drug product line. The continuous production
of spherical agglomerates allows for changes in operating parameters to produce
agglomerates of different qualities, which is an improved method of product quality control
over batch operation. The proposed two-stage MSMPR crystallizer setup also serves as a
product design approach because of the ability to decouple nucleation/growth and
agglomeration mechanisms. This ability to decouple mechanisms allows for direct product
design whereby in one stage biopharmaceutical properties are enhanced, and in the other
stage processing properties are improved. The benefits of the setup and production will
also include the ease with which these spherical particulates can then be filtered, dried, and
compressed when compared to traditional crystallization. The use of PAT tools in CSCMSMPR setup will also add degrees of freedom to the operation allowing for the possibility
of other model-free approaches from the literature6,10,18,192 to be implement in the different
stages as part of the continuous MSMPR system.

Experimental work
The two-stage continuous MSMPR crystallizer setup proposed for CSC allows the tailoring
of internal and external properties of spherical agglomerates. As depicted in Figure 6.3, in
the system the first stage serves as the nucleation and growth dominant stage where altering
of the operating conditions produces crystals of a specific size distribution, morphology
and dissolution properties. The second stage serves as the agglomeration dominant stage
where the operating conditions produce agglomerates of specific size distribution, flow and
disintegration properties. The decoupling of the crystallization and agglomeration
mechanisms will provide flexibility in final product properties. For example, one
combination could produce large spherical agglomerates of loosely packed fine crystals
but alternatively one could potentially produce the same size agglomerates with densely
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packed coarse crystals. This opens the door for better product specific design that can
potentially achieve specification levels that granulation cannot. To the best of our
knowledge, no previous work in the literature has taken this approach to SC and very little
work exists on CSC.

Figure 6.3 Schematic representation of proposed two-stage MSMPR setup for CSC.

To control the particulate properties in each stage, understanding of the critical
operating parameters and their effect on each stage is important. Table 6.1 lists the critical
parameters for each stage. The mean residence time will be a critical parameter for both
stages as it will determine approximately the average time for crystal growth in the first
stage and the average time for agglomerates to consolidate in the second stage. The
agitation rate is critical in both stages. In the first vessel, it is important to limit secondary
nucleation, reduce breakage and agglomeration so that crystal counts in the vessel are close
to constant throughout the experiment. Keeping agitation at a moderate level will
accomplish this. However, in the second vessel the opposite is true. It is important to
operate the second stage at high agitation rates to produce more spherical and stronger
agglomerates. The SASR in the first stage, and subsequently throughout both stages, will
change the supersaturation and plays the most significant role in the CSD in the first vessel.
These primary crystals then become the internal crystals that makeup the agglomerates.
The last parameter of importance is the BSR. Proven in the literature, through batch
experiments, there exists a critical range for the BSR.139 In continuous experiments, the
critical operating range to guarantee SA production needs to be developed. The BSR,
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residence time in the second stage and agitation have a combined effect of the size
distribution of agglomerates (ASD) and their micromeritic properties.
Table 6.1 Critical Operating Parameters in two-stage MSMPR
1st Stage
Residence time (RT)
Agitation rate (N)
Operating volume (V)
Solution to anti-solvent ratio (SASR)

6.3.1

2nd Stage
Residence time (RT)
Agitation rate (N)
Operating volume (V)
Bridging liquid to solute ratio (BSR)

Materials and methods

Lab grade benzoic acid (C6H5COOH) (>99% purity Fisher Science Education) was used
as the model drug compound. Benzoic acid is a good model drug for SC given that its
crystal habit from traditional crystallization techniques is poorly flowing thin plates or
needles.26 It was dissolved in ethanol (pure, 200 pf, KOPTEC, USP Grd) which served as
the good solvent. Deionized water induced anti-solvent crystallization, and served as the
poor solvent given its poor solubility of the model drug. Toluene (>99.5% Macron Fine
Chemicals) served as the bridging liquid as it has proven to be a suitable bridging liquid in
the literature.137,139 Nitrogen (dry, 99.9% purity) and vacuum moved slurry into and out of
the transfer zones. A Nikon microscope was used to take pictures of the resulting spherical
agglomerates.
The proposed two-stage MSMPR system (shown in Figure 6.3) was used for the CSC
studies. The stages consist of 500 ml lab scale jacketed crystallizers. An overhead stirrer
with a three-blade retreat curve impeller was used to agitate the system. At agitation rates
ranging from 250 to 500 RPM good mixing was observed. Peristaltic pumps (Cole-Palmer)
and platinum cured silicon tubing (MasterFlex L/S) fed solution and anti-solvent into the
first stage. A KDS 100 syringe pump or a Cole-Palmer peristaltic pump using MasterFlex
L/S tubing fed bridging liquid into the second stage. All inlet liquids (solution, anti-solvent,
and bridging liquid) were added to the vessel at the surface, equidistance from the impeller
and crystallizer wall. The slurry transfer of each stage was carried out in a manner similar
to the process described in Hou et al. (2014).193 Using a dip tube intermittent slurry transfer
occurred by a combined vacuum and pressure, which removed and then purged the slurry
into and out of the transfer zone (Figure 6.3). For the first and second stage, withdrawal
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was no more than 4.2% and 6.8% of the suspension, respectively. The ratio of the transfer
zone volume to the volumetric feed rate determined the cycle times (CT), or the constant
intervals at which transfer occurred. A programmable control unit allowed for the
automation of the solenoid valves that controlled both vacuum and nitrogen (control unit
and transfer line provided by Eli Lilly & Co). In all the experiments, bridging liquid is fed
to the second stage at the same CT as the volume of slurry transferred from the first stage.
Lasentec FBRM S400 and FBRM G400 by Mettler-Toledo were used to monitor the
process in the first and second stage, respectively. The probes allowed the identification of
nucleation/growth and agglomeration mechanisms as well as identification when the CSO
was achieved.
Product samples used in this study were collected every residence time from the
agglomeration stage using a wide-mouth pipette and were filtered. Samples were air dried
at room temperature for 24hrs then off-line imaging and dissolution studies were conducted.
During operation, the rest of products were continuously collected in a collection vessel.
For the dissolution studies, an attenuated total reflection ATR-UV/Vis probe was used to
measure absorbance of benzoic acid. The UV peak absorbance for benzoic acid is at a
wavelength of about 220-240 nm. A 230-nm wavelength was used for this studies. A 27%
ethanol and 73% water mixture served as the dissolution medium. The ethanol-water
mixture improved the wettability of the spherical agglomerates and assured the spheres
remained suspended. For each study, a 500-mL jacketed vessel was used with 100 mg of
agglomerates dissolved in 300 ml of the dissolution medium. The temperature was constant
at 37 °C and the agitation rate was set at 250 rpm for all dissolution studies. The dissolution
differences were assessed based on the t80 of each respective experiment. The t80 represents
the amount of time it takes to reach 80% of the maximum dissolved concentration. The
studies were repeated three times and the standard deviation has been included as error bars
in the dissolution profiles. SEM images were taken of the spheres from the experiments
used for dissolution studies.
6.3.2

Procedure

Solution preparation consisted of dissolving benzoic acid in ethanol at 40 °C then allowing
the solution cool to room temperature. The saturation temperature of the maximum
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concentration used was 15 °C. The critical operating parameters for the present
experiments were those presented in Table 6.1 combined with the bridging liquid, solution
and anti-solvent flow rates and benzoic acid concentrations. Compared to the second stage,
in the first stage agitation rate and operating volume were lower to promote the minimal
amount of nucleation and growth by reducing secondary nucleation and residence time.
Initially, the first stage is operated in semi-batch mode feeding the benzoic acid in ethanol
solution into a specified amount of anti-solvent until the specific SASR is reached after
which both solution and anti-solvent are fed and are then transferred from the first stage to
the second is initiated. The second stage operated at a higher agitation rate and residence
time to promote better agglomeration and allow the granules to mature. In a few
experiments, bridging liquid feed to the second stage initiated after the first stage
approached a CSO in terms of counts and mean size. For the dissolution studies, when the
UV absorbance reached an equilibrium, the study was terminated and the equilibrium value
was taken to be the maximum UV absorbance. The percent dissolution becomes the UV
absorbance over the maximum multiplied by 100.

Results and discussion
In total 10 experiments were performed to assess the viability of the proposed CSCMSMPR setup. Table 6.2 lists the specific operating conditions and outcomes of each
experiment. The experiments consisted of conditions that proved to be successful for batch
operation in the literature.26 Two concentration levels were attempted 0.25 and 0.375 g/ml
of benzoic acid in ethanol. The SASR and BSR range were 0.20-0.33 and 0.59-1.25,
respectively. Two levels of agitation rate were attempted for each stage; 250 and 300 rpm
for the first stage, and 400 and 500 rpm for the second stage. The volume of each stage was
adjusted multiple times to assess the influence of residence time.
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Table 6.2: Operating Conditions for CSC experiments in two-stage MSMPR
Conc.
of BA
Exp.
in
Feed
(g/ml)
1

0.250

2

0.250

3

0.250

4

0.250

5

0.375

6

0.375

7

0.375

8

0.375

9

10

Flow Rates (ml/min)
Op.
Stage

N
V
SASR BSR
(rpm) (ml)

RT
(min)

CT
(min)

BL

S

AS

Overall

1st

0.33

--

300

300

60.00

2.48

--

1.25

3.75

5.00

2nd

0.33

1.00

400

500 100.00

6.72

0.20

--

--

5.20

1st

0.33

--

300

300

37.50

1.55

--

2

6

8.00

2nd

0.33

1.00

400

500

62.50

4.20

0.32

--

--

8.32

1st

0.33

--

250

300

37.50

1.55

--

2

6

8.00

2nd

0.33

1.25

400

500

62.50

4.20

0.40

--

--

8.40

1st
2nd
1st

0.20
0.20
0.33

-1.00
--

250
500
250

300
500
250

33.33
55.56
31.25

1.37
3.73
1.55

-0.24
--

1.5
-2.00

7.5
-6.00

9.00
9.24
8.00

2nd

0.33

0.59

400

400

50.00

4.20

0.26

--

--

8.26

1st
2nd
1st
2nd
1st
2nd

0.33
0.33
0.33
0.33
0.33
0.33

-0.82
-1.00
-0.82

250
400
300
400
250
400

200
450
250
450
250
500

25.00
56.25
25.00
45.00
25.00
50.00

1.55
4.20
1.23
3.37
1.23
3.37

-0.36
-0.55
-0.45

2.00
-2.5
-2.5
--

6.00
-7.5
7.5
--

8.00
8.36
10.00
10.55
10.00
10.45

1st

0.33

--

250

300

37.50

1.55

--

2

6

8.00

2nd

0.33

1.25

400

500

62.50

4.20

0.56

--

--

8.56

1st
2nd

0.23
0.23

-1

300
500

300
500

37.50
62.50

1.55
4.20

-0.33

1.5
--

6.5
--

8.00
8.33

0.375

0.375

Result

small, loosely
compact and
flakey
spheres
small, loosely
compact and
flakey
spheres
crystals,
paste-like
slurry
large spheres
irregular
shaped
agglomerates,
spheres, and
crystals
spheres and
crystals
spheres and
crystals
spheres and
crystals
irregular
shaped
agglomerates
and paste-like
slurry
uniform
spheres

As shown, only two experiments produced solely spherical agglomerates (experiments
4 and 10). The other experimental conditions produced small, loosely compact spheres,
irregularly shaped agglomerates, or combination of spheres and crystals. The most
influential operating parameters that differentiated the product quality in these experiments
were the agitation rate (N) in the second stage and the BSR. The agitation rate in the second
stage for the two successful experiments was 500 rpm. The experiments that produced
spheres and crystals and were in the mid-range of the BSR ratios attempted would have
produced spheres had the agitation rate been sufficient. In previous batch experiments, 400
rpm was successful due to the smaller scale at which the experiments were conducted. At
the scale of these continuous experiments, 400 rpm is not sufficiently high to produce the
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necessary agglomeration needed for uniform spherical agglomerate products. Experiments
at the lowest and highest BSR coincided with the experimental results found in the
literature and the mechanisms described in Figure 6.2. At low BSR there is insufficient
bridging liquid to promote complete agglomeration and at high BSR large, very porous and
irregularly shaped agglomerates are formed. The SASR plays an important role in
determining the supersaturation of the system. Higher SASR results in a lower
supersaturation and therefore less yield. The combination of high SASR and high BSR will
produce a paste-like slurry due to the lower crystal yield and excess bridging liquid as
shown in Table 6.2. The remaining parts of this work will focus on examining the two
successful experiments.
Table 6.2 has the operating conditions for experiment 4 and Figure 6.4 presents the insitu FBRM data. As previously mentioned, initially the first stage operates in semi-batch
mode to produce the crystals for the continuous experiment. This accounts for the ~50-min
shift at the start of data collection in the second stage. In experiment 4, bridging liquid
addition to the second stage was initiated after one RT (~55.6 min) and was fed
continuously using a syringe pump. As can be seen in Figure 6.4b, the counts in the second
stage immediately begin to decrease at the start of bridging liquid addition. There is also
an immediate increase in mean chord length (Figure 6.4d). These are clear indications that
agglomeration occurs in the system. In Figure 6.4d the mean chord length is seen to be
oscillating this is potentially due to the to the competing phenomena of nucleation, growth,
and agglomeration as slurry is being transferred from the first stage to the second. There
has been work in the literature that shows how different operating conditions can cause
continuous MSMPR to have multiplicity and oscillatory behavior due to changes in the
complex interactions between the different crystallization mechanims.39,194 Figure 6.4b
shows the effect of nucleation as the counts <10 microns are the highest. Figure 6.2f shows
the chord length distribution of the agglomerates and it shows a wide, almost bimodal
distribution.
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Figure 6.4 In-situ FBRM counts/s, mean chord length, and chord length distribution, (left) Stage1
(Nucleation/Growth): a) Counts/s; c) Square Weighted Mean Chord Length (SWMCL); e) Square
Weighted Chord Length Distribution; (right) Stage 2 (Agglomeration): b) Counts/s; d) SWMCL; f)
Square Weighted Chord Length Distribution. Note that bridging liquid addition to the second stage
initiated after one RT (~55.6 min).

In approximately 1.5 RT from the start of bridging liquid addition, the counts in the
second stage begin to reach a CSO (Figure 6.4b). However, Figure 6.4a shows the first
stage lags, taking slightly longer to reach a CSO. The first stage begins to reach a CSO at
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7 RT (7×33.3 min) and the second stage reaches a CSO at 2.5 RT (2.5×55.6 min). This is
common from a two-stage operation as the second stage tends to attenuate future variations
from the periodic addition of slurry from the first, and therefore reaches a CSO faster.
These observations point out the key benefits of in-line PAT tools, such as FBRM, that it
allows for the identification of different process mechanisms like agglomeration and
process monitoring to determine that a suitable CSO is achieved.
Figure 6.5 shows pictures of agglomerates at different times after initiation of bridging
liquid addition. As can be noted from the pictures, the agglomerates from experiment 4 are
very irregular in shape and not very uniform in size. The two top pictures in Figure 6.5a
show some agglomerates that are very spherical and somewhat uniform in size while Figure
6.5b shows an agglomerate that was so large that it was out of the view of the microscope
used. The scale in each picture is 1000 µm. The irregularities in shape in this experiment
can be attributed to several operating issues. For one, it appears that the bridging liquid was
added prematurely and there were not enough particles in the second stage for bridging
liquid being added. Also, because the bridging liquid was added to the second stage
continuously but the slurry from the first stage was added in intervals there were periods
of imbalance between the amount of bridging liquid and amount of crystals in suspension.
This excessive amount of bridging liquid potentially caused excessive agglomeration and
production of very large, irregularly shaped agglomerates. Another potential reason for the
very large, irregularly shaped agglomerates and wide chord length distribution is the fact
that as the agglomerates got bigger there may not have been representative withdrawal
from the second stage. Combining that with the incoming crystals from the first stage
would undoubtedly cause a wider agglomerate size distribution.
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a)

b)

c)

d)

Figure 6.5 Spherical agglomerates at different times after bridging liquid addition: a) 1 RT after
bridging liquid addition; b) 3 RT after bridging liquid addition; c) 4 RT after bridging liquid
addition; d) 5 RT after bridging liquid addition.

Table 6.2 has the operating conditions for experiment 10 and Figure 6.6 below presents
the in-situ FBRM data. The results from the experiments produced very spherical
agglomerates and a more uniform ASD in comparison to experiment 4. Figure 6.6a shows
that CSO was achieved in the first stage within approximately six residence times and
maintained for approximately four residence times. The second stage approached a CSO
at approximately 5 to 6 residence times (Figure 6.6b). In experiment 10, bridging liquid
addition began after the first stage had reached a CSO (six residence times) and the second
stage had nearly reached a CSO (three residence times) in terms of counts/s. In this
experiment, the bridging liquid addition to the second stage occurred intermittently at the
same cycle time as the slurry coming from the first stage. This allowed for bridging liquid
addition at the exact BSR needed for the slurry coming in. The data from the second stage
(Figure 6.6b and Figure 6.6d) clearly depicts the decrease in counts/s and the increase in
mean chord length after bridging liquid addition started, allowing for the clear
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identification of agglomeration. One difference between experiment 4 and 10 is that once
bridging liquid addition began the mean chord length increased and reached a new CSO
rather than oscillating as it did in experiment 4. This is a sign of a more uniform size
distribution (Figure 6.6f) as there are fewer fluctuations in the mean chord length. Figure
6.6f shows the chord length distribution to be uniform compared to in experiment 4. The
chord length distributions before and after bridging liquid addition indicates a significant
decrease in the counts/s. Overall, this experiment show less instability and oscillations
when compared to the previous experiment. From the FBRM counts it appears that the
effects of nucleation in the second-stage are also less pronounced in this experiment which
could account for the improved stability in the mean chord length.
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Figure 6.6 In-situ FBRM counts, mean chord length, and chord length distribution, (left) Stage1
(Nucleation/Growth): a) counts/s; c) SWMCL; e) Chord Length Distribution; (right) Stage 2
(Agglomeration): b) counts/s; d) SWMCL; f) Chord Length Distribution.

Visual and qualitative assessment of the improvement in agglomerate size and shape
can been done through Figure 6.7, which shows pictures of the agglomerates at different
times after the bridging liquid addition was initiated. Figure 6.7a-c shows the clear
improvement in sphericity and size uniformity with time. The scale in each the picture is
1000 µm.
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a)

b)

c)

Figure 6.7 Spherical agglomerates at different times after bridging liquid addition: a) 1 RT after
bridging liquid addition; b) 2 RT after bridging liquid addition; c) 3 RT after bridging liquid
addition.

6.4.1

Dissolution studies

Comparison of dissolution properties from experiments at different conditions illustrates
the potential ability of the proposed system for product design by producing agglomerates
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with different release profiles based on tailoring the combination of internal CSD, external
ASD and micromeritic properties through manipulating the operating conditions in each
stage. The spherical agglomerates produced from experiments 9 and 10 were compared for
these studies. The t80 for experiment 9 (higher BSR and SASR than experiment 10) is
approximately 2.5 min whereas for experiment 10 is approximately 7.5 min (Figure 6.8).
The dissolution results present a clear difference in biopharmaceutical properties,
illustrating the potential control of dissolution rate, hence drug release profile, through
varied operating conditions of the CSC system. The agglomerates obtained from the
experiment with a higher BSR and higher SASR dissolved three times faster than at lower
BSR and lower SASR.
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Figure 6.8 Dissolution profiles of spherical agglomerates obtained under different operating
conditions.

There are two contributing reasons for this based on the two operating parameters that
were changed. Figure 6.2 explains the contribution of an increased BSR to the dissolution
properties. As the BSR is increased, it goes from suboptimal to critically optimal to
excessive bridging liquid. When excess bridging liquid exists, it produces agglomerates
with loose, very porous structures and more solvent inclusion (Figure 6.2f). Due to the fair
solubility of the compound in the bridging liquid, when the agglomerate is filtered and
dried, crystallization of fine crystals will occur. However, due to the porous nature of the
agglomerate the new fine crystals do not pack into the structure of the agglomerates tightly.
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These fine crystals and the loose structure of the agglomerate cause rapid disintegration
and dissolution compared to the tightly packed spheres from experiment 10.
Figure 6.9 shows SEM images of the spheres produced from the experiments 9 and 10.
The top pictures (a) are spheres from experiment 9 which show a more porous structure as
well as irregularly shaped primary crystals. The bottom pictures (b) are of a spherical
agglomerate from experiment 10, which show less porosity and void space and the primary
crystals have a consistent structure (plate-like crystals). The spherical agglomerates from
experiment 10 resemble the agglomerates corresponding to the SA mechanism stages given
in Figure 6.2b-c. This is further validated by the fact that Thati & Rasmuson found the
critical operating BSR range for a benzoic acid and ethanol-water-toluene system to be
0.47-1.16 (at 20 °C).137 The higher SASR increases the rate of supersaturation generation.
This level of supersaturation generation can also cause the system to precipitate fast, which
can lead to unstructured crystals seen in the Figure 6.9a.
a)

b)

Figure 6.9 SEM Images of agglomerates form different operation (a) experiment 9 (b) experiment
10.

Figure 6.10 displays agglomerated particles from experiment 9. The figure indicates clearly
the irregularly shaped agglomerates that are obtained from these operating conditions.
From the figure, it is also clear that the agglomerates are far more ‘flaky’ than the spherical
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agglomerates from Figure 6.7c. This is evident by the small fine crystals that appeared to
have fallen off the agglomerates when placed on the slide. The agglomerates in Figure 6.7c
correspond to the BSR level shown in Figure 6.2b-c, whereas the agglomerates from Figure
6.10 correspond to the BSR level shown in Figure 6.2e-f. The results of the dissolution
study combined with the entire experimental design provide validation for the proposed
CSC-MSMPR setup. The results presented demonstrate the ability to tailor the properties
of the product for both biopharmaceutical and processing benefits.

Figure 6.10 Agglomerate particulates from experiment 9 (BSR = 1.25, SASR = .33).

Conclusions
In this work a two-stage MSMPR setup for CSC is proposed that serves as a combined
process and product design platform. To go along with the ability to decouple different
mechanisms by allotting different stages for each mechanism, the setup allows for
continuous spherical agglomerate production. This new process and product design
approach represents a novel continuous manufacturing platform for pharmaceutical solid
products; hence supporting current trends in the pharmaceutical industries to move toward
continuous processes. By implementing CSC, the setup also serves as a PI technique
thereby reducing the total number of unit operations that would be need in a pharmaceutical
production line. The spherical agglomerates have the potential to be directly compressed
and as proven by the dissolution results a specific drug compound can be produced in such
a way as to have different final properties (size, dissolution, compactibility). The properties
of the spherical agglomerates produced by the CSC platform can be altered by changes in
operating parameters, which is an improved method of meeting product specifications over
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batch crystallization and granulation. The benefits of the setup also include the ease with
which these spherical particulates can be processed post-crystallization (filtering, drying,
and compressing). In this study, the FBRM served as a useful PAT tool to indicate when
the system reaches a CSO and in identifying the agglomeration process. However, due to
the large size of the spherical agglomerates, true particle size analysis of the spherical
agglomerates needs to be conducted offline as part of a characterization study. Transition
from BSC to CSC-MSMPR should be straightforward and feasible. The results here have
demonstrated that the critical operating parameters remain the same for both BSC and CSC.
The extra parameters in CSC are mainly flow rate and crystallizer volume that control
residence time. Given a sufficient residence time, increased or decreased residence time
affects strength and sphericity more so than the ability to produce spherical agglomerates.
The proposed two-stage MSMPR-based approach for CSC allows for greater degrees
of freedom to tailor product properties. The added benefit of the proposed approach is the
ability to independently tailor the properties of the crystalline particulates that compose the
spherical agglomerates and the characteristics of the agglomerates produced by CSC.
Hence the proposed two-stage MSMPR system for CSC serves as both a product and
process design approach.

140

7. PROCESS INTENSIFICATION THROUGH CONTINUOUS
SPHERICAL CRYSTALLIZATION USING AN OSCILLATORY
FLOW BAFFLED CRYSTALLIZER (OBCF)

This chapter is reprinted with minor modification with permission from Peña, R., Oliva, J.
A., Burcham, C. L., Jarmer, D. J., & Nagy, Z. K. (2017). Crystal Growth and Design,
acs.cgd.7b00731. Copyright 2017 American Chemical Society

Introduction
As the pharmaceutical industry continues to adopt different aspects of continuous
processing, PI will be a key driver towards more integrated unit operations. PI is defined
as the integration of innovative techniques and technologies to create sustainable solutions
to current industrial production difficulties. It is comprised of two parts: novelty in
equipment43,195 and novelty in processing techniques.3,19,21,96,196-199 Continuous PI
techniques lead to improved product quality, process safety and efficiency, and a reduction
in waste/maintenance. These techniques allow for development and manufacturing at
laboratory scale, ultimately reducing time to market and improving patent life
utilization.17,43,46,96,196
Spherical crystallization is inherently a PI technique due to its ability to eliminate
further downstream unit operations and improve particulate flow properties while
promoting higher processing efficiency. CSC provides the ability to directly connect
upstream reaction synthesis to separation and purification unit operations. Peña & Nagy
(2015) and Tahara et al. (2015) implemented CSC using MSMPR systems.130,170 Tahara et
al. (2015) used a single-stage MSMPR to carry out a QESD SC technique with a solvent
recycle stream.125,200 The recycling of solvent from the mother liquor resolves two major
issues common to SC: low yield and maintaining the low ratio of solvent (API carrier) to
anti-solvent. Peña & Nagy (2015) used a SA technique in a two-stage MSMPR system
where the first stage was the nucleation/growth dominated stage and the second stage was
the agglomeration dominant stage through the use of a bridging liquid (binder).26,123,139
Their work focused on the ability to alter both the properties of the internal (primary)
crystals and the agglomerates by independently changing operating conditions in each
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stage. Independent control of internal and external properties provides the ability to achieve
a target primary crystal size for bioavailability and a target agglomerate size for drug
product manufacturability. The ease of ‘knowledge transfer’ from batch to continuous
operation using the design concept of a MSMPR was evident when comparing the
feasibility of SC in Peña & Nagy (2015) and Tahara et al. (2015) to those of batch
operations.125,139
The MSMPR framework provides a straightforward technology transfer from batch
operations since the mixing dynamics for both systems can be similar (independent of the
net flow). The MSMPR system can be expanded in capacity and degrees of freedom
through the addition of a cascade of multiple stages.200,202 These characteristics make the
MSMPR one of the more flexible continuous systems. However, broad CSDs are typically
obtained as a result of the broad residence time distributions (RTD) experienced by
crystals.38,203 Another concern when using multistage MSMPR systems is appropriately
transferring crystal slurry through each stage while maintaining the crystallizer operating
conditions.40,130,193 Plug flow reactors (PFRs) are an alternative continuous system that are
known to deliver narrower CSDs. However, PFRs usually require high flow rates to create
the desired mixing quality via turbulence. This requirement can lead to physically
unrealistic lengths to achieve appropriate residence times.43,170 As a design alternative to
PFRs, the oscillatory flow baffled reactor (OFBR) is a plug flow reactor where an
oscillatory motion is superimposed on the net fluid flow through the use of a piston near
the reactor inlet. Periodically spaced baffles along the reactor length create changes in the
reactor internal diameter, leading to paired eddy propagation as the net flow oscillates back
and forth.43 The zone between each pair of baffles is assumed to be uniformly mixed and
acts as a continuous stir tank reactor. Figure 7.1 is a schematic that illustrates the fluid flow
pattern of the oscillatory system. In some cases, the mixing capabilities of an OFBR are
enhanced relative to a PFR, leading to improved heat transfer, longer residence times,
turbulent mixing with laminar net flow Reynolds (𝑅𝑒𝑛 ), smaller reactor volume, and
narrower CSDs.42,43,204,205
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a

b

Figure 7.1 Schematic of the fluid flow pattern in an OFBR/C with net flow to the right: a) forward
stroke b) backward stroke. Adapted with permission from [204] Copyright 2002 Elsevier and [42]
Copyright 2003 Elsevier.

There are four key dimensionless parameters often used to define the fluid flow patterns
in an OFBR, which include the oscillatory Reynolds number (𝑅𝑒𝑜 ), the net flow Reynolds
number (𝑅𝑒𝑛 ), the Strouhal number (𝑆𝑡), and 𝛹, the ratio of oscillatory and net flows.
𝑅𝑒𝑜 =

2𝜋𝑥0 𝑓𝜌𝐷

𝑅𝑒𝑛 =

𝜌𝑢𝐷

µ
µ
𝐷

𝑆𝑡 = 4𝜋𝑥
𝑅𝑒

𝛹 = 𝑅𝑒𝑜

𝑛

0

7.1
7.2
7.3
7.4

The variables in equations 7.1-7.4 are as follows: 𝑥0 is the piston amplitude, 𝑓 is the
oscillation frequency, 𝜌 is the fluid density, 𝐷 is the internal diameter of the tube segment,
𝑢 is the mean superficial fluid velocity, and µ is the fluid viscosity. The Strouhal number
(𝑆𝑡) represents the effective eddy propagation through the ratio of the tube diameter to
piston stroke length.42,205 The 𝑅𝑒𝑜 measures the intensity of the oscillations generated by
the piston and therefore, the turbulence level imposed on the fluid. The Reynolds number
(𝑅𝑒𝑛 ) is the ratio of inertial to viscous forces. The volumetric flow rate limits the 𝑅𝑒𝑛 in
the system, despite the impeding oscillatory flow imposed by the piston. The ratio of the
Reynolds numbers (𝑅𝑒𝑜 /𝑅𝑒𝑛 ) results in a dimensionless mixing parameter, 𝛹, a measure
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of oscillatory versus net flows. Large 𝛹 values result in “well-mixed” sections between the
baffles.42,206
The objective of this study was to conduct CSC in an OFBC system. Conceptually, the
system enables the application of various types of SC techniques; allowing for both
simultaneous and independent nucleation, growth, and agglomeration mechanisms. The
ability to have spatially independent zones within a crystallizer where only one
crystallization mechanism is dominant offers additional degrees of freedom for the control
of final product properties. This technique allows for products to be tailored for
biopharmaceutical benefit and efficacy (e.g., bioavailability, dissolution rate, particle
morphology) and processing efficiency (e.g., filtration and drying times). The feasibility
of SC within a OFBC was studied via a series of experiments in which the control
crystallization mechanisms and final product properties were investigated.

Materials and methods
7.2.1

Materials

Benzoic acid (C6H5COOH) (≥99.5% purity, Sigma Aldrich) was used as the model
compound in this study. Benzoic acid SA has been studied in the literature making it an
ideal candidate for this study.26,130,139 The solvent system consisted of ethanol (pure, 200
pf, USP grd, Decon Labs), deionized water, and toluene (≥99.5% assay, Fisher Scientific).
Ethanol served as the solvent in which to prepare benzoic acid solutions, water as the antisolvent, and toluene as the bridging liquid. Acetic acid (≥99.5% assay, Fisher Chemical),
water (Optima LC/MS grade, Fisher Chemical) and methanol (Optima LC/MS grade,
Fisher Chemical) were used for ultra-performance liquid chromatography (UPLC)
quantification of benzoic acid. The spherical agglomerates created were filtered and dried
at 60 °C for 24 hours. A Nikon microscope was used to take images of the spherical
agglomerates. Image analysis software (ImageJ) was used to determine the agglomerate
size distribution (Feret diameter) and assess final agglomerate morphology.
7.2.2

Experimental setup

The OFBC was evaluated for a CSC process using a spatially distributed solvent/antisolvent/binder addition strategy. In this system, nucleation and growth occur in the first
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four segments due to supersaturation created by mixing solution and anti-solvent, while
bridging liquid is added at the end of the fourth segment, leaving a four-segment
agglomeration zone. Figure 7.2 is a picture of the experimental setup and illustrates the
nucleation, growth, and agglomeration zones. Changing the binder addition location makes
the agglomeration zone flexible in that adjusting this residence time allows one to tailor
agglomerate size to a desired size target.
The OFBC used in this work (Figure 7.2) was a Nitech DN15 (Alconbury Weston Ltd)
consisting of eight segments and a total volume of 1250 mL. All segments and elbows of
the DN15 were jacketed for temperature control. The temperature was controlled by using
four thermo-regulators (Huber Ministat 125/Julabo F25-ME) effectively dividing the
OFBC into four temperature zones. The first zone (consisting of one segment) was kept at
40 °C to dissolve particles and prevent particles from reaching the piston which can lead
to damage/leaking. The rest of the zones (consisting of seven segments) were kept at 22 °C.
There is a temperature gradient from 40 °C to 22 °C at the interface between the first and
second segments, however the temperature converges to 22 °C by the exit of the second
segment and is uniform through the remaining segments of the OFBC. The solution was
added at the end of the first zone to ensure an antisolvent process. Peristaltic pumps
(MasterFlex L/S by Cole-Palmer) and platinum cured silicon tubing (MasterFlex L/S by
Cole-Palmer) were used for both solution and anti-solvent feed into the OFBC (100-150
mL/min). A Waters 515 HPLC pump was used to feed toluene at the bridging liquid
injection point through an injector (1.32-1.65 mL/min). A control unit allows for setting
the oscillation amplitude (mm) and frequency (Hz). A Lasentec FBRM S400 was used for
on-line monitoring of the particle chord length distribution within the system.
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Figure 7.2 OFBC configuration indicating location of anti-solvent, solution and binder addition as
well as PAT port (FBRM).

7.2.3

UPLC method of benzoic acid quantification

UPLC techniques differ from high performance liquid chromatography (HPLC) techniques
in that they utilize columns with smaller diameters and particles (larger surface area to
volume ratio), and therefore higher pressures to increase peak capacity (number of peaks
resolved per unit time) and decrease retention time.207 Benzoic acid quantification for both
the determination of steady state and solubility data used an Acquity UPLC system (Waters
Corporation). The system utilizes column, sample, and binary solvent managers coupled
with Tunable Ultraviolet (TUV) detection in an offline setup to create an output signal that
is later processed using the Empower 3.1 software (Waters Corporation). The stationary
phase was an Acquity UPLC BEH C18 column 2.1 mm x 100 mm, 1.7µm, while the mobile
phase was a combination of 1.5 % (v/v) acetic acid (in water) solution and HPLC grade
methanol in an 85:15 ratio by volume. The diluent contains the same two solutions as the
mobile phase, but in a 55:45 ratio by volume. Each sample injection was 10 µL and the
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flow rate of the mobile phase was 0.5 mL/min. The temperature of the column was 40°C
and the UV detection wavelength was 243 nm.
7.2.4

Benzoic acid solubility determination

Benzoic acid was dissolved in ethanol/water solutions of varying proportions (0.1-0.4
ethanol/water (v/v)) and were held at ambient conditions for 24 hours with intermittent
mixing to reach equilibrium. The supernatant fluid was assumed to be at saturation. The
samples were centrifuged for five minutes and the supernatant fluid was nano-filtered (200
nm pore size). Using this filtered saturated solution in a 10x dilution with ethanol and a
manually prepared benzoic acid standard, the UPLC method generated a solubility curve
as a function of SASR. To validate the equilibrium measurement, a second approach was
also implemented. Benzoic acid was dissolved in pure ethanol (the solvent) before water
(the anti-solvent) was added in a dropwise manner. This anti-solvent addition induced
crystallization and the slurry was held at ambient conditions for 24 hours with constant
mixing to reach equilibrium. With this additional step, both nucleation and dissolution rates
are removed from the uncertainty as the measured concentration of benzoic acid in solution
should be the same using either method. Figure 7.3 shows experimentally determined

Conc. (mg of BA / mL of mix.)

solubility data that was used for choosing operating conditions in the OFBC.
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Figure 7.3 UPLC generated solubility of benzoic acid in ethanol solution-water mixtures of
different ratios.
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Experimental procedure
7.3.1

Degassing feed solution

An in-house degassing system was built to remove the risk of generating air bubbles during
the operation of the OFBC. To remove the dissolved gas prior to injection, the solution was
heated to 40°C with constant stirring (150 rpm) in a 5L jacketed vessel with a retreat curve
stirrer (dia. 140 mm). In addition to the temperature shift, the vessel pressure was decreased
using a vacuum pump (ultimate vacuum pressure of 110 torr, Welch by Gardner Denver).
The decrease in pressure also decreases the solubility of air in solution. The entire system
was held under these conditions for one hour before injection into the OFBC. The
degassing process was limited to an hour because there is a tradeoff in removing trapped
air and evaporating ethanol from the vessel. However, the concentration of benzoic acid
was determined offline prior to injection, ensuring comparable starting conditions between
experiments. The degassing process was a batch operation which impacted the length of
each experimental run time.
7.3.2

OFBC concentration sampling

After reaching steady state based on stabilized particle counts measured by the FBRM, a
sample was taken from the bridging liquid injection port before connecting the toluene feed
line (refer to Figure 7.2). Once bridging liquid addition was initiated, samples (3 mL) were
taken at the outlet to determine if steady state was also maintained in the liquid phase
throughout the process. This approach serves to cross-validate the solid phase (particle
counts) and liquid phase (concentration) based steady state assumption since crystallization
processes depend on both phases. The samples taken at the outlet were filtered through
(200 nm) pores before being diluted 10x with ethanol and inserted into the UPLC (Figure
7.4) shows an example of the concentration data used to monitor the process for 12
residence times (refer to experiment 3 from Table 7.1). The figure shows the benzoic acid
concentration as a function of time for the duration of the experiment with the slight
oscillation in the measurement due to the RTD in the liquid phase.208 The measured
concentration data corresponds to a steady state supersaturation of ΔC = 23 mg/mL
(absolute supersaturation) or expressed as a ratio S = 1.6 (S = C/Csat). S is the
supersaturation ratio, C is the concentration, and Csat is the saturation concentration.
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Figure 7.4 Concentration of benzoic acid as a function of time measured at the outlet of the OFBC.

Results and discussion
Several process parameters were varied between each experiment (Table 7.1). As
previously mentioned, the lumped parameter 𝛹 determines the intensity of mixing within
the OFBC. Five distinct values of 𝛹 (12, 33, 56, 58, and 82) were chosen to determine the
sensitivity of agglomerate formation to the mixing conditions. The lower and upper values
were chosen based on the manufacturer’s recommendations for mixing and safe operation
of the equipment; with two intermediate values to assess the operating range.
Supersaturation, and hence slurry density, in the initial OFBC tube segments are varied by
changing the SASR (0.18-0.30) and the benzoic acid (BA) concentration of the feed (0.080.125 g/mL). The BSR impacts both the extent of agglomeration and the agglomeration
mechanism. The BSR was varied (0.6-1.2) to alter agglomeration size and decrease the
number of un-agglomerated particles. The SASR, concentration, and BSR ranges were
chosen based on previously successful SA experiments.137 The remaining variables in
Table 7.1 include the amplitude, frequency, residence time, oscillatory Reynolds (𝑅𝑒𝑜 ) and
mean particle size (Dm).

149
Table 7.1 Summary of experimental conditions
Conc. of
RT
𝒇
Dm
SASR
BSR
𝒙𝟎 (mm)
𝑹𝒆𝒐 𝜳
BA (g/mL)
(min)
(Hz)
(mm)
1
0.08
0.30
0.80
10.0
1.5
15
12
3.0
1974
2
0.08
0.30
0.80
8.33
3.0
25
33
1.8
6581
3
0.08
0.30
1.00
10.0
3.5
30
56
2.3
9213
4
0.08
0.30
0.80
12.5
3.5
35
1.4
10748 82
5
0.08
0.18
0.80
12.5
3.5
35
1.6
11015 82
6
0.08
0.25
0.80
12.5
3.5
35
1.6
10853 82
7
0.125
0.30
0.80
12.5
3.5
35
1.5
10748 82
8*
0.08
0.30
0.85
12.5
3.5
35
1.7
10748 82
9**
0.08
0.25
0.85
12.5
2.5
35
58
1.3
7752
*Agglomeration zone consisted of three segments, **Agglomeration zone consisted of two segments

Exp.

7.4.1

Evaluation of mixing conditions

Experiment 1 had the least turbulent mixing conditions (𝛹 = 12) and resulted in a broad
ASD as shown in Figure 7.5. In SA systems, the bridging liquid preferentially wets the
crystals in suspension. Agglomerate formation then depends on particle collisions. Poor
oscillatory mixing prevented uniform bridging liquid distribution, caused particle settling,
and reduced collision events, resulting in a tri-modal ASD. This tri-modality is a result of
particles left un-agglomerated due to reduced collisions, larger particles created due to
particle settling, and very large particles created from over-agglomeration due to poor
bridging liquid distribution. As mixing intensity increased ( 𝛹 = 33 to 82), the ASD
improved significantly, average agglomerate size decreased, and the system could run at a
controlled state. The ASDs and images of agglomerates at the different mixing intensities
are shown in Figure 7.5 and Figure 7.6. Note that images were not presented for experiment
1 due to the large particles that were out of the viewing field of the microscope and the
broad size distribution that could not be represented in a single image. At a constant total
flowrate, there was significant improvement in the ASD by increasing the amplitude and
frequency of oscillations (experiment 1 vs. 3). Increasing residence time combined with
increasing oscillatory mixing, allowed for improved agglomeration due to more sustained
collisions and consolidation of agglomerates (experiment 1, 2 and 4). Overall, increased
oscillatory mixing led to a narrower ASD, smaller average agglomerate sizes, and reduced
particle settling/fouling. For these reasons, the mixing intensity remained high in each of
the latter studies. Note that experiment 3 (𝛹 = 56) does not follow the trend of decreasing
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mean size and narrower ASD as mixing intensity increases due to the difference BSR value
when compared to experiments 2 and 4.
0.5
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Figure 7.5 Agglomerate size distributions for different oscillatory mixing intensities.

Figure 7.6 Agglomerates from experiments with increasing mixing intensity from left to right (exp.
2-4).

7.4.2

Initial supersaturation variations via SASR

Benzoic acid solution and anti-solvent are mixed in the first segment of the OFBC.
Assuming the system is perfectly mixed, the SASR dictates the initial operating point in
the phase diagram (initial supersaturation). In experiment 5, the SASR is low at 0.18,
resulting in a higher initial supersaturation compared to experiments 4 and 6. Operating at
such a low SASR (high supersaturation) increases slurry density due to higher nucleation.
This supersaturation, and subsequent nucleation, is maintained throughout the
agglomeration zone (refer to Figure 7.4), resulting in many un-agglomerated crystals (far
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right of Figure 7.7) and a bimodal ASD (Figure 7.8). As the SASR increases from 0.18 to
0.25 to 0.30, the ASD narrows, the average agglomerate size decreases, and the maximum
agglomerate size decreases as shown in Figure 7.8. It is important to note the maximum
agglomerate size, or the breadth of the ASD, as it is related to the RTD of the system. 208
For each set of operating conditions, the maximum agglomerate size of each experiment
captures a portion of the system dynamics. From Figure 7.8 it is apparent that increasing
the slurry density (at constant net flow) broadens the ASD due to increased dispersion,
suggesting that the RTD of the system is related to slurry density.208 From a phase diagram
perspective, a decrease in SASR can have the same effect on the RTD of the system as
increases in concentration. At constant concentration, increasing the SASR past 0.30
results in an increase in the solubility of the system impeding sufficient supersaturation to
crystallize. It is important to note that changes in the SASR (at a constant BSR) will also
affect the operating point within the ternary phase diagram (ethanol-water-toluene).137
Changes in the operating point in the ternary phase diagram affect the immiscibility of the
bridging liquid which can cause changes in the agglomeration mechanism. Very low SASR
increases the immiscibility of the bridging liquid moving it above the critical maximum
BSR limit. Very high SASR will have the opposite affect; moving the bridging liquid below
the critical minimum. At the SASR conditions studied, no significant differences in the
agglomeration mechanisms were observed.

Figure 7.7 Agglomerates from experiments with decreasing SASR from left to right.
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Figure 7.8 Agglomerate size distributions for different SASR ratios.

7.4.3

Initial supersaturation variations via benzoic acid concentration

At a constant SASR, the initial concentration of benzoic acid in solution dictates the
crystallization starting point in the phase diagram (initial supersaturation). Increasing the
concentration from 0.08 g/mL to 0.125 g/mL, induced more clogging/fouling in the system,
broadened the ASD and the maximum agglomerate size dramatically increased (Figure
7.9). Increasing the initial supersaturation increases both primary and secondary nucleation.
As with changes in the SASR, an increase in slurry density via increases in concentration
can result in inconsistent agglomerate sizes and clogging/fouling. As concentration
increases, the effects of RTD contribute significantly to the broadening of the ASD and the
increase of the maximum agglomerate size. Concentrations above the values reported here
were attempted but were unsuccessful due to clogging/fouling. Based on the observed
trends, there is an optimal slurry density that minimizes the effects of RTD and avoids
clogging/fouling.
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Figure 7.9 Agglomerate size distributions for different solution concentrations of benzoic acid.

7.4.4

Variations in BSR

Spherical agglomeration techniques generally have narrow BSR operating ranges which
induce spherical agglomerate formation.26,130,139 Changing this ratio drastically changes the
final ASD and can change the agglomeration mechanism.137 After increasing the BSR from
0.8 to 1.0, the average agglomerate size increased from 1.4 to 2.3 mm. The ASD broadened
and the maximum agglomerate size dramatically increased as shown in Figure 7.10. As the
bridging liquid is increased to the critical range, the agglomeration mechanism becomes
increasingly adhesive as the particles have a greater bridging liquid film. The increased
adhesiveness of the particles results in a greater propensity for successful collisions
(collisions that result in agglomerate formation), particularly in agglomerate-agglomerate
collisions. When two agglomerates adhere, the system generates large particles and results
in the broad distributions shown in Figure 7.10.
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Figure 7.10 Agglomerate size distributions for different BSR.

7.4.5

Set point variations in BSR

One of the proposed advantages of continuous processes is the ability to make set point
changes to operating conditions to adjust final product properties. For this study, set point
changes in BSR were investigated to assess the feasibility of adjusting the final
agglomerate properties while maintaining constant primary crystal properties. Set point
changes in BSR were carried out at intermediate time steps during experiment 6 (Table 7.1)
before setting the system to its original operating conditions afterwards. Figure 7.11 shows
the FBRM total counts and SWMCL data over time as well as images of primary crystals
from the experiment. The data shows that a CSO was attained after four residence times
(50 min). The primary crystals in the images were collected at the end of the third residence
time at the outlet of OFBC after which binder addition was initiated. The images of the
primary crystals show the needle/rod-like morphology of the benzoic acid crystals and their
relatively large size.
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Figure 7.11 Total counts and SWMCL from FBRM probe.
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Figure 7.12 Images of the primary crystals prior to agglomeration.

Once under a CSO, the BSR was changed at the end of each residence time. The
following set point changes in BSR took place: the system began operation with a BSR of
0.80, increased to a BSR of 1.0, decreased to 0.85 and then brought back to its original
value of 0.80. Figure 7.13 shows the ASDs and images of agglomerates after the various
set point changes. The fifth residence time corresponds to the first residence time after a
CSO is reached per the FBRM data. However, given the breadth and maximum frequency
of the ASD at the fifth residence, it is apparent that the agglomeration portion of the OFBC
was not yet in a CSO. This observation suggests that there is a delay in the CSO of the
primary crystals versus that of the agglomerates. However, the observation is not
unexpected given that the binder addition was not initiated until the third residence time.
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When the BSR is increased to 1.0 (RT 6) the ASD has a significant shift to the right as
expected. Due the fact that only one RT was allowed for the step change response there is
still a portion of the distribution corresponding to the original ASD prior to the change (RT
5). This observation suggests that one RT is not enough to achieve a CSO after a set point
change. After the BSR is decreased to 0.85 and then to 0.80, the ASD shifts to the left
returning to the uniform, normal distributions observed in previous sections. From the
ASDs and images, it is evident that agglomerate properties can be adjusted throughout
operation by set point changes in the operating conditions.
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Figure 7.13 Agglomeration size distributions for step changes in BSR.

Figure 7.14 Images of agglomerates at different residence times and BSR (top left) BSR = 0.8, (top
right) BSR = 1.0, (bottom left) BSR = 0.85 and (bottom right) BSR = 0.8.

7.4.6

Evaluation of different agglomeration zone lengths

The ability to easily change the configuration of the OFBC is a major advantage of the
Nitech DN15. Changes in the jacket temperature of individual segments and location of
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injection points can allow for optimized experimental conditions. The previous results used
the configuration shown in Figure 7.2. Injecting the binder at the beginning of the fifth
segment created an agglomeration zone consisting of the final four segments. For the
studies that evaluated the impact of the agglomeration zone, the system is reconfigured by
changing the location of the binder injection to change the length of the agglomeration
zone while keeping the total length of the OFBC constant. Experiments were run for
agglomeration zones consisting of three, two and one segment(s) with the operating
conditions of experiment 4 used as reference.
When the operating conditions were held at the reference point, none of the
configurations produced spherical agglomerates. Decreasing the agglomeration zone by
one segment decreases the volume of the zone by approximately 1/7 or 14%. This decrease
in volume, along with an already short residence time (12.5 min), does not provide
sufficient time for agglomeration to occur. To create spherical agglomerates, changes in
the operating conditions must compensate for the lost time for agglomeration. Experiment
8 (Table 7.1) used a three-segment agglomeration zone and required an increase in BSR to
produce spherical agglomerates. Experiment 9 (Table 7.1) used a two-segment
agglomeration zone and required an increase in BSR and a decrease in 𝛹. Figure 7.15
shows the ASDs for experiment 4, 8 and 9 along with images of the spherical agglomerates.
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Figure 7.15 Agglomerate size distributions for different agglomeration zone configurations.
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Figure 7.16 Images of agglomerates from experiments 4, 8 and 9 (left to right).

As evident by the ASDs and images of the agglomerates the experiments produced
agglomerates of similar size distributions and mean sizes; with experiments 8 and 9 having
broader ASDs and slightly larger mean sizes. The broader ASD can be attributed to the
larger growth zone compared to experiment 4 which would contribute to a broader and
larger crystal size distribution prior to agglomeration. As the agglomeration zone length
decreases, the effects of dispersion/back mixing have a greater effect on the nucleation and
growth than on the agglomeration mechanism with proper adjustments of the BSR.
Experiment 8 required an increase in BSR to increase agglomeration and counteract the
reduced agglomeration zone residence time. Experiment 9 required an increase in BSR to
increase agglomeration and a decrease in the mixing intensity to reduce the dispersion of
crystals from the growth zone. Reducing the crossing particles from the growth zone into
the agglomeration zone allows the agglomeration to proceed without the effects of
introducing new particles. Two segment agglomeration zone experiments at higher mixing
intensities consistently produced a combination of spherical agglomerates and fine crystals.
The effects at the interface between the growth and agglomeration can be overcome when
the agglomeration zone is larger.

Summary of results
Spatially distributing API solution, anti-solvent, and bridging liquid along the length of the
crystallizer led to independent control of mechanisms within the OFBC system. Various
crystallization operating conditions were evaluated in the OFBC. Knowledge of the initial
point in the phase diagram and the mixing ability of the OFBC allowed for an assessment
of the effects of various operating parameters on the implementation of a SA technique.
Increased mixing intensity significantly improved the final agglomeration size distribution
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(narrower, smaller mean size). A 𝛹 = 82 was found to be optimal in this study. 𝛹 = 82 was
the limit attempted in this study due to the stability of system as excessive vibrations can
affect the crystallization process. However, further increasing the 𝛹 parameter should
follow the same trends observed in this study at the expense of increased back
mixing/dispersion. To achieve successful SA experiments, residence time (8.33-12.5 min)
and benzoic acid solution concentration (0.08 and 0.125 g/mL) were kept relatively low.
The slurry density should be limited to avoid fouling, clogging and particle settling, and
decrease the effects of residence time distributions. Broadening of the residence time
distribution can be limited with decreased slurry density which leads to more
narrow/uniform distributions. The supersaturation and slurry density was controlled by
maintaining the solution concentration and the SASR at appropriate levels (BA conc. at
0.08 g/mL, SASR at 0.30). Higher flow rates and mixing intensities also slow the buildup
of fouling on crystallizer walls by reducing the possibility of particle settling. A solution
concentration of 0.08 g/mL benzoic acid in ethanol and a SASR of 0.3 were found to be
the optimal values in this study. The experimental conditions present in this study were
largely determined by the avoidance of fouling. Thus, the experiments created very large
primary crystals and spherical agglomerates. Higher nucleation rates could lead to smaller
primary particle sizes and ultimately much smaller agglomerate sizes. However, fouling
will be a bottleneck in such a process unless a continuously seeded system is studied. Lastly,
as has been shown in the literature, the critical BSR range narrows for continuous
systems.130 A BSR of 0.80 was found to be the optimal in this study, with minimum room
for adjustment. Table 7.2 summarizes the overall trends in mean size and ASD for the
various process parameters.
Table 7.2 Summary of experimental results
Properties
Mean Size

ASD

Effect of Process Parameters
decreases with

Ψ↑

SASR ↓

Conc. ↓

BSR ↓

Agg. Segs ↓

increases with

Ψ↓

SASR ↑

Conc. ↑

BSR ↑

Agg. Segs ↑

narrows with

Ψ↑

SASR ↑

Conc. ↓

BSR ↓

Agg. Segs ↑

broadens with

Ψ↓

SASR ↓

Conc. ↑

BSR ↑

Agg. Segs ↓
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Conclusion
The OFBC is a viable option for applications in continuous crystallization. Given the
OFBC’s ability to be configured to optimize specific properties of interest, it also has
application in PI. The benefit of a plug flow type of crystallizer is the ability to achieve
product of narrower final properties. The broad agglomerate size distributions observed
throughout this study contradict this fact. The results presented here suggest the OFBC
deviates from an ideal PFC; with the effects of dispersion of the residence time distribution
appearing to be most significant factor in that deviation. The findings in this study agree
with RTD studies in literature that suggest the operating ranges studied here could cause
significant dispersion.208 The results show RTD to be related to slurry density. Increases
the slurry density appeared to have led to increases in dispersion and back mixing. The
effects of slurry density should be investigated further, especially for SA processes. Overall
the agglomerate size distributions show improvement (narrower, more uniformity) over the
distributions observed in an MSMPR.130 A series of staged MSMPRs proves to be more
efficient in decoupling the crystallization mechanisms because the stages are physically
separated and are completely independent from one another. In the OFBC, the mixing
(expressed through the Ψ) was the same through and between the different crystallization
zones which can lead to multiple mechanisms occurring at the interface of different zones
due to dispersion or back-mixing. Within the experimental framework studied here and in
Peña & Nagy (2015), the MSMPR does not exhibit fouling issues allowing it to operate at
much higher supersaturation ratios; leading to finer smaller primary crystals.130 However,
for optimal operating conditions, the OFBC proves effective in producing agglomerates of
consistent quality. The superimposed oscillatory mixing of OFBC allows for process
development at a wide range of productivity levels (from benchtop to pilot to
manufacturing scale) without changes in equipment volume.
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8. EVALUATION OF MIXED SUSPENSION MIXED PRODUCT
REMOVAL CRYSTALLIZATION PROCESSES COUPLED
WITH A CONTINUOUS FILTRATION SYSTEM

This chapter is reprinted with minor modification with permission from Acevedo, D., Peña,
R., Yang, Y., Barton, A., Firth, P., & Nagy, Z. K. (2016). Chemical Engineering and
Processing: Process Intensification, 108, 212–219. Copyright 2016 Elsevier.

Introduction
Various works have been performed in the design, optimization and control of
crystallization processes in order to improve and maintain crystal product qualities such as
crystal size, shape and purity, among others.6,7,15,21,47,209,210 However, batch operations are
well known to affect the overall efficiency of pharmaceutical manufacturing processes and
often affect the quality of products due to the significant batch-to-batch variability.
Therefore, the study on the design and control of continuous operations has increased
significantly. Continuous processing offers the advantage of consistency in product quality
and achievement of operating conditions unattainable in batch processes. Other advantages
of implementing continuous processing involve the reduction of cost by asset utilization,
shorter down time and ease of scale up. Continuous processing has been identified as a key
paradigm shift in the pharmaceutical industries with high potential of improving
pharmaceutical production.102,104,211
The two-main type of continuous crystallizer designs for pharmaceutical applications
are the plug flow and mixed suspension mixed product removal (MSMPR) crystallization
systems. Advanced optimization and control strategies have been implemented in these
types of crystallizers such as recycle and fines reduction.194,212-214 The choice of which type
of continuous processing to use depends mainly on the kinetics of the process. However,
the MSMPR system offers the advantage of simple transfer of existing batch capacity to
continuous.211 The MSMPR crystallizer is an idealized vessel in which supersaturation is
generated continuously while crystals nucleate and grow from a feed of homogeneous
solution. It is assumed that the product slurry removed continuously has the same
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composition and crystal properties as the vessel content. This is an important assumed
property of an MSMPR crystallizer and leads to specific designs of downstream processes.
Filtration has long been developed through practical and empirical understanding
instead of exact theory because of the complex nature of the development of the filter
cake.215,216 Due to this, many issues have arisen in terms of scaling from laboratory to
industrial scale and process transfer from batch to continuous operation. Traditionally,
laboratory filtration has taken place in batch mode with vacuum as the main driving force.
At the manufacturing scale, filtration has mostly been carried out in batch mode consisting
of very different geometries and introducing greater uncertainties because of interactions
between filter feed and mechanical movement of the filter. Filtration is often assessed in
terms of two parameters: mass of solids recovered from the slurry and the moisture content
of the recovered solids.216 Since the majority of the liquid content in a solid-liquid
suspension is removed during the filtration process, the effectiveness of unit operations
that proceed filtration are directly correlated to these two factors. Drying, for example, is a
unit operation that typically proceeds filtration, but is only accountable for a small fraction
of the liquid removed from the solids. Therefore, incremental improvements in the
filtration process can significantly improve the efficiency and energy consumption of a
drying unit.217

Materials and methods
Crystallization precedes filtration, and poor filterability of the crystallization product is a
common problem for industrial scale pharmaceutical crystallizations. However, it has been
shown in the literature that improvements in CSD can greatly improve the efficiency and
time of filtration.216,218,219 The filtration efficiency impacts the crystallization design as
different operating conditions produce markedly different crystal properties. Jones et al.
(1987) conducted a study analyzing the filterability of potassium sulfate crystals from a
batch crystallization carried out through cooling or anti-solvent addition for both seeded
and unseeded cases.218 They found that the unimodal nature of unseeded crystallization
processes greatly improved the permeability of the filter cake allowing for greater liquid
removal and lower moisture content. The bimodal nature of seeded crystallization
processes introduced greater uncertainty in the filter cake development causing reduced
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permeability. The study showed no significant effect on filterability from changes in the
cooling rate. However, for seeded processes Matthews et al. (1998) proposed an
optimization framework to reduce the mass of nucleated crystals by controlling the
temperature profile and found significantly reduced filtration times when fines were
reduced.219 Jones et al. (1987) also pointed out that there is a greater room for improvement
in filterability for anti-solvent crystallization as opposed to cooling due to the smaller
crystal size, faster rate of supersaturation generation, and potential for agglomeration of
the crystals.218 Fines reduction is not only important during crystallization but during and
after filtration, too. Nucleation at the point of filtration is also commonly observed in
industrial processes caused by rapid removal of saturated solution from the filter and
residual solution dried up on filter parts.220, 221
There have been numerous studies on the integration of continuous filtration systems
coupled to continuous crystallization systems within integrated continuous manufacturing
(ICM) systems.103, 222 However, this studies do not delve into much detail regarding the
actual filtration process efficiency, productivity and operating parameters. This is partly
due to simple filtration setups with minimal operating parameters built around other unit
operations. A few continuous filtration setups are worth mentioning, in Ley et al. (2015)
work two systems are discussed: (1) the rotating sintered glass filter system which is
usually used for liquid collection, is a simple setup with a rotating filtration plate that
collects solids while the filtrate can be sent to other unit operations; (2) vacuum assisted
filter system that works similar to the sintered glass filter system but is used for solids
collection equipped with a slurry dispenser, scraper, wash solvent.223 The vacuum assisted
system was used by Mascia et al. (2103).102 Lastly, Gursch et al. (2015, 2016) have
conducted studies of a dynamic cross-flow filtration (CFF) system which is a membrane
based system for the filtration of model APIs.105,224 Their results show the CFF to be a
suitable continuous filtration technology with a material-specific linear relationship
between feed and permeate rate. However, the effects of shear on the crystals was not
studied although membrane based systems have a high dependence on shear rate.
In this work, the feasibility of coupling a CFC system with a continuous crystallization
process is demonstrated. The aim is to demonstrate the impact of the type of crystallization:
(a) cooling and (b) antisolvent on the operation, productivity and product obtained from
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the continuous filtration system. Paracetamol (PCM) in ethanol is used as the model
system for the case study for the cooling crystallization due to the high nucleation and slow
growth kinetics, which make the product crystals difficult to filter. Furthermore, benzoic
acid (BA) in ethanol drowned out by water was used as the model system for the antisolvent
crystallization case study. This system produces crystal morphologies (i.e., needles and
plates) common to many APIs. The variation in the crystal properties produced from the
crystallization processes assessed the practicability of the continuous filtration system
coupled with a MSMPR crystallizer for pharmaceutical crystallization processes.
8.2.1

Materials

4-Acetaminophenol (paracetamol, PCM, Alfa Aesar) with a purity of 98.0% in mass
fraction was used in the cooling crystallization experiments. Benzoic acid (BA, Fisher
Scientific Education) with a purity of 99.0% was used during the antisolvent crystallization
case studies. Solubility data for paracetamol in ethanol and benzoic acid in water-ethanol
were obtained from the literature.187,225
8.2.2

System setup

The continuous MSMPR crystallizer consists of a 500-mL round-bottom jacketed vessel
and a transfer line, as shown in Figure 8.1a. The transfer line has a similar structure and
working mechanism as the one described in literature.19,130,193,198,199 The transfer line
contains a transfer zone and four valves, which are used to control nitrogen gas, vacuum,
inlet and outlet of the transfer zone, respectively. The slurry is transferred intermittently.
Within one transfer, first the vacuum valve is opened for 5 seconds to evacuate the transfer
zone, followed by 5 seconds opening of the inlet valve that allows slurry to be vacuumed
into the transfer zone. Then the nitrogen valve as well as the outlet valve are opened
simultaneously for 5 seconds to push the slurry out into the next vessel. The volume of the
transfer zone is 32mL. The transfer interval is controlled by a controller box to maintain
constant slurry levels in both vessels.
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Figure 8.1 Schematics of (a) continuous MSMPR crystallizer using a transfer line and (b) CFC
system.

A commercially available CFC system (Alconbury Weston Ltd, UK) is coupled with
the continuous MSMPR crystallizer to filter the product slurry. As presented in Figure 8.1b,
the CFC system contains a 2.5-liter slurry vessel, a wash solvent vessel, a clean-in-place
(CIP) solvent vessel, a filtration unit, and three valves that are used to control slurry, wash
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solvent and CIP solvent, respectively. The filtration unit consists of five cylindrical-shaped
chambers (0.6’’ diameter and 3.5’’ height) and a poremet 10 (five-layer plate-type filter
medium, 2.5’’ diameter, 21μm geometrical pore size, 1.7 mm thickness) at the bottom. The
filter medium spans the chambers located in positions 1, 2, 3 and 4. The chambers rotate
counterclockwise every one filtration time. Slurry is fed into the chamber at position 1, as
shown in Figure 8.1b. The slurry in that chamber is then washed in position 2 before being
filtered through positions 3 and 4, and finally discharged at position 5. The bottom of
position 5 is open, which allows the cake to be discharged through a chute by a piston.
Therefore, the filtration unit works as a sequential-batch or semi-continuous operation, like
a semi-batch Nutsche type filter. The bottom of the filtration unit is connected to a vacuum
pump, which typically works at around 200 mmHg. The filtration time, as well as the slurry
valve open time (or slurry time) and the wash solvent valve open time (or wash time) within
every one filtration time are parameters that are controllable from the built-in user interface.
Each chamber, therefore, operates under variable pressure and filtration rate as these
parameters can be controlled and adjusted by the filtration, slurry, or wash timer. In
addition, the inner pressure is monitored by the CFC system. Once the pressure drop
increases past a user-defined normal operation pressure level, due to blockage of the
poremet, an auto-clean function is actuated automatically by feeding CIP solvent into the
chambers to dissolve the solids that cause blockage. The filtration unit returns to normal
operation once the pressure drop normalizes after auto-clean. However, the small crosssectional area of each chamber allows for slow ramp in pressure drop which allows for
continued productivity without blockage. The appearance of the coupled continuous
MSMPR crystallizer and CFC is shown in Figure 8.2.

167

Figure 8.2 Coupled continuous MSMPR crystallizer and CFC.

8.2.3

Methods

The continuous crystallization was performed in the MSMPR-CFC system described in
section 2.2. The temperature in a 500-mL lab scale glass jacketed vessel was controlled
with a PT100 thermocouple using a Huber Ministat 125 refrigerated and heating circulator.
An overhead stirrer with a three-blade retreat curve impeller was used to agitate the system.
The saturated solution or antisolvent was fed to the MSMPR system using a Masterflex
L/S pump. An S400 FBRM probe was used to monitor the dynamics and chord length
distribution in-situ during the continuous experiments in order to infer the product
CSD.226,227 The data was collected every 15 s in the range of 0.1-1000μm. The crystals
obtained from the CFC were weighed every half residence time to monitor the productivity
and dynamics of the filtration system. Samples of filtrated crystals were collected every
residence time to measure the moisture content by weight loss. Two types of continuous
crystallization experiments were performed using PCM and BA.
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The cooling crystallization of PCM in ethanol was performed in a one stage MSMPR
crystallizer as described in section 2.2. A saturated feed solution was prepared by
dissolving PCM in 2 L of ethanol in a beaker at a concentration of 0.24 g/g solvent. The
initial saturated solution in the crystallizer was prepared at a similar concentration as the
feed solution. The feed temperature was set to above the saturation temperature to avoid
crystallization throughout the feed tubes. The crystallizer temperature was set to 20 °C to
avoid significant impact of temperature variation between the MSMPR stage and CFC
slurry stage shown in Figure 8.1. The agitation speed was set to be 300 rpm throughout the
experiments, which is enough to guarantee the suspension of particles. The total residence
time was set to 60 minutes to ensure significant growth of the crystals since PCM is a
relatively slowly growing and mainly nucleation dominated system.

The set of

experimental conditions for the MSMPR-CFC system for the cooling crystallization
experiments are shown in Table 8.1. The crystals were continuously washed with solvent
to minimize the CIP steps which can affect the steady state operation.
Table 8.1 Experimental conditions for cooling crystallization of PCM in ethanol in a 1 stage
MSMPR crystallizer coupled with continuous filtration (CFC) system.
Variable

Description

Value

Units

C0

initial conc.

0.24

g/g

RPM
𝑇𝐹
𝑇𝐶
𝑇𝑠𝑎𝑡
𝐹
𝜏
𝜏𝐹
𝜏𝑆
𝜏𝑊

agitation
feed temp.
cryst. temp.
sat. temp.
flow rate
res. time
filter time
slurry time
wash time

300
50
20
40
5.0
60
90
0.4
0.4

rpm
°C
°C
°C
mL/min
min
s
s
s

The antisolvent crystallization of BA in ethanol-water was performed in a one stage
MSMPR crystallizer as described in section 2.2. The feed solution was prepared by
dissolving BA in 700 mL of ethanol in a beaker at a concentration of 0.285 g/g solvent at
50 °C. The initial solution in the crystallizer was an ethanol-water mixture prepared at the
same solution to antisolvent ratio (SASR) of the inlet streams. The SASR used for this
experiment was 0.43 determined by the ratio of the solution flow rate (SFR) to antisolvent
flow rate (ASFR). This allowed for a slow progression in the crystallization of BA crystals
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as opposed to initializing with pure water which causes a crashing out effect. The inlet
streams, crystallizer and CFC unit were all operated at ambient temperature (~20°C). The
agitation speed was set to be 350 rpm throughout the experiments, which is enough to
guarantee the suspension of particles. The total residence time was set to 40 minutes, which
was enough to show significant growth of the crystals. The set of experimental conditions
for the MSMPR-CFC system for the antisolvent crystallization experiments are shown in
Table 8.2. During operation two CIP procedures were needed due to pressure drop
increases from clogging of the filter plate.
Table 8.2 Experimental conditions for antisolvent crystallization of BA in ethanol-water in a
1 stage MSMPR crystallizer coupled with continuous filtration (CFC) system.
Variable

C0
RPM
𝑆𝑜𝑙𝐹𝑅
𝐴𝑆𝐹𝑅
𝑆𝐴𝑆𝑅
𝐹
𝜏
𝜏𝐹
𝜏𝑆
𝜏𝑊

Description

Value

Units

initial conc.
agitation
sol. flow rate
antisol. flow
rate
Ratio
overall flow
rate
res. time
filter time
slurry time
wash time

0.285
350
3

g/g
rpm
mL/min

7

mL/min

0.43

-

10.0

mL/min

40
120
1
0.15

min
s
s
s

Results and discussion
8.3.1

Cooling crystallization of paracetamol

The cooling crystallization of paracetamol was performed in a one stage MSMPR system
and monitored using the FBRM. The SWMCL is shown in Figure 8.3a. First order
dynamics are observed, which is expected since the continuous process was initiated with
a saturated solution in the MSMPR vessel. The dynamic variation of the SWMCL
demonstrates that the system achieved steady state behavior around 3 residence times (180
min). The oscillations in the dynamic profile, shown in Figure 3a, are commonly observed
during the continuous crystallization in a MSMPR system.15,39,194,228 The oscillations in the
SWMCL are within ±8µm. Therefore, the system is considered to reach a CSO after three
residence times. The SWMCL achieved at steady state shows that the system does not grow
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significantly, which is expected for a nucleation dominated system, such as PCM.6 The
small size achieved will impact the filtration behavior as observed in Figure 8.3a.
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Figure 8.3 (a) SWMCL (µm) and (b) mass flowrate from CFC (g/min) during cooling
crystallization of PCM in a MSMPR crystallizer coupled with CFC system.

The mass flowrate of PCM crystals obtained from the continuous filtration system
(CFC) shows higher order dynamics. The continuous filtration processes were not started
until half residence time to allow the filtration vessel to reach a minimum working volume
in which the system could be operated with low fluctuations. Furthermore, the system was
operated at low volume to avoid further growth or dissolution of crystals. Figure 8.4 shows
microscope images of slurry samples taken after the system reached steady state, and
filtered crystals after drying. No significant growth was observed between samples from
the MSMPRS and filtered crystals. There is no clear evidence of breakage or attrition on
the final crystals, which could affect the final crystal quality. Figure 8.4 demonstrates no
significant variation in the crystal habit of PCM before and after the continuous filtration.
Therefore, there is no observable impact due to growth, breakage or attrition on the PCM
crystals that can occur while the slurry is in the filtration feed vessel or in the filtration
chambers. These results indicate that the CFC system is a good isolation platform for the
studied system as the crystallization product properties are preserved during the filtration.
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100µm
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Figure 8.4 Microscope images obtained of (a) slurry at outlet of MSMPR and before the CFC and
(b) filtered crystals after the CFC. Samples were obtained at steady-state.

The startup of the filtration system depends on the control of the volume at which the
CFC is operated but also on the dynamics of the continuous crystallization process. As
observed, steady state behavior was achieved between 2 to 2.5 hours of operation. A mean
mass flow rate of 0.17±0.03 g/min during the steady state operation was achieved. The low
productivity obtained can be attributed to the use of wash during the process to avoid
disturbances in the continuous operation due to the CIP programmed step. However, higher
productivity can be achieved by increasing the filtration timer which will maintain the same
throughput and loose some running time to CIP. The continuous crystallization experiment
was continued for 3.5 residence times after the system reached steady state as observed in
Figure 8.3a. However, the continuous filtration system was operated until all the slurry in
the vessel was filtered. This allowed the observation of the impact of decreasing working
volume on the mass flowrate of crystals as demonstrated in Figure 8.3b. A monotonic
decrease in the mass flowrate was observed after stopping the transfer from the MSMPR
vessel to the filtration system. The startup and shutdown period observed in Figure 8.3b
demonstrates that it is necessary to operate the CFC at constant volume since this has a
direct impact in the output from the system; the amount of slurry pushed from the vessel
when the filtration valve opens depend on the working volume dynamics (refer to section
2.2).
The moisture content was determined for the samples collected at each residence time
from the filtered crystals at the outlet of the CFC. Figure 8.5 shows the moisture content
(MC) dynamics calculated by weight loss after a 24 h drying period. The dynamics
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demonstrated that the system reaches a steady state behavior after two residence times. An
average MC of 22.2 ± 2.8 % was achieved at steady state. The MC before reaching steady
state is significantly lower due to the lower amount of material in the filtration chambers.
As demonstrated before, the mass flowrate before reaching steady state is lower, thus the
vacuum system can remove solvent more efficiently. If the filtration operating conditions
are constant throughout the processes, higher removal of solvent should be expected during
startup due to the lower amount of material in the chambers.
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Figure 8.5 Moisture content (%) of filtered crystals obtained at each residence time throughout the
cooling crystallization of PCM in a one stage MSMPR crystallizer coupled with the CFC system.

8.3.2

Anti-solvent crystallization of benzoic acid

The antisolvent crystallization of benzoic acid was performed in a one stage MSMPR
system and monitored using the FBRM. The SWMCL is shown in Figure 8.6a. Higher
order dynamics is observed, during the startup indicated by the initial overshoot and
oscillations in the system behavior, which is generally expected for a continuous
antisolvent crystallization process. The dynamic variation of the SWMCL demonstrates
that the system achieved a steady state behavior at around four residence times (160 min).
The oscillations in the dynamic profile after reaching steady state in this case study were
negligible and can be attributed to intermittent operation. The steady state mean chord
length was around 110 µm. This mean size showed good filtration properties aside from
the two CIP procedures required at 120 and 200 min.
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Figure 8.6 (a) SWMCL (µm) and (b) mass flowrate (g/min) during antisolvent crystallization of
BA in a MSMPR crystallizer coupled with the CFC system.

The mass flowrate of BA crystals (Figure 8.6b) obtained from the CFC shows well
maintained dynamics and was unaffected by the CIP procedures. Like the case of PCM,
the continuous filtration process was not started until half residence time and there was no
observable impact on BA crystal attributes due to the added holdup filtration period. The
startup of the filtration system depends on the operating volume the CFC but also on the
dynamics of the continuous crystallization process. Since antisolvent crystallization
technique was used for BA there the induction time for crystallization was shorter and there
was a significant amount of crystal mass in the slurry from the onset, although the solid
concentration was relatively small. A mean mass flow rate of 0.10±0.003 g/min during the
steady state operation was achieved. The low productivity obtained can be attributed to low
solids concentration in the slurry. Given that filtration was not initiated until the appropriate
working volume was achieved the mass flow rate for the antisolvent system was
sufficiently constant. This is also attributed to the fact that the antisolvent system produces
a constant solids concentration from the onset due to the short induction time
Figure 8.7 shows the morphology of the BA crystals obtained from the antisolvent
crystallization. As the microscope images show, the morphologies present are both rigid
plates and needles. This had a significant impact on the filtration process, specifically on
the moisture content. The moisture content was determined for the samples collected at
each residence time from filtered crystals at the outlet of the CFC.
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Figure 8.7 Microscope images of filtered crystal samples obtained at steady-state.

Figure 8.8 shows the MC dynamics obtained for BA after a 24-hour drying period; an
average MC of 45±4% was achieved at steady state. The high moisture content can be
attributed to the different morphologies of the benzoic acid crystals present. This directly
impacts the development of the filter cake inside the filtration chambers and has a liquid
entrapment affect. This is evident from the microscope images in which the crystals appear
clustered together due the liquid entrapment. From Figure 8.8 two points of decreased
moisture content are observed at 120 and 200 min. These points coincide with the two CIP
procedures. The results show that after a CIP there is a significant improvement in the
amount of solvent removed and shortly after the moisture content increases again. This
proves that there is a combination of crystals that clog the pores of the filter medium as
well as liquid entrapment in the filter cake that cause gradual increase in moisture content.
The crystals clogging the pores of the medium are easily removed by the CIP solvent
allowing for continued operation with small deviation in the process output.
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Figure 8.8 Moisture content (%) of filtered crystals obtained at each residence time throughout the
antisolvent crystallization of BA in a one stage MSMPR crystallizer coupled with the CFC system.

8.3.3

Assessment of continuous filtration system

The CFC system presented in our work also allows washing the filter as a wash vessel and
injection port onto the filter cake is available. Cleaning is also made easier by the presented
system given the CIP vessel, which can contain a solvent that has a high solubility for the
solids being recovered so that efficient cleaning can take place. However, whenever the
CIP takes place the filtration step shows small deviation from steady state operation and
the properties, including the moisture content, change. The impact of the CIP on the
filtration step was observed for both scenarios studied but it was more frequent for the
antisolvent crystallization of BA compared to the cooling crystallization of PCM. This
could be attributed to the differences in crystal habit between the two systems as observed
in Figure 8.7 and Figure 8.4b. Needle-like and plate shape crystals were obtained for BA
during steady state operation. The PCM crystals obtained show a prismatic crystal habit.
Hence, clogging occurred more frequently during the crystallization of BA due to the wide
crystal shape distribution. The operating conditions of the CFC system would depend on
the type of process and crystallization system. An important observation is that the
performance of the filtration step depends significantly on the crystallization system and
process. The achievable productivity and moisture content are correlated with the filtration
parameters, which will also depend on the crystallization system. However, the small
variability in the productivity and moisture content observed for both processes,
demonstrate the robustness of the continuous crystallization process coupled with the CFC
system. The highest variation in the moisture content occurs for both systems whenever a
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CIP step initiates. Therefore, the variance observed throughout the operation of the CFC
should be minimized if optimal operating conditions are implemented. Furthermore, the
filtration buffer vessel should be operated at small residence times to avoid significant
impact on the quality of the crystals produced from the continuous crystallization process.
The temperature in the filtration buffer vessel should also be controlled, to avoid additional
nucleation or growth. In our study the MSMPR stage was operated close or at ambient
temperature to avoid any impact of the filtration buffer vessel temperature variation on the
product.
The presented study demonstrated that the CFC system is a viable process for the
continuous filtration of pharmaceuticals compounds and can be easily coupled with
continuous crystallization to form a fully integrated platform. The ease of use and
controllability of the CFC system make it feasible to operate continuously, while coupled
with a continuous crystallization process

Conclusions
The operation of a continuous crystallization coupled with a novel continuous filtration
system (CFC) was demonstrated through different case studies, (a) cooling crystallization
of paracetamol and (b) antisolvent crystallization of benzoic acid. The continuous filtration
showed significant dependence on the crystallization system due to the variations in crystal
properties such as size and shape. This could lead to operation of the CFC system at suboptimal conditions that could affect the efficiency of the process. However, the robustness
of the system is demonstrated due to the low variability during steady-state operation. The
continuous operation of the MSMPR coupled with the CFC system shows significant
promise due to the robustness and fast start-up observed for the cooling and antisolvent
crystallization of paracetamol and benzoic acid, respectively.
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9. CONCLUSIONS AND FUTURE DIRECTIONS

Conclusions
Drug substance purification by crystallization is a key interface in going from drug
substance synthesis to final formulation and can often be a bottleneck in process efficiency.
Of utmost importance in the crystallization of APIs, in the pharmaceutical industry, is to
produce crystals of desired physical, processing, and biopharmaceutical properties. The
desired physical properties depends on what the end goal and the drug formulation that the
crystals will be a part of, but often processing and biopharmaceutical properties are
competing interests. In most cases, the crystallization process is tailored to improve
downstream process efficiency rather than improve drug molecule efficacy in the human
body. Thus, there has been increased importance in the development of continuous
crystallization systems of APIs to produce crystals with targeted physical and
biopharmaceutical properties.
Spherical crystallization can potentially completely alter a typical pharmaceutical
product manufacturing line. By improving both bioavailability and manufacturability, the
technique enables processes to be complimentary to biopharmaceutical and processing
properties. The unique value proposition and ability to consolidate unit operations make
SC an example of PI. Moreover, CSC as a PI technique can address many of the present
flaws (e.g., size distribution, downstream processing efficiency) of traditional
crystallization systems. Understanding the current state of SC will be essential to the
development of new strategies and finding knowledge gaps that can be improved. In this
thesis, a thorough literature review of SC was conducted followed by a study focused on
gaining insight of SC mechanisms and applications of CSC. Moreover, a first principles
model was developed that enabled to optimization of both bioavailability and
manufacturability. Lastly, to further the concept of PI, a continuous filtration unit was
evaluated to assess its application with an MSMPR system.
A review of SC literature aimed at identifying the controlling process parameters,
understanding the mechanisms involved, and evaluating the current state of modeling was
conducted. The controlling parameters were identified as: solvent system composition,
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temperature, amount of bridging liquid, constituent particle properties, agitation rate and
batch/residence time. An understanding of agglomeration mechanisms proposed in
literature provided fundamental knowledge that guided experimental and modeling studies
conducted herein. The current state-of-the-art in modeling of SC and agglomeration in
suspension systems was reviewed, and combined with the mechanistic understanding, a
PBM was developed to include the simulation of both primary crystal and agglomerate
population. Evaluation of the current state of CSC lead to the development of the CSC
processes outlined in this thesis.
To this point, mechanistic studies of SC systems had not used process analytical
technologies to assist in developing an understanding of the complex mechanisms
occurring in a SC technique. Here common process analytical technologies were used to
conclusively determine the mechanisms of SC. Moreover, since there a many different
implementations of SC, the study here focused on a subset referred to as SA or
agglomeration in suspension; SA uses a bridging liquid to agglomerate fine crystals into
spherical particles. The study evaluated how different methods of incorporating the
bridging liquid affect the mechanisms that ultimately form agglomerates. The results
showed that the most robust method of incorporating the bridging liquid is post
crystallization. The study then further evaluated how the properties of the constituent
particles and their interaction with the bridging liquid droplet affects agglomerate size and
flow properties. The results prove that there is a critical relationship between bridging
liquid droplet size and crystal size that determines whether the agglomeration mechanism
is immersive or distributive. The difference in mechanism leads to different size, flow and
compression properties.
In regards to modeling, the PBM is the common approach to simulation and prediction
of the size distribution and other properties of particulate systems. Population balance
models can include nucleation, growth, breakage and agglomeration mechanisms that are
relevant to a particulate process. However, there are some limitations to many of the
previous PBM formulations for systems with agglomeration. These limitations have
prevented the use of PBMs to accurately predict and simulate agglomeration in suspension
techniques such as SC. To overcome these limitations, an extension of the concept of a
coupled PBM was presented for application in the simulation and optimization of a SA in
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suspension system. A coupled PBM formulation was developed for a semi-batch, reverse
addition, anti-solvent crystallization system with agglomeration. The system included
nucleation and growth of the primary crystals and subsequent agglomeration. The
advantages presented by a coupled PBM formulation include the ability to optimize for
specific primary and agglomerate sizes. Allowing for identification of optimal operating
conditions that meet both bioavailability and manufacturability demands.
Relating to CSC, a method to help satisfy both processing and biopharmaceutical
interests was proposed, based on performing crystallization and SA in a two-stage
continuous MSMPR system and in an OFBC. For the MSMPR, under suitable operating
conditions, the system enabled the decoupling of nucleation and growth from the
agglomeration mechanisms, while performing efficient continuous manufacturing of
particles with desired properties. Decoupling offers more degrees of freedom for the
control of each mechanism, and in turn, provides how properties can be tailored to those
of most biopharmaceutical benefit and efficacy (e.g., bioavailability, dissolution,
morphology). While allowing agglomeration to be tailored to produce spherical
agglomerates of the most processing efficiency (e.g., filtering, drying, friability). OFBCs
are comparable to PFCs in that they are both tubular crystallizers, however, the OFBC has
periodically spaced orifice baffles with oscillatory motion overlapped on the net flow.
Independent crystallization mechanisms can theoretically be achieved through spatially
distributed solution, solvent, anti-solvent, and bridging liquid addition; offering more
control of each mechanism. However, the studies here showed that the OFBC allowed for
spatially distributed addition of solvents but achieving control of each mechanism
individually was not attainable due to the back mixing of the system.
Lastly, as the pharmaceutical industry evolves and goes through the paradigm shift
from batch to continuous crystallization, innovative processes will need to be developed to
replace unit operations that have historically been batch operations. This requires
innovation in downstream processes (e.g., filtration, drying, milling, and granulation).
Herein a commercially available CFC was assessed for its feasibility of continuous
filtration while coupled with a continuous MSMPR crystallizer. The filtration system was
assessed using two different crystallization systems (i.e., cooling and antisolvent) with
significantly different kinetics and morphologies to assess the robustness of the integrated
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platform. With proper optimization of the various filtration parameters, each crystallization
system could achieve a CSO. The crystal product from the CFC system shows good
consistency with the crystals in the slurry in the MSMPR. Moisture content and
productivity of the filtration system were reported and show dependency on crystal
properties. The CFC system was equipped with solvent vessels that aided the continuous
filtration by acting as a wash or a clean-in-place solvent, preventing or removing filter
clogging, respectively.

Future Directions
Recommendations for future work are provided here:
•

Supersaturation control (SSC) and direct nucleation control (DNC) have been
widely used to control and attained crystals of optimal quality as well as crystals of
different properties. Given the effects constituent particle properties can have on
final agglomerate properties, SSC and DNC can be implement during the
crystallization phase of a SC process to create optimal crystals for the
agglomeration phase. Since supersaturation determines the growth of different
crystal faces, SSC can be used to evaluate of the wetting ability of a bridging liquid
on different faces of a crystal can also been evaluated by either control approach.
DNC can be used to evaluate the efficient of an agglomeration process at different
solids concentrations by studying various particle count set points. Final properties
of traditional SC can be compared with SSC/DNC-SC to evaluate differences and
identify any significant improvement final properties.

•

Both the MSMPR and the OFBC proved to be suitable CSC platforms in this thesis.
However, both platforms had significant operational pitfalls. In the MSMPR, the
broad particle residence times can make particle design of the constituent particle
difficult. In the case of the OFBC, fouling due to nucleation is a constant
operational issue caused by its high surface area to volume ratio. Moreover, the
operating conditions required to make spherical agglomerates are not
recommended because of a significant level of dispersion is created which negates
plug-flow. Since the MSMPR has a much longer induction time for fouling, it can
be used as a nucleator to feed crystals into the OFBC. The OFBC can then be used
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as a cooling crystallization system operating at close to plug-flow conditions,
allowing for uniform growth of crystals. The outlet of the OFBC can be then fed
back to an MSMPR where an over stirrer can induce agglomeration. The MSMPROFBC-MSMPR setup would be a novel coupling of equipment that lead to superior
spherical agglomerates than the units individually.
•

The two-stage MSMPR studies presented here successfully show the used of one
stage as nucleation and growth stage and another as a agglomeration stage. The
two-stage approach can be reconfigured and extended to include other unit
operations. For example, the first stage can be replaced with a wet mill unit. The
wet mill would serve as a nucleator that can provide micronized particles to the
second stage for agglomeration. The wet mill (WM) can also be coupled in the
same manner to the OFBC which would grow the crystals uniformly and then feed
those particles to the an MSMPR. The WM-OFBC-MSMPR setup would be a novel
coupling of unit operations that can lead to superior spherical agglomerates.

•

The CFC was successfully coupled with the continuous crystallization processes in
an MSMPR. However, due to clogging and other configuration limitations, the first
version of the CFC was not coupled with CSC in an MSMPR. The newer versions
of the CFC appear to be avoid of such technical issues and coupling of CSC in an
MSMPR/OFBC with a CFC could prove to be another milestone in PI of
pharmaceutical manufacturing.

•

PCA can be employed as a method of bridging liquid selection from simple physical
properties data for solvents and compounds. Analysis of the principal components
could lead to rapid solvent system selection. Combined with regime maps, process
development of tailored spherical agglomerates for specific compounds and solvent
systems can be achieve with greater success.

•

Multiple hypothesis-based iterative robust model identification approach can be
used to develop an iterative model-based experimental design approach (IMED).
This approach uses a constrained model-based optimization framework to
determine the optimal experimental conditions within the feasible operating region
that maximize the information content of the experiments to obtain the model
parameters with minimum uncertainty. The model with improved parameters is
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then used to design the next experiments and the procedure is repeated until no
further improvement are observed in the parametric uncertainties. Typical
optimality-criteria (e.g., A-opt, D-opt, E-opt, etc.) can be used in the IMED
depending on how the information content in the experiment is quantified. When
the actual mechanism for which the model parameters are identified is unknown,
the same procedure is repeated for the candidate set of mechanisms and the model
with the mechanism or combination of mechanisms that provide prediction with
lowest uncertainty will be selected based on quantitative model discrimination
procedures. Therefore, this approach provides an automated structural and
parametric model identification procedure that enables not only the determination
of a robust predictive model for model-based optimization using the minimum
number of experiments, but also enables the elucidation of the correct mechanisms
that govern a manufacturing process.
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APPENDIX A. PRODUCT DIFFERENCE ALGORITHM

The PD algorithm enables the estimation of the weights and abscissas used in the QMOM
approach detailed in Chapter 5. The first step in the estimation is to construct a triangular
𝑷 matrix. The 𝑷 matrix has components 𝑃𝑖𝑗 constructed from the moments. The
components of the first column of 𝑷 are:
𝑃𝑖,1 = 𝛿𝑖1 , 𝑖 ∈ 1, … ,2𝑁 + 1

A.1

where 𝛿𝑖1 is the Kronecker delta. The components in the second column of 𝑷 are:
𝑃𝑖,2 = (−1)(𝑖−1) 𝜇𝑖−1 ,

𝑖 ∈ 1, … , 2𝑁 + 1

A.2

The calculations can be done assuming 𝜇0 = 1 (i.e., a normalized distribution). The final
weights can be multiplied by the true 𝜇0 afterwards. The remaining components of the 𝑷
are found using the PD algorithm (equation A.3).
𝑃𝑖,𝑗 = 𝑃1,𝑗−1 𝑃𝑖+1,𝑗−2 − 𝑃𝑖,𝑗−2 𝑃𝑖+1,𝑗−1
𝑗 ∈ 3, … , 2𝑁 + 1 𝑎𝑛𝑑 𝑖 ∈ 1, … , 2𝑁 + 2 − 𝑗

A.3

A simple example is the case of 𝑁 = 2 quadrature points. For this case 𝑷 becomes:
𝜇1
1
1
−𝜇
0 −𝜇1
2
𝜇3
𝑷 = 0 𝜇2
0
0 −𝜇3
[0
0
0

𝜇2 − 𝜇12 𝜇3 𝜇1 − 𝜇22
−𝜇3 + 𝜇2 𝜇1
0
0
0
0
0
]
0
0

A.4

Moment inversion of the first row is then used to find the coefficients of the continued
fraction (𝛼𝑖 ). The coefficients are generated by setting the first element equal to zero (𝛼1 =
0) and computing the remaining coefficients via the following recursive relationship:
𝛼𝑖 = 𝑃

𝑃1,𝑖+1
1,𝑖 𝑃1,𝑖−1

,

𝑖 ∈ 2, … ,2𝑁

A.5

The Jacobi matrix is then constructed as a symmetric tridiagonal matrix obtained from
sums and products of 𝛼𝑖 ,
𝑎𝑖 = 𝛼2𝑖 + 𝛼2𝑖−1 ,

𝑖 ∈ 1, … ,2𝑁 − 1

𝑏𝑖2 = 𝛼2𝑖+1 𝛼2𝑖−1 , 𝑖 ∈ 1, … ,2𝑁 − 2

A.6

184
where 𝑎𝑖 and 𝑏𝑖 are the diagonal and off-diagonal of the Jacobi matrix. Once the
tridiagonal Jacobi matrix is constructed the weights and abscissas are obtained from the
eigenvalue problem around the matrix 𝑱. The abscissas (𝐿𝑗 ) are simply the eigenvalues of
𝑱 and the weights (𝑤𝑗 ) can be obtained from the first component of the 𝑗𝑡ℎ eigenvector
(𝑣𝑗1 ).
2
𝑤𝑗 = 𝜇0 𝑣𝑗1

A.7
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APPENDIX B. DIMENSIONAL ANALYSIS OF SPHERICAL
CRYSTALLIZATION SYSTEMS

This section details the use of regime maps and dimensional analysis to aid in the
development of SC processes. Here it is demonstrated how the critical process parameters
are reduced to dimensionless quantities that can be used to determine the mechanism or the
final product properties. The first step is to identify parameters that are critical to a SC
process and develop relationships that allow of dimensional analysis.
As the previous sections detail, the most important process parameters include: the BSR,
supersaturation, agitation rate, and batch or residence time. For the BSR, there is a critical
range for which a SC process will be successful. This range is identified by the BSRmin and
BSRmax. Both quantities are system specific and are found empirically through trial and
error. The supersaturation is the main control variable in determine the size and
concentration of the particles in suspension which influence the agglomeration mechanism
and final agglomerate properties. For agitation rate, there is a lower bound where below
the bound agglomeration would not be successful and agitation rates slightly above bound
increases agglomerate size. However, the generally observed trend is agglomerate size
decreases with increasing agitation rate above the sufficient agitation rate. Batch or
residence time is also an important parameter as it determines the consolidation phase
which directly affects final properties of agglomerates.
With knowledge of these parameters, two dimensionless numbers can be development.
The first is the bridging liquid saturation ratio (𝑆𝐵 ). 𝑆𝐵 expressed as the ratio of the
difference between the BSR and the BSRmin to the difference between the BSRmin and
BSRmax (equation B.1).
𝐵𝑆𝑅 − 𝐵𝑆𝑅𝑚𝑖𝑛

𝑆𝐵 = 𝐵𝑆𝑅

𝑚𝑎𝑥

− 𝐵𝑆𝑅𝑚𝑖𝑛

B.1

𝑆𝐵 serves as to balance BSR between the sufficient low bound and maximum upper bound.
A negative ratio or a ratio above 1 would indicate that the process is outside the ideal range
for SA. 𝑆𝐵 directly relates to and can determine the agglomeration process. To further
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incorporate the crystallization process, 𝑆𝐵 is multiplied by the supersaturation (𝑆). The
combined term is referred to as 𝑆𝑆.
𝑆𝑆 = 𝑆𝐵 ∗ 𝑆

B.2

The second dimensionless number is time under agitation. Time under agitation (ν) is
the multiplication of agitation rate (𝑁) and the batch or residence time (𝑡 or 𝜏) (equation
B.3). By considering the agitation speed and residence, the time under agitation directly
relates to the agglomeration and consolidation phases of SC.
𝜈 = 𝑁 ∗ 𝑡 or 𝜈 = 𝑁 ∗ 𝜏

B.3

Here the time under agitation is calculated for the formation and agglomeration phases.
The formation phase (𝜈𝐹 ) refers to the solution or bridging liquid addition phase. This
represents the initial forming and flocking of agglomerate particles. The agglomeration
phase (𝜈𝑎𝑔𝑔 ) refers to the post solution or bridging liquid addition phases. Table B.1 shows
the experimental conditions for the dimensional analysis of batch studies carried using a
BAM1 technique. It is important to note that the effect of flow rate is not accounted for the
set of dimensionless parameters evaluated here. Table. B.2. shows the dimensionless
parameters from those experiments.
Table B.1 Experimental conditions for batch regime maps
Exp.

F (min)

1
2
3
4
5
6

1,5
2,5
3,6,9,12

Agg
(min)
20,30
10,20,30
30
30
0,30,60
15

BA conc.
(g/mL)
0.25
0.25
0.25
0.38
0.38
0.38

SASR

S

BSR

RPM

FR

0.09
0.18
0.35
0.35
0.35
0.35

1.9
3.5
4.6
6.7
6.7
6.7

0.9
0.9
0.9
1.0
0.9
0.9

600
600
400
600
400
600

5
5
5
2.4
5
5

Table B.2 Dimensionless parameters
Exp.

Sb

SS

1
2
3
4
5
6

0.623
0.623
0.623
0.768
0.623
0.623

1.2
2.2
2.9
5.1
4.2
4.2

νF
(x103)
0.6,3
1.2,3
1.8, 3.6, 5.4, 7.2

νagg
(x103)
12,18
6,12,18
12
12
0,12,24
9
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The dimensionless parameters for plot against each other to assess the different regimes
of the various experiment. Figure B.1 shows the regime map for the formation phase of the
SC process. The corresponding agglomerates from these times are shown in Figure B.2.
From the regime map and the images, it is evident that the formation phase occurs within
the first three minutes of the process. For experiments at lower concentration, the initially
formed agglomerate nuclei are much larger in size. By five minutes into the process
agglomeration of multiple nuclei is apparent. Significant agglomerate growth is observed
after nine minutes.
6

Exp6-3min Exp6-6min Exp6-9min Exp6-12min

SS = Sb*S

4

Exp2-2min Exp2-5min

2
Exp1-1min

0
0

2x103

4x103

F (N*t)

Figure B.1

6x103

8x103
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Exp. 1: 1min

1min

Exp. 2: 2min

5min

Exp. 6: 3min

6min

9min

12min

Figure B.2

Figure B.3 shows the regime map for the agglomeration phase of a SC process. The
agglomeration phase can be divided into low 𝑆𝑆, medium 𝑆𝑆, and high 𝑆𝑆 regimes. At low
𝑆𝑆 (< 2), final agglomerates are small and there is minimal agglomerate growth with
increase in time under agitation. As evidenced by the minimal increase in agglomerate size
over time for experiment 1 (Figure B.4). The medium 𝑆𝑆 (> 2, < 4) regime corresponds to
experiments 2 and 3. The agglomerates produced in this regime are spherical and appear
uniform in size. It is also observed that this regime seems insensitive to increases in the
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time under agitation (Figure B.4). The high 𝑆𝑆 (> 4) regime corresponds to experiments 4,
5, and 6. This regime shows rapid agglomerate growth with increase in time under agitation.
Agglomerates in this regime show over agglomeration with evident smaller agglomerates
on their surface (Figure B.4). At low to moderate νagg (<15x103), agglomerate sphericity is
maintained. Higher νagg (>15x103) displays excess agglomeration. However, the 𝑆𝑆
parameter shows the most sensitivity to agglomerate properties. At constant νagg (12x103),
experiments 1, 2, 3, 4 and 5 in Figure B.3 and B.4, increase in 𝑆𝑆 shows agglomerate
growth from consolidation (experiments 1) to layering (experiments 2, 3) to coalescence
(experiments 4, 5).
6
Exp4-30min

Exp6-15min

SS = Sb*S

4

Exp5-0min

Exp5-30min

Exp5-60min

Exp3-30min
Exp2-10min

2

Exp2-30min

Exp2-20min
Exp1-5min

Exp1-30min
Exp1-20min

0
0

1x104

agg (N*t)

Figure B.3

2x104

3x104
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Exp. 1: 5min

20min

30min

Exp. 2: 10min

20min

30min

Exp. 5: 0min

30min

60min

Exp. 3: 30min

Exp. 4: 30min

Exp. 6: 15min

Figure B.4

Table B.3 shows the experimental conditions and dimensionless numbers for the
MSMPR experiments. The 𝑆𝑆 and νagg are plotted against each other in Figure B.5. Similar
trends are observed in the low, medium and high 𝑆𝑆 regimes for the MSMPR compared to
the batch. However, for the MSMPR, the low 𝑆𝑆 exhibits low agglomeration efficiency
with fine crystals evident. While the high 𝑆𝑆 exceeds that of the batch experiments and
displays very porous and unstructured agglomerates. For 3.5<𝑆𝑆<5 the agglomerates the
same qualitative properties as the equivalent regime for the batch, i.e., excessive
agglomeration leading to significant agglomerate growth (Figure 5.6).
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Table B.3 Experimental conditions and dimensionless parameters for MSMPR
Agg (min)
50.00
56.25
62.50
62.50
55.56
29.50
60.00

BA conc. (g/mL)
0.38
0.38
0.38
0.38
0.25
0.38
0.38

SASR
0.33
0.33
0.23
0.33
0.20
0.10
0.10

BSR
0.59
0.82
1.00
1.25
1.00
0.76
1.08

RPM
400
400
500
500
500
400
400

S
6.9
6.9
6.2
6.9
4.7
3.0
3.0

Sb
0.174
0.507
0.768
1.130
0.768
0.420
0.884

10
Exp 4

8

SS = Sb*S

Exp.
1
2
3
4
5
6
7

6
Exp 3

4

Exp 2

2

Exp 6

Exp 5

Exp 7
Exp 1

0
0

1x104

2x104

agg (N*t)

Figure B.5

3x104

4x104

SS
1.2
3.5
4.8
7.8
3.6
1.3
2.7

νagg (x103)
20.0
22.5
31.3
31.3
27.8
11.8
24.0
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Exp. 1

Exp. 6

Exp. 3

Exp. 4

Exp. 5

Figure B.6

Exp. 7
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